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ABSTRACT 
As pattern recognition receptors of the innate immune system, Toll-like receptors 
(TLRs) sense microbial components and mediate cell activation leading to protective 
inflammatory responses. TLRs are type-1 transmembrane receptors that are activated by 
forming dimers; an event driven by the coordinate binding of a cognate microbial ligand. 
Bacterial lipoproteins are the most potent microbial agonists for the TLR2 subfamily and 
this pattern recognition event induces cellular activation leading to host immune 
responses. TLR2 mediates cellular responses to triacylated and diacylated bacterial 
lipoproteins by forming heterodimers with either TLR1 or TLR6, respectively.  Crystal 
structure analysis revealed that triacylated bacterial lipoproteins coordinately bind TLR1 
and TLR2 resulting in a stable ternary complex that drives intracellular signaling. 
However, the order of complex formation upon recognition of microbial components is 
poorly understood. The primary objectives of this dissertation are to define the sequence 
of events by which lipoproteins from bacteria are delivered to TLR1 and TLR2 leading to 
the formation of a stable TLR1/TLR2/lipoprotein ternary complex as well as to identify 
important amino acid residues in the TLR1 extracellular domain that are necessary for 
ligand recognition and/or formation of the dimer interface with TLR2. 
Chapter One of this thesis provides an overview of the field of innate immunity 
and a review of the latest developments in Toll-like receptor studies, with an emphasis on 
the members of the Toll-like receptor 2 subfamily. We describe in detail the extracellular 
domain of TLRs and their importance in ligand recognition.  
Chapter Two assesses the role of two lipid-binding serum molecules, 
lipopolysaccharide binding proten (LBP) and cluster of differentiation 14 (CD14), in the 
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delivery of microbial components to TLRs 1 and 2. The sensitivity of TLR-expressing 
cells to lipoproteins is greatly enhanced by LBP and soluble CD14 (sCD14). However, 
the physical mechanism which underlies this increased sensitivity is not known.  To 
address this, we have measured the ability of LBP and sCD14 to drive ternary complex 
formation between soluble extracellular domains of TLR1 and TLR2 and the synthetic 
triacylated lipopeptide agonist Pam3CSK4.  Importantly, addition of sub-stoichiometric 
amounts of either LBP or sCD14 significantly enhances formation of a 
TLR1/TLR2/Pam3CSK4 ternary complex as measured by size exclusion chromatography. 
However, neither LBP nor sCD14 is physically associated with the final ternary complex. 
Similar results were obtained using OspA, a naturally-occurring triacylated lipoprotein 
agonist from Borrelia burgdorferi.  Activation studies reveal that either LBP or sCD14 
sensitize TLR-expressing cells to nanogram levels of either Pam3CSK4 lipopeptide or 
OspA lipoprotein agonist.  Together, our results show that either LBP or sCD14 can drive 
ternary complex formation and TLR activation by acting as mobile carriers of triacylated 
lipopeptides or lipoproteins. 
Chapter Three describes the measurement of interactions between TLRs and 
lipopeptides to assess the possible competition between TLR1 and TLR10 for 
lipopeptides and the TLR2 co-receptor. Using microtiter plate assays, we have 
demonstrated that Pam3CSK4 induces the formation of the TLR1/TLR2 and 
TLR2/TLR10 heterodimeric complexes, and have further shown that ternary complex 
formation is ligand-specific and can be blocked by monoclonal antibodies against the 
TLRs.  TLR2 was shown to prefer TLR1 as co-receptor compared to TLR10 for 
assembly of a final ternary complex with Pam3CSK4. To quantitatively measure the 
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kinetics of the interaction, surface plasmon resonance experiments based on a two-
component system were initially performed. However, two major problems encountered 
in this system were the aggregation of the small 1.5 kDa Pam3CSK4 ligand in solution, as 
well as the non-uniformity of binding conditions after each regeneration step. To address 
these issues, we purified a larger 12kDa lipoprotein (Lip12) expressed in E. coli and used 
the Octet system to obtain uniform and repeatable results. The calculated dissociation 
constant (KD) of Lip12 binding to Fc-tagged TLRs 1, 2, and 10 immobilized on protein A 
sensors were 7.45x10
-7
 M (chi
2
: 0.0193), 1.58x10
-6
 M (chi
2
: 0.02892), and 3.34x10
-7
 M 
(chi
2
: 0.07317), respectively, based on a 1:1 Langmuir binding model. Moreover, TLR4 
did not show any binding to Lip12, and neutralizing mAbs against TLR2 and TLR1 
prevented interaction with Lip12, suggesting that the binding events are real and specific. 
TLR1 showed the highest affinity for the agonist, followed by TLR10, and finally by 
TLR2. This, together with the reported CD14-Pam3CSK4 interaction (KD = 5.7x10
-6
M) 
suggest that CD14 preferentially delivers the lipopeptide to TLR1 first followed by the 
binding of TLR1-lipopeptide to TLR2. In cells that express both TLR1 and TLR10, a 
competition for the agonist could take place, and the receptor that has a higher expression 
level on the cell surface would most likely win. Measuring the KD in a three-component 
system, while a critical step, is outside the scope of current work until the issues of 
protein aggregation, handling lipoproteins in solution, and steric hindrance brought about 
by non-specific dimerization of Fc-tagged TLRs can be resolved. Addition of LBP and/or 
sCD14 to this system did not resolve the aggregation problem.  
Chapter Four addresses the important regions in the TLR1 extracellular domain 
(ECD) that are required for activation of TLR1/TLR2 in response to a variety of natural 
v 
 
agonists. We have previously shown that the central leucine-rich repeat motifs (LRRs 9 
through 12) of TLR1 and TLR 6 are critical for lipoprotein discrimination.  TLR1/TLR2 
and TLR2/TLR6 heterodimers also mediate responses to a wide variety of other acylated 
microbial ligands and we show here that similar to lipopeptides, LRRs 9-12 of TLR1 and 
TLR6 are also required for this sensing function.  To further delineate the residues 
important for this function, random mutagenesis was used to create a library of TLR1 
clones with various single amino acid substitutions within LRRs 9-12.  Using this library, 
the epitope of GD2.F4, an inhibitory anti-TLR1 mAb, was mapped to amino acid 
residues located in the flexible loop of LRR11. Additionally, the amino acids F314, P315, 
Q316 and V339, within LRRs 11 and 12, were each found to be necessary for the sensing 
of triacylated lipopeptides by TLR1. More importantly, mutation of these same critical 
residues greatly inhibited cellular responses to other TLR1/TLR2 microbial agonists. 
These results demonstrate that regardless of the molecular structure of the agonist, the 
same critical residues of TLR1 are required for ternary complex formation with TLR2 to 
initiate cellular activation. These residues lie at the interface between TLR1 and TLR2 in 
the TLR1/TLR2/lipopeptide complex suggesting that the overall structure of the ternary 
complex is the same regardless of the activating microbial agonist. 
Chapter Five summarizes the important findings from this dissertation, 
highlighting the contributions and implications of this work to the TLR field. We also 
describe future experiments that are predicted to provide further insights on the structure 
and function relationship between TLRs and their agonists. A better understanding of 
TLR sensing of bacterial cell wall components may lead to improved therapeutic 
strategies for treating inflammatory diseases. 
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CHAPTER ONE 
INTRODUCTION 
The innate immune system and its link to adaptive immunity 
 Innate immunity is the first-line of host defense that protects vertebrate and 
invertebrate animals from infectious microorganisms and viruses. The innate immune 
response happens instantaneously after infection with a wide variety of infectious agents, 
and systemically in mammals, is characterized by fever, increased white blood cell 
counts, and elevated acute phase proteins. Innate immune responses are driven by a 
limited diversity of invariant, germline-encoded receptors. Since cells of the innate 
immune system do not have memory, they generate the same response upon subsequent 
exposure to an infectious agent. Adaptive immune responses on the other hand, are 
highly-specific and directed to the infectious agent that initiated it. However, adaptive 
immune responses are not immediate, and usually take several days (4-7 days) to 
develop. The lymphocytes, B cells and T cells, which facilitate the adaptive immune 
response, have extensive diversity due to a wide range of randomly generated B-cell 
receptors and T-cell receptors. Moreover, memory cells confer amplified responses upon 
subsequent exposure to the same infectious agent. Only vertebrate animals possess 
adaptive immune systems (Janeway Jr. et al., 2001). 
Invertebrates do not possess an adaptive immune system, yet, they are able to 
mount immune responses against natural pathogens, suggesting that they have a system 
for recognizing foreign components. In 1883, Elie Metchnikoff (1845-1916), a Russian 
scientist considered to be the father of the field of innate immunity, observed that starfish 
larvae are able to engulf particles. He used a wide range of experimental model 
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organisms, some of them transparent, to test the susceptibility of an organism to 
infection. He described that white blood cells of the human body have the ability to 
engulf or phagocytose foreign bodies and microbes, and believed that these cells played a 
central role in natural immunity to microbial infection. He also identified microphages 
(polymorphonuclear leukocytes) and macrophages as important components of the innate 
immune system involved in phagocytosis and production of lytic agents, resulting in the 
killing and inactivation of infectious microorganisms (Gordon, 2008). 
 Louis Pasteur (1822-1895) was the first to show that microbes cause infectious 
diseases and are responsible for the decomposition of organic matter. Robert Koch (1843-
1910) then showed that an infectious living microorganism that has entered a host species 
is able to multiply within and eventually cause disease together with all its symptoms. 
Ludwig Brieger (1849-1919) further advanced the field by discovering that microbes 
secrete poisonous substances, which he called “toxins”. Emil von Behring (1854-1917) 
and Shibasaburo Kitasato (1856-1931) discovered an anti-toxin for diphtheria and used it 
for therapeutic applications. Richard Pfeiffer (1858-1945) discovered that the toxicity of 
Vibrio cholerae was not dependent on a viable microbial cell, since heat-killed Vibrio 
cholerae retained their poisonous activity. He then referred to this heat-stable substance 
“endotoxin”, and also identified the presence of this substance in other Gram-negative 
microorganisms such as Salmonella typhi and Haemophilus influenzae. Today, we know 
that endotoxin is an important structural component of the outer membrane of Gram-
negative bacteria called lipopolysaccharide (LPS), that is sensed by leukocytes resulting 
in the production of endogenous pyrotoxins which cause fever in an individual 
[Reviewed in (Beutler & Rietschel, 2003)]. 
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 For a long time, it was a mystery as to how the innate immune system recognizes 
microbes and ultimately distinguishes between self and non-self. Furthermore, it was not 
understood how foreign antigen alone was insufficient to elicit an adaptive immune 
response. It was known that foreign components (antigens) had to be mixed with crude 
extracts or adjuvants like mineral oil, mycobacteria, and aluminum hydroxide in order to 
get T and B cells activated. In 1989, Charlie Janeway Jr. (1943-2003) was the first to 
hypothesize that there exists a group of receptors, which he termed “pattern recognition 
receptors (PRRs)”, that recognize “pathogen-associated molecular patterns (PAMPs)”      
(Janeway Jr., 1989). Pattern recognition receptors (PRRs) act as a barrier in the host cell 
and serve as the first line of innate immune defense against infectious microorganisms. 
He hypothesized that innate immune cells recognize microorganisms through PRRs, and 
ultimately provided evidence that this interaction transmits a “second signal” required for 
lymphocyte activation.   
The path to the discovery of the Toll-like receptors 
In 1940, Interleukin-1 (IL-1) was the first pro-inflammatory cytokine discovered 
by researchers. IL-1 is secreted by macrophages in response to LPS from Gram-negative 
bacteria [Reviewed in (Bowie & O'Neill, 2000)]. It is a cytokine known to be involved in 
T-cell activation, pyrogenicity, and the acute phase response (Dinarello, 1991). Around 
1988, the gene for the IL-1 receptor 1 (IL-1R1) was cloned, but its signaling mechanism 
remained unknown, because its cytoplasmic domain had no recognizable motif (Sims et 
al., 1988).  
In 1985, the German word “Toll”, which means “fantastic” or “super”, was used 
by C. Nüsslein-Volhard to describe a new mutant of abnormal embryonic development in 
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the fruit fly Drosophila melanogaster (Anderson et al., 1985). The Toll gene was found 
to be involved in the development of the dorso-ventral axis of the embryo as a loss-of-
function mutation led to dorsalization, while a gain-of-function mutation resulted to 
ventralization (Anderson et al., 1985). In 1991, the cytoplasmic domain of Drosophila 
Toll and human IL-1R were found to be homologous, suggesting that their signaling 
pathway may have similar mechanisms [Reviewed in (Gay & Keith, 1991)]. Shortly 
thereafter, the Drosophila toll and the IL-1 receptor were both demonstrated to signal 
through the NF-kB pathway (Baeuerle & Henkel, 1994; Belvin & Anderson, 1996; 
Wasserman, 1993). In 1994, the N-protein (encoded by the virus-resistance gene in 
tobacco plants) was shown to be homologous to the Toll protein with both a leucine-rich 
repeat (LRR) extracellular domain and a Toll/IL-1R signaling domain (Whitham et al., 
1994). In 1995, adult fruit flies with a mutation in their Toll gene were observed to be 
more susceptible to fungal infection, reflecting the role of the Toll receptor in the 
induction of anti-fungal peptide production as part of their innate immune response. 
(Lemaitre et al., 1996).  
Toll is a transmembrane protein with an extracellular domain (ECD) and a 
cytoplasmic domain. The ECD is characterized by its LRRs, while the cytoplasmic 
domain is related to the human interleukin-1 receptor (IL-1R). The stimulation of human 
cells with IL-1 leads to the phosphorylation of IkB, which in turn leads to the dissociation 
of the IkB-NFkB complex, thus enabling NF-kB to migrate to the nucleus (Wasserman, 
1993). NF-kB is a transcription factor that activates a number of genes known to be 
involved in immunity and inflammation (Sen & Baltimore, 1986). Dorsal is a 
transcription factor in Drosophila that is homologous to NF-kB, while Cactus is a 
5 
 
cytoplasmic protein whose role in Drosophila is analogous to that of the IkB (Belvin & 
Anderson, 1996). Analogously, activation of Toll on the membrane is correlated with the 
accumulation of Dorsal in the nucleus.  
In 1997, the first human homologue of Drosophila Toll was cloned and 
characterized by Charlie Janeway Jr.’s group (Medzhitov et al., 1997). Without knowing 
the ligand for the human receptor, they performed an elegant experiment to generate a 
constitutively active receptor. They engineered a recombinant human Toll (hToll) by 
fusing the mouse CD4 ectodomain, a receptor that naturally forms dimers, to the 
transmembrane and cytoplasmic domains of human Toll gene homologue. They then 
transfected human cell lines such as Jurkat cells and the human monocytic cell line THP-
1 cells with their recombinant constructs and measured NF-kB activation using the NF-
kB reporter assay. They also detected the expression of NF-kB-controlled genes for 
proinflammatory cytokines (IL-1, IL-6, and IL-8) along with the co-stimulatory molecule 
B7.1 (Medzhitov et al., 1997). B7 molecules are expressed by B cells, macrophages, and 
dendritic cells, collectively known as antigen presenting cells of the immune system, and 
are required for activation of naïve T cells. This provided preliminary evidence that the 
human homologue of Drosophila Toll has a functional link to adaptive immunity 
(Janeway Jr., 1989). Other homologues of Toll were later identified and named Toll-like 
receptors. 
In the early 1960s, a strain of inbred mice (C3H/HeJ) at The Jackson Laboratory 
was found to be resistant to LPS. Genetic studies led to a single LPS resistance locus that 
was named Lps and mapped to mouse chromosome 4. Using inbred strains of mice, 
Bruce Beutler’s group demonstrated that the C3H/HeJ defect reflects a proline to 
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histidine mutation at amino acid position 712 in the cytoplasmic domain of Toll-like 
receptor 4 (TLR4). This mutation was demonstrated to create a dominant negative form 
of the TLR4 receptor and the LPS hyporesponsive phenotype (Poltorak et al., 1998). 
Additionally, another LPS-hyporesponsive mouse strain, C57BL/10ScCn, was found to 
be missing an exon in TLR4 (Poltorak et al., 1998). In 1999, Shizuo Akira and colleagues 
generated TLR4 knock-out mice and showed that they were unresponsive to LPS, 
affirming that TLR4 is the pattern recognition receptor for LPS (Hoshino et al., 1999). 
This led to the search for ligands recognized by other TLRs. 
 Even though TLR4 was the first TLR whose ligand was identified, other TLRs 
were quickly mapped in the human chromosome using expressed sequence tags (Taguchi 
et al., 1996). The identification, molecular characterization, and cloning of TLRs 1 
through 5 were first published in 1998 (Rock et al., 1998). However, their function 
remained obscure as their ligands were still unknown. Gene targeting studies performed 
by Akira and colleagues led to the generation and phenotypic characterization of 
knockout mutant mice for TLRs 2, 6, and 9 (Hemmi et al., 2000; Takeuchi et al., 1999; 
Takeuchi et al., 2001).  They demonstrated that these TLRs can mediate induction of NF-
kB in mammalian cells in response to different sets of microbial molecules. This set the 
stage for an in-depth analysis of TLRs in microbial sensing (Takeuchi et al., 1999). 
The discovery of the Drosophila Toll, the identification of human TLRs, and the 
demonstration of LPS/endotoxin as ligand of human TLR4 were landmark discoveries in 
the field of immunology research, and led to a rapid increase in research studies focused 
on TLRs. Jules Hoffmann and Bruce Beutler, the principal investigators who respectively 
pioneered research on Drosophila Toll and TLR4 as the LPS receptor, were recently 
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awarded with the 2011 Nobel Prize in Physiology or Medicine together with Ralph 
Steinman, for his discovery of dendritic cells.   
Toll-like receptors 
Through sensing of microbial components, Toll-like receptors (TLRs) act as 
immediate triggers of the innate immune system in response to infection. TLRs are type 1 
transmembrane proteins that recognize pathogen-associated molecular patterns (PAMPs) 
in both the extracellular and intracellular compartments of the mammalian cell. Their 
extracellular domains contain 19-25 leucine-rich repeat (LRR) motifs involved in ligand 
recognition, while their intracellular domains, referred to as Toll/Il-1 receptor (TIR) 
domains, are involved in signaling. This intracellular signaling activates the transcription 
factor nuclear factor kappa B (NFκB), leading to the expression of proinflammatory 
cytokines such as TNF-α, IL-1β, IL-6, IL-8, and IL-12 [Reviewed in (Takeda & Akira, 
2005).   
There are currently ten TLRs identified and characterized in humans. They can be 
grouped primarily based on their subcellular location. TLRs 1,2,4,5,6, and 10 have direct 
access to the external environment as they are found on the surface of the cell membrane, 
while TLRs 3,7,8, and 9 are expressed within endosomal compartments inside the cell 
(Figure 1.1). All TLRs are directly involved in the recognition of conserved structural 
components of bacteria, viruses, and fungi. For example, TLRs 4, 5, and 9 recognize 
bacterial lipopolysaccharides, flagellin, and unmethylated cytosine-phosphate-guanine 
(CpG) DNA, respectively. On the other hand, TLRs 3, 7 and 8 discriminate viral double 
stranded and single stranded RNA [Reviewed in (Takeda & Akira, 2005).  
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The TLR signaling pathways 
Toll-like receptors and IL-1 receptors are two classes of membrane receptors that 
belong to a superfamily of proteins that have a Toll-IL-1 receptor (TIR) cytoplasmic 
domain in their structure (O’Neill, 2006). Following TLR recognition of specific 
microbial molecular patterns, it is now known that TLRs form either homodimers (in the 
case of TLR3, TLR4, TLR5) or heterodimers (in the case of TLR1/TLR2 and 
TLR2/TLR6) in order to initiate signaling (Figure 1.1). The dimerization of two TLRs 
upon recognition of ligand leads to the assembly of a TIR-TIR platform at the 
cytoplasmic domain of the receptors. This sets the stage for various cytoplasmic adaptor 
molecules to dock and initiate a signaling cascade, culminating in the expression of pro-
inflammatory cytokines, chemokines, and co-stimulatory molecules. The first signaling 
adaptor molecule to be characterized was MyD88. It has a domain that associates with 
the TIR domain of all human TLR dimers except for TLR3 (O’Neill, 2006). At present, 
there are three other adaptors aside from MyD88 that are involved in TLR signaling: the 
TIR-domain containing adaptor protein (TIRAP) also known as MyD88 adaptor-like 
(MAL), the TIR-related adaptor protein inducing interferon (TRIF), and the TRIF-related 
adaptor molecule (TRAM) (O'Neill et al., 2013). All of these adaptor proteins have TIR 
domains and are differentially recruited by TLRs through TIR-TIR interactions. Adaptor 
recruitment induces assembly and the activation of kinases in a series of downstream 
signaling events. The preferential association of TLRs with any of these four adaptor 
proteins provides differential responses and gene expression profiles (O'Neill et al., 
2013).  
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The MyD88-dependent pathway drives the synthesis of TNF-α, IL-1, and IL-6 
(Akira & Takeda, 2004). Upon binding to the TIR domain of TLRs, MyD88 recruits 
IRAK-4 through its “death” domain. The activation of IRAK-4 leads to the 
phosphorylation of IRAK-1, followed by the activation of the TNF receptor associated 
factor 6 (TRAF-6).  A series of ubiquitinylation and phosphorylation steps eventually 
leads to the degradation of the inhibitor of NF-κB kinase, thus allowing NF-κB 
translocation to the nucleus where transcription of proinflammatory genes takes place 
(O’Neill, 2006). In addition to NF-κB, p38 MAPK and an N-terminal kinase (JNK) are 
also activated downstream of TRAF-6 (Figure 1.1). For TLRs that are activated in 
endosomal compartments via a MyD88-dependent pathway (TLRs 7, 8, and 9), the 
transcriptional regulator that gets activated downstream of IRAK-4 is the interferon 
regulatory factor 7 (IRF-7), which has a role in the induction of the type I interferon 
(IFN) gene expression (Honda et al., 2005). MyD88 knockout mice are resistant to LPS, 
peptidoglycan, and lipopeptides. MyD88-deficient mice are also defective in T-cell 
proliferation (Takeda et al., 2003).The adaptor TIRAP/Mal is a bridging adaptor involved 
in the MyD88-dependent pathway of TLR4 and, to a lesser extent, TLR2, as TIRAP/Mal-
deficient mice had impaired responses to TLR2 and TLR4 ligands (Yamamoto et al., 
2002).  
TRIF is a third TIR adaptor molecule involved in the MyD88-independent 
signaling pathway observed in TLR3 and TLR4, and leads to the activation of interferon 
genes through the transcription factor interferon regulatory factor-3 (IRF-3) (Yamamoto 
et al., 2003). The fourth TIR adaptor protein TRAM is required for optimal recruitment 
of TRIF to TLR4 (Yamamoto et al., 2003). 
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 In addition to the four known TIR adaptor proteins, two other adaptors were 
discovered recently. The sterile-α- and armadillo-motif-containing protein 1 (SARM1) 
inhibits gene induction downstream of TRIF, but not of MyD88 (Carty et al., 2006). The 
sixth adaptor molecule is called B cell adaptor for PI3K (BCAP) (Ni et al., 2012; 
Troutman et al., 2012). BCAP is a cytoplasmic protein expressed in B cells, and were 
originally shown to mediate B-cell signaling through the B cell receptor and the co-
stimulatory molecule CD19 via activation of phosphoinositide 3-kinase (PI3K) (Okada et 
al., 2000). The phosphorylation of PI3K leads to Akt activation, which is critical for 
survival and proliferation of B cells (Inabe & Kurosaki, 2002). BCAP is also expressed in 
myeloid cells (such as macrophages, monocytes, and dendritic cells) and connects TLRs 
to PI3K/Akt pathway via a cryptic TIR domain (Troutman et al., 2012). Macrophages 
deficient for BCAP produce higher amounts of pro-inflammatory cytokines compared to 
wild-type controls upon stimulation of TLR agonists (Ni et al., 2012; Troutman et al., 
2012). Moreover, BCAP-deficient mice are more susceptible to LPS toxicity as well as a 
model of inflammatory colitis as a result of reduced PI3K activation, suggesting that 
BCAP acts as a negative regulator of inflammation through TLRs (Troutman et al., 
2012).  
The TLR2 sub-family 
TLR2 is phylogenetically related to TLRs 1, 6, and 10. The latter three receptors 
are the most highly related and are believed to have arisen from successive gene 
duplication as they share a common locus on chromosome 4 (Roach et al., 2005). The 
gene for TLR2 is also found on chromosome 4 (http://www.ncbi.nlm.nih.gov). 
Evolutionary studies show that the first of these gene duplication events took place 300 
11 
 
Mya leading to the establishment of TLR10 in the mammalian lineage. This was followed 
by the emergence of TLR1 and TLR6 in placental mammals 130 Mya (Temperley et al., 
2008). This presumably increases the diversity of agonists that the host is able to 
recognize. The extracellular domains of TLRs were also found to have a higher 
functional divergence compared to the cytoplasmic TIR domain, suggesting that the ECD 
is important for ligand recognition (Zhou, et al., 2007). 
Studies on chicken TLRs have revealed that they possess two TLR1 genes that 
share ancestral origins with the TLR1-6-10 cluster in mammals and two additional TLR 
isoforms that share origins with TLR2 (Temperley et al., 2008). The chicken TLRs are 
thought to predate the mammalian duplication events of the TLR1-6-10 cluster. Co-
expression of chTLR1 with chTLR2 resulted in lipopeptide-mediated NF-kB activation, 
suggesting that the ligand recognition function predates the mammalian divergence of the 
TLR1-6-10 cluster (Keestra et al., 2007; Temperley et al., 2008). As a result, human 
TLR10 has been speculated to be a potential partner for TLR2. In addition, the 
independent maintenance of TLR10 and its associated TIR domain suggest a distinct 
biological role for this receptor (Roach et al., 2005). Another unusual aspect about 
TLR10 is that there is no homologue in mice due to the interruption of the mouse TLR10 
gene by deletions and retroviral gene insertion (Hasan et al., 2005). However, TLR10 is 
conserved in rat, pig, cow, dog, macaque, platypus, and opossum among other mammals 
(Temperley et al., 2008).  
TLRs 1, 2, 6, and 10 are differentially expressed in various cell types, as 
measured by mRNA transcript levels. TLR1 is highly or ubiquitously expressed in most 
cell types (Muzio et al., 2000). TLR2 is widely expressed in myeloid-derived cells 
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(including monocytes, macrophages and dendritic cells), non-myeloid cells (such as 
endothelial and epithelial cells), and B cells. TLR expression pattern also depends on 
maturity of cells. In immature dendritic cells, for example, TLR1 and TLR2 are 
expressed at high levels, but gradually decrease as the DCs mature. Expression of TLRs 
is also upregulated in the presence of their specific agonists [Reviewed in (Akira & 
Hemmi, 2003)]. Unlike the wide expression pattern of TLR1 and TLR6, TLR10 
expression appears to be more tissue- and cell type- specific, indicative of the functional 
divergence of TLR10 from the other two receptors. TLR10 mRNA is highly expressed in 
lymphoid tissues such as the spleen, lymph nodes, thymus, tonsils, and lung (Chuang & 
Ulevitch, 2001). The analysis in isolated cell types has shown a high level of TLR10 
expression in the B cell lineage and weak expression in plasmacytoid dendritic cells 
(pDC), a cell type known to produce large amounts of IFNs upon recognition of viral 
components by TLRs (Bourke et al., 2003; Hasan et al., 2005). 
TLR2 recognizes a wide variety of molecules such as bacterial lipoproteins, 
atypical lipopolysaccharide (LPS) from non-enteric bacteria, peptidoglycan and 
lipoteichoic acid (LTA) from Gram-positive bacteria, lipomannans and 
lipoarabinomannans from mycobacteria, zymosan yeast particles, and microbial 
components from spirochetes [Reviewed in (Takeda & Akira, 2005)]. The extracellular 
domain of TLR2 has been confirmed to interact directly with peptidoglycan from S. 
aureus (Iwaki et al., 2002) and the yeast cell wall particle zymosan (Sato et al., 2003). 
Studies in TLR2 knockout mice have demonstrated that TLR2 is absolutely required for 
cellular response to Staphylococcus aureus peptidoglycan and mycoplasmal lipopeptide 
(Takeuchi et al., 1999). Using TLR1- and TLR6-deficient mice, it has been shown that 
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TLR2 cooperates with TLR1 and TLR6 for the recognition of triacylated and diacylated 
lipopeptides, respectively (Ozinsky et al., 2000; Sandor et al., 2003; Takeuchi et al., 
2001; Takeuchi et al., 2002; Wyllie et al., 2000). It has also been shown that human 
TLR10 interacts with TLR2 by co-immunoprecipitation experiments, suggesting that 
TLR10 acts as another TLR2 co-receptor (Guan et al., 2010; Hasan et al., 2005).  
Recently, several studies have shown that TLR2 also serves as the receptor for 
endogenous ligands such as β-defensins (Funderburg et al., 2007; Gariboldi et al., 2008; 
Lee et al., 2008), eosinophil-derived neurotoxins (Yang et al., 2008), acute-phase serum 
amyloid A proteins, and high-mobility group box 1 (HMGB1) (Park et al., 2004; van 
Zoelen et al., 2009).  
TLR2 knockout mice serve as an excellent model for assessing the importance of 
the inflammatory response induced by TLR2 ligands in protecting the host from diseases. 
Studies using TLR1- and TLR2-deficient mice have shown that TLR1 and TLR2 are 
necessary for signaling induced by the triacylated outer surface lipoprotein (OspA) from 
Borrelia burgdorferi (Alexopoulou et al., 2002), the causative agent of Lyme disease. 
TLR2 knockout mice infected with B. burgdorferi have a higher bacterial load and 
develop greater ankle swelling due to Lyme arthritis several days post infection compared 
to their wild-type littermates (Wooten et al., 2002). Macrophages from TLR2-deficient 
mice are unresponsive to lipoproteins and are characterized by the lack of IL-6 
production (Wooten et al., 2002).  
TLR2 deficient mice have also served to establish TLR2 function in response to 
Streptococcus pneumoniae and Listeria monocytogenes infection. Serum IL-6 levels and 
bacterial load in the blood and peripheral organs were similar for both wild-type and 
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TLR2-deficient mice. However, it was observed that there is a higher bacterial load in the 
brain of TLR2 knockout mice compared to wild-type mice. As a result, TNF-α levels in 
the central nervous system are also greater in the TLR2-deficient mice. This increase 
correlated with an earlier time of death in untreated knockout mice due to pneumococcal 
meningitis (Echchannaoui et al., 2002).  
The role of TLRs in disease 
TLRs are important components in the regulation of both innate and adaptive 
immunity. Activation of TLRs in response to microbial infection leads to the production 
of a variety of proinflammatory cytokines, chemokines, and costimulatory molecules, an 
excess of which could lead to profound deleterious effects, including septic shock and 
death. A number of reports have implicated TLRs in the pathogenesis of chronic 
inflammatory and infectious diseases. TLR2, for example, has been linked to candidiasis 
(Netea et al., 2004), diabetes (Kolek et al., 2004), and cardiomyopathy (Eriksson et al., 
2003). It is quite logical to assume that there must be a mechanism that tightly regulates 
TLR-mediated activation of these proinflammatory molecules. Several mechanisms of 
negative regulation of TLR-mediated immune response exist [Reviewed in (Liew et al., 
2005)], some of which include production of extracellular decoy receptors, transcriptional 
regulation of TLRs, and prevention of intracellular signaling.  
Iwami et al. reported the existence of naturally-occurring soluble forms of TLR4 
in mice (Iwami et al., 2000). This soluble mouse TLR4 inhibited LPS-mediated TNF-α 
production as well as NF-kB activation in mouse macrophage cell lines (Iwami et al., 
2000). Naturally occurring soluble forms of TLR2 (varying in molecular weight) have 
been detected in human plasma, breast milk, and saliva (Kuroishi et al., 2007; LeBouder 
15 
 
et al., 2003). Stimulation of monocytes with Pam3Cys in the presence of soluble TLR2 
inhibits IL-8 production (LeBouder et al., 2003). Moreover, immunodepletion of soluble 
TLR2 from serum increases sensitivity of peripheral blood monocytes to Pam3Cys, as 
evidenced by increased IL-8 production (LeBouder et al., 2003). Ongoing studies in the 
lab (Johnson and Tapping, unpublished results) have shown that upon stimulation of 
monocytes with synthetic ligands for TLR2, there is an upregulation of TLR2 
transcription and a down-regulation of both TLR1 and TLR6 required for TLR2 
signaling, suggesting a regulatory response. How upregulation of TLR2 transcription 
correlates with the production of soluble TLR2 remains to be elucidated.  
Mutations in TLRs have profound effects on the development of inflammatory 
diseases. In humans, numerous polymorphisms have been associated with inflammatory 
diseases. For example, polymorphisms in the TLR4 gene have been linked to the 
development of septic shock from Gram-negative bacterial infections. The single 
nucleotide polymorphism D299G has been identified in human patients that exhibit poor 
response to LPS upon inhalation, thus making them susceptible to systemic inflammatory 
syndrome and an increased risk of septic shock (Agnese et al., 2002). As expected, since 
patients with the D299G polymorphism exhibit diminished response to Gram-negative 
pathogens, they have a decreased risk of atherosclerosis (Kiechl et al., 2002). In TLR2, 
patients that were heterozygous for the R753Q polymorphism were protected from late 
stage Lyme disease due to their impaired pro-inflammatory cytokine responses to 
lipoproteins from Borrelia (Schröder et al., 2005).  
MyD88 is a key adaptor molecule that functions downstream of all TLRs (with 
the exception of TLR3) and MyD88-deficient mice are susceptible to numerous 
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pathogens. A genetic study performed on nine children with a history of recurring 
pyogenic bacterial disease revealed deleterious mutations in the MyD88 gene. Fibroblast 
cell lines isolated from these MyD88-deficient patients stimulated with IL-1β exhibit no 
phosphorylation of the mitogen-activated protein kinases (MAPKs) p38 and c-Jun N-
terminal kinase (JNK), and no production of IL-6, IL-8, interferon-β (IFN-β), and IFN-λ. 
Interestingly, recurring severe infections are no longer clinically observed in patients 
beyond 6 years of age, suggesting either there are other redundant innate immune 
mechanisms independent of the MyD88 signaling pathway that compensate for the 
clearance of pathogens, or the development of the adaptive immune system at later age 
compensates for the MyD88 mutation (von Bernuth et al., 2008). In an earlier study, 
children suffering from recurring infections and poor inflammatory response were found 
to have a deficiency in IRAK-4, thus affecting the TIR-IRAK signaling pathway. Blood 
cells and fibroblast cells from these patients did not respond to agonists for TLRs 1 
through 6 and TLR9, based on the absence of NF-kB and p38-MAPK activation (Picard 
et al., 2003).  
Accessory molecules that assist in TLR recognition of agonists 
 Some TLRs possess accessory molecules that increase their sensitivity towards 
minute amounts of agonists. Accessory molecules of TLRs also direct specific 
downstream signaling events, as in the case of TLR4, which uses MAL to activate the 
MyD88 pathway and TRAM to engage the TRIF pathway (Figure 1.1). As previously 
mentioned, TLR4 is the receptor for LPS molecules from Gram-negative bacteria. TLR4 
recognition of LPS requires the assistance of three different accessory molecules, namely 
the LPS-binding protein (LBP), CD14, and MD-2. LBP is a serum protein that binds to 
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LPS (Tobias et al., 1986) and catalytically delivers it to CD14, rendering cells more 
sensitive to LPS by at least 1,000-fold (Wright et al., 1990).  CD14 is a GPI membrane-
anchored glycoprotein in myeloid cells (Antal-Szalmas et al., 1997; Haziot et al., 1988; 
Setoguchi et al., 1989), but a soluble form of the protein is also found in the serum 
(Funda et al., 2001; Haziot et al., 1993). Both membrane-bound and soluble forms of 
CD14 are able to mediate LPS responses (Frey et al., 1992; Lee et al., 1993). Several 
biophysical studies have demonstrated that CD14 delivers the monomeric form of LPS to 
MD-2 (Gioannini et al., 2005; Nagai et al., 2002). Myeloid differentiation factor 2 (MD-
2) is a small protein that physically associates with TLR4 and confers LPS 
responsiveness to TLR4 (Hoshino et al., 1999; Schromm et al., 2001). Taken together, 
LBP delivers monomeric LPS to CD14, which then presents the agonist to either soluble 
MD-2 or to MD-2 bound to TLR4. 
Accessory molecules also directly assist in TLR2 stimulation [Reviewed in (Botos 
et al., 2011; Kang & Lee, 2011). LBP has been shown to physically bind various TLR2 
agonists, and enhance TLR2 sensing of microbial agonists in cell-based assays (Schröder 
et al., 2004; Schröder & Schumann, 2005). However, very little information is available 
about how LBP interacts with TLR2. Additionally, it is not well understood how CD14 
mediates lipopeptide recognition and how it delivers the agonist to the TLR1/2 complex. 
There have been conflicting reports on the affinity of CD14 for lipidated agonists. Also, 
conflicting reports have been made with regards to how CD14 enhances Pam3CSK4 
recognition of the TLR1/2 complex. Using fluorescence resonance energy transfer 
(FRET), confocal microscopy, and flow cytometry to demonstrate protein interactions, 
Manukyan et al. (Manukyan et al., 2005) proposed that CD14 facilitates binding to 
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lipoprotein, followed by formation of a stable receptor complex composed of lipoprotein, 
CD14, TLR2, and TLR1. Similarly, using both coimmunoprecipitation experiments as 
well as surface plasmon resonance analysis, Nakata et al. (2006) demonstrated that CD14 
enhances recognition of the synthetic triacylated lipopeptide Pam3CSK4 by the 
TLR1/TLR2 complex and that it directly binds Pam3CSK4. However, in contrast to the 
results generated by Manukyan et al. (2005), they showed that CD14 does not 
coimmunoprecipitate with the TLR1/TLR2 receptor complex, suggesting that it does not 
stably bind to the complex. Despite all these data, the sequence of events following 
ligand recognition by TLR2, in cooperation with TLR1 remains ill-defined and therefore 
requires further studies.  
The role of the extracellular domain of TLRs in ligand recognition 
Even though TLR1 and TLR6 are highly homologous, the greatest amount of 
variation occurs in the ECD, which is the region responsible for ligand recognition 
(Takeuchi et al., 1999). The TLR ECD forms an evolutionarily conserved structure 
comprised of the leucine rich repeat (LRR) motifs. Each LRR is typically made up of 22-
29 amino acid residues starting with a consensus sequence of LxxLxLxxN (Bell et al., 
2003; Botos et al., 2011; Kang & Lee, 2011). TLR1, TLR2, and TLR6 each have 20 
LRRs with N-terminal LRR-NT and C-terminal LRR-CT capping modules (Jin et al., 
2007; Kang et al., 2009). Upon protein folding, the LRRs stack upon one another to form 
a solenoid structure with each LRR forming a complete turn of the solenoid.  The entire 
solenoid is bent with a concave and convex side.  The hydrophobic residues of each LRR 
form short β-strands that collectively form parallel β sheets lining the concave side (Bella 
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et al., 2008). The convex side is made up of loops and α-helices formed by the variable 
regions of each LRR (Bella et al., 2008). 
To date, the crystal structures of seven TLRs in complex with their respective 
agonists have been solved: TLR1/TLR2/Pam3CSK4 (Jin et al., 2007), 
TLR2/TLR6/Pam2CSK4 (Kang et al., 2009), TLR4/MD2/LPS (B. S. Park et al., 2009), 
TLR3/double-stranded RNA (Liu et al., 2008), TLR5/FliC flagellin (Yoon et al., 2012), 
and TLR8/single-stranded RNA (Tanji et al., 2013). The TLR4/MD-2/LPS complex 
reveals that five of the six lipid chains of LPS are buried inside the hydrophobic pocket of 
MD-2, which is in turn anchored to the concave surface of the TLR4 ECD. The sixth 
lipid chain of LPS interacts with hydrophobic phenylalanine residues on the surface of 
the neighboring TLR4 that is also bound to another MD-2 and LPS molecule (Park et al., 
2009). In the TLR3-dsRNA crystal structure, a double stranded RNA that is at least 45bp 
in length is sandwiched between the glycan-free surface of two TLR3 ECDs, with the 
dsRNA interacting at two sites in each of the TLR3 ECD – one near the N-terminus and 
the other near the C-terminus (Leonard et al., 2008; Liu et al., 2008). In the TLR5 
complex, one TLR5 ECD binds one molecule of FliC flagellin, and together, this TLR5-
FliC heterodimer binds to another TLR5-FliC to form a functional quaternary complex 
that is stabilized by a couple of interaction sites between FliC and the convex surface of 
the neighboring TLR5 molecule. TLR8 has been demonstrated to exist as a pre-formed 
homodimer that undergoes conformational changes upon binding to two molecules of a 
small/short single-stranded RNA ligand (Tanji et al., 2013). The unifying theme taken 
from all these available TLR-ligand crystal structures is that upon ligand binding, the 
TLRs undergo conformational changes to form a stable “m-shaped” complex that allows 
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the TIR cytoplasmic signaling domains of the two interacting TLRs to come into close 
proximity with one another. This sets the stage for intracellular signaling (Figure 1.2).  
Early mutational studies mapped the region of the TLR2 extracellular domain 
responsible for ligand recognition. Seven LRR motifs at the N-terminal region of the 
TLR2 extracellular domain are not required for recognition of di- or tri-palmitoylated 
peptides (Meng et al., 2003). Moreover, it has also been shown that the LRR regions 7-12 
of TLR2 are critical for species-specific recognition of triacylated lipopeptides (Grabiec 
et al., 2004). Similarly, domain swapping experiments on the extracellular domain of 
TLR 1 and TLR 6, each containing 19 LRR motifs, have shown that LRRs 9-12 of both 
TLR1 and TLR6 are important for recognizing ligands specific to these receptors 
(Omueti et al., 2005). Interestingly, a naturally-occurring but rare variant of TLR1 with a 
single nucleotide polymorphism P315L located at the outer loop of LRR motif 11 
exhibits attenuated responses towards synthetic lipopeptide as well as a variety of other 
microbial agonists (Omueti et al., 2007). These early mutational studies performed on the 
TLR1 and TLR2 ECD provided solid support for the crystal structure of 
TLR1/TLR2/Pam3CSK4 later solved by Jie-Oh Lee and colleagues (Jin et al., 2007). 
TLR2 is unique because instead of forming homodimers, it heterodimerizes with 
either TLR1 or TLR6 to recognize triacylated and diacylated lipoproteins, respectively. 
Lipoproteins are potent agonists of TLR2 and its co-receptors, which bind to the 
extracellular domain of the TLRs tightly and induce dimer formation by orienting the 
receptors in their proper signaling conformation. The triacylated synthetic agonist 
Pam3CSK4 coordinately binds TLR1 and TLR2. Two ester-bound palmitoyl chains are 
bound with a hydrophobic binding pocket of TLR2, while the single amide-bound 
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palmitoyl chain is accommodated within a narrow hydrophobic channel of TLR1 (Jin et 
al., 2007) (Figure 1.3). In TLR6, two phenylalanine residues (F343 and F365) block the 
entrance to its lipid-binding channel thus leading to the selectivity of the TLR2/TLR6 
pair for diacylated lipopeptides (Kang et al., 2009). 
Thesis outline 
Despite the availability of the TLR1/TLR2/Pam3CSK4 crystal structure, it remains 
unclear as to how TLR2 and its co-receptors recognize naturally-occuring ligands to form 
the ternary complex and how accessory proteins play a role in the delivery of monomeric 
forms of microbial agonists to the TLRs. It has been proposed that the large surface area 
of the TLR extracellular domain confers TLRs with the ability to bind a broad range of 
ligands (Bell et al., 2003), but there has been very little work showing the physical 
interaction of the TLR2 sub-family of receptors to their respective natural agonists.  The 
studies described here aim to further our understanding of the molecular mechanisms by 
which TLR2, in cooperation with either TLR1 or TLR10, recognize a wide array of 
PAMPs and form a stable ternary complex.  
This chapter provides an overview of Toll-like receptors (TLRs), focusing on the 
members of the TLR2 sub-family. Chapter 2 describes the biophysical studies we 
performed to elucidate the role of LBP and CD14 in TLR1/TLR2/Pam3CSK4 ternary 
complex formation. These studies utilized functional soluble forms of human LBP, CD14 
and the extracellular domains of TLR1 and TLR2. LBP and CD14 are accessory 
molecules known to be required in TLR4/MD2 sensing of LPS. Even though several 
studies have shown that both LBP and CD14 can bind to known TLR2 agonists, it is not 
clear how the two proteins play a role in the delivery of agonists to TLR1/TLR2 system. 
22 
 
We performed size exclusion chromatography experiments to demonstrate that the 
addition of substoichiometric amounts of either LBP or soluble CD14 (sCD14) to a 
mixture of TLR1, TLR2, and Pam3CSK4 significantly enhances ternary complex 
formation. Western blot analyses of the eluted fractions from the size exclusion column 
show that neither LBP nor sCD14 are physically associated with the final TLR1-TLR2-
Pam3CSK4 ternary complex. We also show that a naturally-occurring lipoprotein agonist 
from B. burgdorferi, outer surface protein A (OspA), can induce TLR1/TLR2 ternary 
complex formation. Furthermore, this complex formation can be enhanced by the 
addition of LBP and sCD14. Cell-based assays likewise reveal that the addition of either 
LBP or sCD14 to TLR1/TLR2-transfected HEK 293F cells grown in serum-free media 
can independently sensitize the cells to low amounts of either Pam3CSK4 (0.6nM) or 
OspA (0.036nM), with sCD14 requiring a longer time to bind to the agonist prior to 
delivery to the TLRs. The amount of agonists used is approximately 20-fold lower than 
the typical amount (~13nM for Pam3CSK4) used for stimulation assays. Our results show 
that either LBP or sCD14 can drive ternary complex formation by acting as a mobile 
carrier of the triacylated lipopeptide Pam3CSK4 or lipoprotein OspA. These findings 
define a critical role for LBP and CD14 in TLR2 signaling with implications for 
improved drugs designed to target this receptor system. 
Chapter 3 describes our efforts to quantitatively measure TLR-ligand interactions 
in order to assess the competition between TLR1 and TLR10 for the lipopeptide agonist 
and the co-receptor TLR2. We performed microtiter plate assays to qualitatively measure 
receptor-agonist interactions and demonstrated specificity of TLR2 binding to either 
TLR1 or TLR10 in the presence of a triacylated lipopeptide agonist. TLR2-Pam3CSK4 
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was also found to prefer TLR1 over TLR10 in our plate assays. Using the Octet system 
and purified proteins, we were able to measure the strength of TLR binding to a 12kDa 
lipoprotein and found that TLR1 has the highest affinity to the lipoprotein followed by 
TLR10, and finally by TLR2. However, we failed to get kinetic measurements for ternary 
complex formation due to the nature of both the purified proteins and the amphipathic 
nature of the lipopeptide agonist. The challenges encountered with the biosensors are 
discussed in detail in this chapter. 
Chapter 4 is a follow-up to the study initiated by Dr. Katherine Omueti, a 
previous graduate student in the laboratory. In her dissertation, she was able to generate 
TLR1 and TLR6 chimeric receptors via domain swapping experiments to demonstrate the 
extracellular regions required for recognition of the lipopeptides. Using the synthetic 
triacylated and diacylated agonists (Pam3CSK4 and Pam2CSK4, respectively), she was 
able to show that LRRs 9-12 of TLR1 and TLR6 are important for discrimination of the 
two ligands. Here we show that the same region (LRRs 9-12) of the TLR1 ECD is 
required for recognition of a variety of microbial cell wall components. To further 
delineate the residues important for TLR1 function, we screened a library of TLR1 clones 
with various single amino acid substitutions within LRRs 9 through 12 that were 
previously generated by random mutagenesis.  We found that the amino acids F314, 
P315, and Q316 within LRR 11 and V339 within LRR12 of TLR1, are involved in 
mediating cellular responses to other microbial agonists for TLR1/TLR2. The results 
demonstrate that regardless of the molecular structure of the agonist, the same critical 
residues of TLR1 are required for formation of an “m-shaped” heterodimeric complex 
with TLR2 to initiate cellular activation.  We attempted to demonstrate complex 
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formation of TLR1/TLR2 with either P. gingivalis LPS or mycobacterial lipomannan in 
solution using size exclusion chromatography. Unfortunately, we were never able to 
detect complex formation in solution, possibly due to a lower binding affinity of TLRs to 
non-lipoprotein agonists. 
Finally, Chapter 5 is a summary chapter that integrates all the work done and the 
findings described in previous chapters. Here we highlight the contributions and 
implications of this work to the exponentially expanding field of TLR studies. Because of 
their role as a first line of host defense against certain microbial pathogens, TLR2 and its 
co-receptors may be a potential target for treating TLR-mediated inflammatory diseases. 
For example, understanding the role of accessory molecules LBP and CD14 could help 
treat lipoprotein-induced bacterial sepsis by blocking their ability to deliver lipoproteins 
to the TLRs. Knowing the order of ternary complex formation may be helpful in targeted 
gene therapy in which either inhibitory monoclonal antibodies against TLRs or soluble 
TLRs that compete with their membrane-bound counterparts may be used for treatment. 
Identifying the critical regions in the TLR1 extracellular domain important for ligand 
recognition and formation of a dimer interface with the co-receptor TLR2 can aid in the 
design of inhibitory compounds that can compete with the natural agonists in order to 
prevent the formation of a signaling ternary complex. Thus, understanding the molecular 
mechanism of how TLR2 signaling, in cooperation with either TLR1 or TLR10, is 
initiated would greatly facilitate the development of new therapeutic strategies for 
dampening microbial agonist-induced inflammation. 
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Figures 
 
Figure 1.1. Mammalian TLR signaling pathways. To date, 10 TLRs have been identified 
in humans
1
.  
 
 
  
                                                          
1
 Figure adapted from O’Neill, LAJ et al. 2013. Nat. Rev. Immunol 13:453-460. 
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Figure 1.2. The overall shape of the TLR-ligand complexes is strikingly similar
2
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2
 Figure adapted from Kang, JY and Lee, J. 2011. Annu. Rev. Biochem. 80: 917-941; Yoon, S et 
al. 2012. Science 335: 859-864; and Tanji, H et al. 2013. Science 339: 1426-1429. 
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Figure 1.3. The crystal structure of TLR1/TLR2/Pam3CSK4 ternary complex
3
. 
 
 
 
 
 
 
 
 
 
                                                          
3
 Figure adapted from Jin, MS et al. 2007. Cell 130: 1073-1075. 
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CHAPTER TWO 
HUMAN LBP AND CD14 INDEPENDENTLY DELIVER TRIACYLATED 
LIPOPROTEINS TO TLR1 AND TLR2 AND ENHANCE FORMATION OF THE 
TERNARY SIGNALING COMPLEX
4
 
Introduction 
As central elements of the innate immune system Toll-like receptors provide a 
first line of immune defense against infectious agents. Through direct sensing of 
bacterial, fungal or viral components TLRs activate intracellular signaling events that 
drive the cellular expression and release of immune mediators (Akira et al., 2009). These 
activation events not only induce inflammatory processes, but also initiate and orchestrate 
the long lasting protective responses of the adaptive immune system (Iwasaki & 
Medzhitov, 2004). Humans possess 10 TLR family members, numbered 1 through 10, 
subsets of which are expressed in leukocytes and the epithelial cells of mucosal surfaces 
(Muzio et al., 2000; Zarember & Godowski, 2002). TLRs 1, 2, 4 and 6 are expressed on 
the plasma membrane, sense microbial and fungal cell wall components and stimulate the 
production of classic proinflammatory molecules. TLRs are type-1 transmembrane 
receptors comprised of an extracellular leucine rich repeat domain and an intracellular 
TIR (Toll-Interleukin-1Receptor homology) signaling domain. TLRs signal via ligand-
induced receptor dimerization resulting in the juxtaposition of two TIR domains which  
act as a scaffold for the recruitment of proximal signaling adaptor molecules (Akira et al., 
2006; O'Neill, 2008).  
 
                                                          
4
 Ranoa, D.R.E., Kelley, S.L., and Tapping, R.I. Journal of Biological Chemistry. 2013 April 5, 
288(14): 9729-9741. 
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The potent proinflammatory activity of Gram-negative bacterial 
lipopolysaccharide (LPS; endotoxin) can be largely ascribed to activation of the cell 
surface TLR4 complex (Poltorak et al., 1998). MD-2, a small secreted protein associated 
with TLR4, is largely responsible for the direct binding of LPS; an event that results in 
TLR4 homodimerization and proinflammatory gene expression (Nagai et al., 2002; 
Shimazu et al., 1999). LPS is a highly amphipathic molecule that naturally exists in 
solution as large aggregates.  LPS-binding protein (LBP) and CD14 are two proteins 
whose coordinate actions result in the disaggregation and delivery of LPS monomers to 
the TLR4-MD-2 complex. LBP is a 60kDa glycoprotein, and a member of the fatty-acid 
binding protein superfamily, which is expressed in the liver and released into the 
bloodstream (Schumann et al., 1990; Tobias et al., 1986).  CD14 is a 55kDa GPI 
membrane-anchored glycoprotein on myeloid cells (Antal-Szalmas et al., 1997; Haziot et 
al., 1988; Setoguchi et al., 1989; Wright et al., 1990) and also exists as a soluble protein 
found in a variety of body fluids (Funda et al., 2001; Haziot et al., 1993).  Numerous 
biophysical studies have revealed that CD14 delivers LPS monomers to MD-2  (da Silva 
Correia et al., 2005; Kim et al., 2007; Nagai et al., 2002; Park et al., 2009; Poltorak et al., 
1998; Shimazu et al., 1999; Teghanemt et al., 2008). Since CD14 binds LPS aggregates 
poorly, the efficiency of TLR4-mediated cell activation is greatly enhanced by LBP 
which quickly disaggregates LPS and then catalytically delivers LPS monomers to CD14 
(Schumann et al., 1990; Wright et al., 1990).  In the presence of both LBP and CD14, the 
sensitivity of TLR4-expressing cells to LPS is enhanced more than 100-fold (Martin et 
al., 1992; Schumann et al., 1990; Ulevitch & Tobias, 1999). 
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TLR2 mediates inflammatory responses to a wide variety of lipidated microbial 
components including bacterial lipoproteins, atypical lipopolysaccharides, and 
lipomannans (Hirschfeld et al., 2001; Lien et al., 1999; Vignal et al., 2003). Among these 
microbial agonists, bacterial lipoproteins are by far the most potent (Hirschfeld et al., 
1999; Lien et al., 1999; Ozinsky et al., 2000; Takeuchi et al., 1999). OspA, an outer 
surface protein of the lyme disease-causing bacterium Borrelia burgdorferi, is a widely 
studied bacterial lipoprotein with potent TLR2 stimulatory activity (Brandt et al., 1990; 
Erdile & Guy, 1997; Morrison et al., 1997). The immunogenic activity of OspA requires 
the N-terminal acyl chains of the lipoprotein (Erdile et al., 1993; Weis et al., 1994). 
Pam3CSK4 is a triacylated N-terminal analogue of OspA and is a widely used synthetic 
lipopeptide agonist for TLR2 (Hoffmann et al., 1988). TLR2-mediated cellular responses 
are the result of microbial agonist-induced TLR2 heterodimerization with either TLR1, 
TLR6 or TLR10 (Guan et al., 2010; Takeuchi et al., 2000; Takeuchi et al., 2001).  The 
crystal structure of human TLR1 and TLR2 bound to Pam3CSK4 reveals that the 
lipopeptide coordinately binds to both receptors to form a stable TLR1-TLR2-Pam3CSK4 
ternary signaling complex (Jin et al., 2007). In this coordinate binding, two acyl chains of 
Pam3CSK4 accommodate a hydrophobic pocket of TLR2 and the third acyl chain 
accommodates a narrow hydrophobic channel of TLR1 (Jin et al., 2007). These 
lipopeptide binding interactions drive TLR1 and TLR2 dimerization enabling the two 
intracellular TIR domains to form a scaffold which subsequently recruits adaptor 
molecules necessary for signaling (Jin & Lee, 2008). 
Similar to LPS, LBP and CD14 have been shown to sensitize cells to lipopeptides 
and lipoproteins (Schröder et al., 2004; Sellati et al., 1998). Since LPS, lipopeptides and 
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lipoproteins are all amphipathic it has generally been assumed that similar to their 
interaction with LPS, LBP functions to disaggregate lipopeptide for delivery to CD14 
which subsequently delivers monomeric lipopeptide agonist to the corresponding TLR. 
However, the mechanism that underlies LBP- and CD14-mediated lipoprotein 
sensitization has not been formally explored. In this study, we examined the role of LBP 
and CD14 in the physical generation of the ternary TLR1-TLR2-lipopeptide complex by 
performing biophysical measurements with functional soluble forms of the TLR1 and 
TLR2 extracellular domains. We found that either LBP or sCD14 was able to 
independently enhance ternary TLR1-TLR2-Pam3CSK4 complex formation even at sub-
stoichiometric concentrations, and that neither protein is associated with the final ternary 
complex. We also found, in cell based assays, that the sensitivity of cells to minute 
amounts of agonist was enhanced by the addition of either LBP or sCD14. 
Materials and Methods 
Reagents 
The synthetic bacterial lipopeptide (S)-[2,3-Bis(palmitoyloxy)-(2-RS)-propyl]-N-
palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH•3HCl] (Pam3CSK4) was purchased from Enzo 
Life Sciences (formerly Alexis Biochemicals; Plymouth Meeting, PA). The non-acylated 
synthetic peptide S-[2,3-bis(acetyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-
[S]-lysyl-[S]-lysyl-[S]-lysine x 3 CF3COOH (Ac2CSK4) was purchased from EMC 
Microcollections (Tuebingen, Germany). The recombinant outer surface protein A 
(OspA) purified from Borrelia burgdorferi bacterial extract (Recombitek Lyme) was 
purchased from Merial Inc. (Athens, GA). 
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HRP-conjugated anti-FLAG (clone M2) monoclonal Ab was purchased from 
Sigma Aldrich (St. Louis, MO), while the HRP-conjugated anti-hemagglutinin (HA) 
monoclonal antibody was purchased from Miltenyi Biotec Inc. (Auburn, CA). 
Unconjugated polyclonal anti-human LBP and anti-human CD14 goat IgG antibodies 
were kind gifts from Dr. Peter Tobias (The Scripps Research Institute, La Jolla, CA). 
Anti-OspA rabbit IgG polyclonal antibody was purchased from Rockland 
Immunochemicals, Inc. (Gilbertsville, PA). The secondary antibodies, HRP-conjugated 
rabbit anti-goat IgG and HRP-conjugated goat anti-rabbit IgG were purchased from 
Jackson ImmunoResearch Laboratories (West Grove, PA). The unconjugated anti-human 
TLR1 mAb (clone GD2.F4, CD281) and anti-human TLR2 mAb (clone T2.5, CD282) 
were obtained from eBioscience (San Diego, CA).  
Human LBP from Xoma Corp. (Berkeley, CA) was generously provided by Dr. 
Theresa L. Gioannini and Dr. Jerrold P. Weiss (University of Iowa, Iowa City, IA). Low 
endotoxin albumin from bovine serum was purchased from Sigma Aldrich (St. Louis, 
MO), and human serum albumin (25%) was obtained from Octopharma (Hoboken, NJ). 
Human soluble CD14 used in HEK 293F cell-based assays was purchased from 
Peprotech Inc. (Rocky Hill, NJ). 
Construction and expression of soluble TLR-Fc fusion proteins 
Soluble extracellular domains of FLAG-tagged TLR2, HA-tagged TLR1, and 
HA-tagged TLR1P315L were produced using the hybrid LRR technique described by Jin, 
MS et al. (Jin et al., 2007). The soluble TLR-Fc fusion expression vectors were 
constructed by overlap extension PCR using primers and methods described previously 
(Guan et al., 2010). Briefly, coding regions for the extracellular domains of TLR1 or 
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TLR2 (aa 22-476 and 17-508, respectively) were fused to the highly conserved LRR C-
terminal capping module of a hagﬁsh variable lymphocyte receptor (VLRB.61) by 
overlap extension PCR and subsequently cloned as BglII/NheI fragments into a modified 
pDisplay vector (kindly provided by Dr. David M. Kranz, Department of Biochemistry, 
University of Illinois at Urbana Champaign). This vector contains the Fc domain of 
human IgG1 downstream of the NheI site, and the sequence for either the FLAG or HA 
tag upstream of the BglII site. A thrombin cleavage site (LVPRGS) was added at the 3’-
end of the TLRvlr hybrid to allow cleavage of the soluble TLR from the Fc fusion 
protein. Recombinant DNA plasmids were verified by DNA sequencing (UIUC Core 
Sequencing Facility). 
Freestyle HEK 293F cells (Invitrogen Life Technologies) were adapted to grow in 
Freestyle serum-free expression medium (Invitrogen Life Technologies). Adherent cells 
were cultured at 37˚C in a humidiﬁed environment containing 5% CO2. Stable HEK 293F 
cell lines expressing soluble TLR2, TLR1, and TLR1P315L were generated by transfection 
followed by G418 selection and limiting dilution as previously described (Guan et al., 
2010). Stable cell lines were grown in Freestyle serum-free expression medium 
containing 0.25 mg/ml G418 and cultured in suspension at 37
o
C with continuous shaking 
at 125 rpm in a humidified environment containing 8% CO2.  
Purification of soluble TLRs 
Soluble TLR-Fc fusion proteins were purified from stable HEK 293F cell 
supernatant by affinity chromatography using Protein G sepharose for fast flow (GE 
Healthcare; Piscataway, NJ) on an AKTA prime purification system (GE Healthcare), as 
previously described (Guan et al., 2010). The Fc tag was removed after the first round of 
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purification by adding restriction grade thrombin protease (Novagen; Madison, WI) at a 
concentration of 1U thrombin per 0.25mg TLR-ECD-Fc protein. After 18 hours 
incubation at room temperature, the TLR extracellular domain was separated from the Fc 
fragments by another round of affinity chromatography in the AKTA prime system using 
a 1ml pre-packed protein A column (Pierce, Rockford, IL) and PBS pH 7.4 running 
buffer. The TLRs were concentrated from the flow-through using an Amicon Ultra-4 
centrifugal device (Millipore) and centrifuged at 2500xg for 15-25 minutes at 4
o
C, to a 
volume of 0.5ml. The concentrated protein was then loaded on a Superdex 200 10/300GL 
gel filtration column (GE Healthcare) in PBS pH 7.4 running buffer at a flow rate of 0.5 
ml/min. The eluted fractions containing monomeric TLR extracellular domains were 
pooled and concentrated using size exclusion centrifugation (Amicon). Final protein 
concentration after three rounds of purification was measured using the Pierce BCA 
protein assay kit (Rockford, IL). The protein yield for recombinant soluble TLR1, 
TLR1P315L, and TLR2 were 0.5mg, 0.3mg, and 0.25mg per liter of media, respectively. 
Protein purity was determined by mass spectrometry (Mass Spectrometry Laboratory, 
School of Chemical Sciences, University of Illinois at Urbana-Champaign) using MALDI 
as the ionization technique and sinapinic acid as a calibration matrix.  
Soluble TLR ELISA assays  
Briefly, 0.5 ug/mL of commercially available anti-TLR 1 (clone GD2F4) and anti 
TLR2 (clone T2.5) monoclonal antibodies were coated onto 96-well microtiter plates at 
4
o
C overnight. Non-specific binding was blocked by 5% BSA in PBS. Diluted samples of 
purified sTLR proteins (1.0 ug/mL) were added to the wells, and incubated at room 
temperature for 2 hours. Binding of soluble TLR1 and TLR2 to their respective 
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antibodies was detected using HRP-conjugated anti-HA antibody and HRP conjugated 
anti-FLAG antibody, respectively, followed by the addition of o-phenylenediamine 
(OPD) substrate. The colorimetric detection was quantified by measuring absorbance at 
490 nm.  
Soluble TLR competition assays 
SW620 cells (a human colonic epithelial cell line, ATCC CCL-227) were seeded 
in 24-well plates overnight at a density of 1x10
5
 cells/ml in RPMI 1640 media 
supplemented with 10% (v/v) FBS and 2mM L-glutamine.  Cells were co-transfected 
with full-length genes for membrane bound TLR2 and TLR1 together with a firefly 
luciferase gene driven by the IL-8 promoter and a Renilla luciferase gene driven by a 
basal promoter (pRL-null) as a transfection control (Promega; Madison, WI). 
Transfections were performed using a cationic lipid agent, Fugene-6 (Roche), at a 4:1 
lipid:DNA ratio. Forty-eight hours post-transfection, the media was replaced with Gibco 
Opti-mem media (Invitrogen Life Technologies) and the cells were stimulated for 6 hours 
by the addition of the triacylated agonist Pam3CSK4 (10ng/ml) with or without sTLR2 or 
sTLR1 (1ug/ml). Following the manufacturer’s protocol for the dual luciferase assay 
(Promega), cell lysates were collected 6 hours post-stimulation and analyzed for firefly 
and Renilla luciferase activity using a BioTek Synergy HT plate reader (BioTek; 
Winooski, VT). The transfection efficiency across different wells was normalized by 
dividing the firefly luciferase activity by the Renilla luciferase control.  
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Generation of bioactive soluble CD14 
Human soluble CD14 protein was cloned, expressed, and purified as previously 
described (Kelley et al., 2012), with the following exceptions.  Briefly, human CD14 (aa 
1-337) was amplified from genomic DNA and cloned into a modified pDisplay vector 
(kind gift from Dr. David Kranz, University of Illinois, Urbana-Champaign), preceding a 
thrombin cleavage site (LVPRGS) and the Fc domain of human IgG1.  The final 
construct was sequenced (UIUC Sequencing Center) following site directed mutagenesis 
(C306S) via primer extension to avoid unnatural disulfide bonding resulting from the 
truncated coding region of our construct.  Following transfection and stable selection of 
human HEK 293F cells (Invitrogen), human soluble CD14 was purified from cell 
supernatant in three chromatographic steps, including protein G affinity chromatography, 
thrombin cleavage, protein A affinity chromatography, and size-exclusion 
chromatography.  Finally, fractions containing CD14 were pooled and concentrated to 10 
mg/mL using an Amicon Ultra-4 unit (Milipore) as measured by Pierce BCA assay 
(Rockford, IL).  Human soluble CD14 (aa 1-337; C306S) was stored at 4
o
C for up to 6 
months and is bioactive as measured by LPS binding activity and ability to facilitate LPS-
induced IL-8 production from human epithelial SW620 cells (Kelley et al., 2012). 
Size exclusion chromatography assays 
The TLR1-TLR2-lipopeptide ternary complex was formed by pre-incubating 
0.25uM TLR2, 0.25uM TLR1, and 2.5uM Pam3CSK4 (with or without 0.05uM LBP 
and/or 0.25uM sCD14) in PBS pH 7.4 buffer to a final volume of 0.5ml. The mixture was 
incubated in a 37
o
C water-bath for 2 hours and injected into a Superdex 200 10/300GL 
gel filtration column (GE Healthcare) at a flow rate of 0.5 ml/min in PBS pH 7.4 running 
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buffer. Twenty minutes after injection of the sample, 0.5ml fractions were collected 
covering one column bed volume (about 24ml, 48 min). The chromatogram was recorded 
using a manual UV recorder. The data was then re-plotted using the xyExtract v5.1 graph 
digitizer software (Wilton and Cleide Pereira da Silva; Campina Grande, Paraíba, Brazil). 
Eluted fractions were separated on a 7.5% SDS-PAGE gel and transferred to an 
Immobilon-P membrane (Millipore). The membranes were blocked with 5% non-fat dry 
milk (NFDM) in TBS buffer containing 0.05% Tween-20. Western blotting was 
performed to detect TLR1 and TLR2 using HRP-conjugated anti-HA and anti-FLAG 
antibodies (both diluted at 1:1000 in 5% NFDM), respectively. LBP and/or CD14 was 
detected using either a polyclonal goat anti-LBP or goat anti-CD14 (diluted 1:500 in 5% 
NFDM), followed by a HRP-conjugated rabbit anti-goat IgG polyclonal antibody (diluted 
1:5000 in 5% NFDM). Chemiluminescence was detected using the Pierce ECL Western 
blotting substrate (Rockford, IL). Membranes were then exposed to a HyBlot CL 
autoradiograpy film (Denville Scientific Inc.; Metuchen, NJ) and developed.  
Cell activation assays 
HEK 293F cells were seeded in a 48-well tissue culture plate overnight at a 
density of 1.6x10
5
 cells/ml (50,000 cells/well) in Freestyle serum-free expression 
medium (Invitrogen Life Technologies). Cells were co-transfected with 50ng each of 
TLR1 and TLR2 together with 75ng of a firefly luciferase reporter gene driven by an NF-
kB promoter and 25ng of a Renilla luciferase (pRL-null) transfection control (Promega; 
Madison, WI). Transfections were performed using a cationic lipid agent, 293fectin 
(Invitrogen), at a 3:1 lipid:DNA ratio. Forty-eight hours post-transfection, LBP, sCD14 
(Peprotech), or a combination of both, was added to the wells to a final concentration of 
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0.1ug/ml. Cells were then stimulated with 1 ng/ml agonist for 6 hours. Alternatively, LBP 
and/or sCD14 were pre-incubated with the agonists for 1 hour at 37
o
C prior to addition to 
cells. Following the manufacturer’s protocol for the dual luciferase assay (Promega), cell 
lysates were collected and analyzed for NF-kB-luciferase and renilla activity using a 
BioTek Synergy HT plate reader (BioTek; Winooski, VT). The transfection efficiency 
across different wells was normalized by dividing the IL-8 luciferase activity with the 
Renilla activity. 
Results 
Purified soluble TLRs are monomeric and biologically functional 
To define the role of LBP and sCD14 in driving the formation of a TLR1-TLR2-
lipoprotein ternary complex, recombinant soluble extracellular domains of TLR1 and 
TLR2 were isolated and purified from HEK 293F cells by affinity chromatography (See 
Materials and Methods). As expected, both proteins were isolated and verified as 
monomeric proteins by gel filtration chromatography (Figs. 2.1A and 2.1B). The size of 
the protein monomers were estimated using gel filtration standard markers that are 
composed of globular proteins. Based on these standard proteins, TLR1 and TLR2 were 
estimated to have a relative molecular weight of about 65 kDa and 83 kDa, respectively. 
This is slightly different from the molecular mass calculated by mass spectrometry (70.65 
kDa for TLR1 and 71.85 kDa for TLR2) since TLRs are extended proteins and not 
globular in nature.  TLR1 and TLR2 were recognized by their respective monoclonal 
antibodies and did not exhibit any cross reaction indicating that each protein is properly 
folded (Fig. 2.1C).  
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To assess the biological activity of the purified proteins, we performed TLR 
reconstitution experiments in human epithelial cells (SW620) and measured the relative 
expression of a luciferase reporter gene driven by the human IL-8 promoter. As expected, 
luciferase expression was induced in cells transfected with TLR1 and TLR2 upon 
stimulation with 10ng/ml Pam3CSK4. However, upon addition of either soluble TLR1 or 
soluble TLR2, SW620 cells showed diminished responses to Pam3CSK4, suggesting that 
each soluble receptor has bioactivity presumably by either actively competing for the 
agonist or by forming a signaling-deficient complex with the transmembrane TLR partner 
(Fig. 2.1D). 
LBP and sCD14 enhance TLR1-TLR2-Pam3CSK4 formation but are not part of the 
stable ternary complex 
To measure receptor complex formation, we performed size exclusion 
chromatography using a Superdex 200 column (GE Healthcare) to distinguish monomeric 
TLRs from larger TLR complexes.  First, we pre-incubated equimolar amounts of soluble 
TLR1 and TLR2 in the absence of agonist for two hours at 37
o
C, but did not observe the 
formation of larger TLR complexes by size exclusion chromatography (Fig. 2.2A). When 
soluble TLR1 and TLR2 were incubated for 2 hours at 37
o
C with a 10-fold molar excess 
of Pam3CSK4 a novel peak eluted at an earlier time compared to the monomeric proteins, 
which correspond to the expected size of a ternary TLR1-TLR2-Pam3CSK4 complex.  
Western blot analysis revealed that both TLR1 and TLR2 were present in the fractions 
that constitute the small peak with a calculated relative molecular weight of 
approximately 183 kDa (Fig. 2.2B). The modest peak size indicates that only a small 
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amount of stable ternary complex is formed from the incubation of purified soluble TLR 
monomers with lipopeptide agonist. 
Since LBP and CD14 are known to sensitize TLR1- and TLR2-mediated 
inflammatory responses to lipopeptides and lipoproteins, we assessed their ability to drive 
ternary complex formation. To this end, purified LBP and sCD14, along with TLR1, 
TLR2 and Pam3CSK4, were incubated for 2 hours at 37
o
C followed by size exclusion 
chromatography. This incubation resulted in a more robust peak corresponding to the 
ternary complex compared to that observed in the absence of LBP and sCD14 (Fig. 
2.2C). Western blot analysis revealed that LBP and sCD14 continued to elute in fractions 
expected of monomers suggesting that they are not part of the final ternary complex (Fig. 
2.2C). Additionally, a 2 hour incubation of LBP and sCD14 with Pam3CSK4 alone did 
not induce any higher order protein complexes (Fig. 2.2D). Ternary complexes were not 
formed when protein mixtures were loaded directly onto the gel filtration column, 
suggesting that incubation at 37
o
C is required to form stable complexes in solution (data 
not shown).  Taken together, these results demonstrate that LBP and sCD14 can enhance 
TLR1-TLR2-Pam3CSK4 ternary complex formation without becoming part of the stable 
complex. 
Lipopeptide induces TLR1 and TLR2 heterodimers, but not homodimers 
To demonstrate that lipopeptides induce heterodimers, and not homodimers, of 
TLR1 and TLR2, we incubated LBP, sCD14, and Pam3CSK4 together with either TLR1 
alone or TLR2 alone. Size exclusion chromatography revealed that neither TLR1 nor 
TLR2 form homodimers even in the presence of LBP, sCD14, and excess agonist (Figs. 
2.3A and 2.3B).  The two peaks observed in Fig. 2.3B correspond to the size discrepancy 
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between the soluble TLR2 monomer (relative molecular weight of ~87.3 kDa) and the 
sCD14 monomer (relative moleacular weight of ~48.3 kDa). Western blot analysis 
revealed that even though TLR1 and TLR2 did not form stable homodimers, sCD14 
behaved differently in the two conditions (Figs. 2.3A and 2.3B, right panel). In the 
presence of TLR1 alone (Fig. 2.3A right panel), sCD14 eluted in earlier fractions, while 
in the presence of TLR2, sCD14 elute in later fractions as a monomeric protein (Fig. 2.3B 
right panel). This suggests that sCD14 and TLR1 interact in a Pam3CSK4-dependent 
fashion. Since sCD14 behaves as a monomeric protein in the presence of all 5 
components, Fig. 2.3C suggests that the binding of TLR2 to the sCD14-TLR1-Pam3CSK4 
complex displaces sCD14 leading to formation of the final ternary TLR1-TLR2-
Pam3CSK4 ternary complex.  To our knowledge, this is the first experiment to suggest a 
defined order of events for ternary complex formation. 
P315L is a naturally-occurring TLR1 polymorphism that has previously been 
shown to greatly attenuate cellular responses to synthetic lipopeptides as well as a variety 
of other microbial TLR1 agonists (Omueti et al., 2007). Subsequent protein 
crystallography work has shown that P315 is physically located at the entrance of the 
hydrophobic channel of TLR1 and forms part of TLR1-TLR2 dimer interface in the 
ternary complex (Jin et al., 2007). We generated the soluble form of the TLR1 315L 
variant which, similar to wild type TLR1, purified as a monomeric protein with a relative 
molecular weight of 77.5 kDa calculated by size exclusion chromatography and a 
molecular mass of 70.84 kDa measured by mass spectrometry (Figs. 2.1A and 2.1B). We 
have previously demonstrated that the P315L mutation destroys the epitope of GD2F4, a 
monoclonal antibody against TLR1 that inhibits lipopeptide-induced cell activation 
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(Omueti et al., 2007). As expected, GD2F4 did not bind soluble TLR1 315L in our 
ELISA assay (Fig. 2.1C). To directly assess the effect of the P315L mutation on complex 
formation, we incubated TLR1 315L with TLR2, Pam3CSK4, LBP, and sCD14 for two 
hours at 37
o
C and analyzed the reaction products by size exclusion chromatography. In 
contrast to wild type TLR1, TLR1 315L did not form a stable ternary complex with 
TLR2 and Pam3CSK4 (Fig. 2.3D). The fact that TLR1 P315 is critical for ternary 
complex formation explains the highly attenuated responses of this naturally occurring 
TLR1 variant to triacylated lipopeptides. 
TLR1 and TLR2 form a ternary complex with the OspA lipoprotein of Borrelia 
burgdorferi 
We next tested our system using a naturally occurring lipoprotein, the outer 
surface protein A (OspA) from Borrelia burgdorferi. OspA is a 30 kDa membrane-
associated lipoprotein with a typical tripalmitoyl-S-glycerylcysteine (Pam3Cys) moiety 
covalently attached to the amino terminus of the protein (Belisle et al., 1994; Brandt et 
al., 1990). Although OspA has been shown to activate cells through TLR1 and TLR2, to 
date there has been no direct physical evidence demonstrating that OspA induces 
formation of a stable ternary complex. On the gel filtration column, OspA did not elute as 
a single peak at 30kDa, perhaps reflecting the amphipathic nature of the molecule which 
may drive aggregation and/or nonspecific binding to the column matrix (Fig. 2.4B).  
However, when TLR1 and TLR2 were incubated with a 5-fold molar excess of OspA 
prior to column loading, a small peak was observed in the region consistent with 
formation of a ternary TLR1-TLR2-OspA complex (Fig. 2.4C). When LBP, sCD14, 
OspA, TLR1, and TLR2 were incubated altogether, we observed a more robust peak 
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corresponding to the ternary complex, suggesting that addition of LBP and sCD14 
enhances TLR1-TLR2-OspA ternary complex formation (Fig. 2.4E). In the absence of 
OspA, TLR1 and TLR2 elute as monomers (Fig. 2.4A) as do LBP and sCD14 (Fig. 
2.4D). Taken together, our data demonstrate that, similar to Pam3CSK4, the naturally-
occurring OspA lipoprotein from B. burgdorferi induces ternary complex formation 
which is enhanced by the addition of LBP and sCD14.   
 Either LBP or sCD14 can independently enhance TLR1-TLR2-Pam3CSK4 ternary 
complex formation 
In the TLR4 system, it is known that LPS is sequentially delivered in monomeric 
form first by LBP to CD14 and then by CD14 to either soluble MD2 or the MD2-TLR4 
complex. To validate whether both LBP and sCD14 are required to enhance TLR 
recognition of lipopeptide, we assessed the ability of either protein to independently 
enhance TLR1-TLR2-Pam3CSK4 ternary complex formation. Surprisingly, we observed 
that addition of either LBP or sCD14 to the two hour incubation independently enhanced 
TLR1-TLR2-Pam3CSK4 ternary complex formation (Figs. 2.5B and 2.5C). Consistent 
with our earlier Western blot data, neither LBP nor sCD14 were part of the final stable 
complex (Figs. 2.5B and 2.5C). Bovine serum albumin (BSA), a well-established lipid 
carrier protein, did not enhance ternary complex formation (compare Fig. 2.5A with Fig. 
2.2B). To our knowledge, this is the first report showing that LBP can independently and 
directly deliver a triacylated lipopeptide to TLR1 and TLR2.  
To determine if enhanced ternary complex formation is mediated by sub-
stoichiometric amounts of either LBP or sCD14, varying concentrations of these proteins 
were independently incubated with a constant amount of TLR1, TLR2 and Pam3CSK4 for 
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two hours at 37
o
C followed by size exclusion chromatography analysis. Sub-
stoichiometric amounts of either LBP or sCD14 enhanced TLR1-TLR2-Pam3CSK4 
ternary complex formation even at 5nM, a concentration which is 50 times lower than 
that of each TLR, and 500 times lower than that of the Pam3CSK4 agonist in the reaction 
(Fig. 2.6A and 2.6B). This demonstrates that neither LBP nor sCD14 is consumed in the 
reaction and suggests that either protein can catalytically deliver lipopeptide agonist to 
the TLRs. Compared to CD14, ternary complex formation was far less dependent on the 
concentration of LBP suggesting that LBP is a more robust catalyst than sCD14 (Figs. 
2.6A and 2.6B). 
Cellular responses to microbial lipoproteins are enhanced by either LBP or sCD14 
To assess the biological significance of our biophysical measurements, we 
measured the effects of LBP and sCD14 on cellular responses to synthetic lipopeptide 
and natural microbial lipoprotein agonists. To this end, HEK 293F cells were transfected 
with full-length TLR1 and TLR2, together with a luciferase reporter gene driven by NF-
κB, and then stimulated with either Pam3CSK4 or OspA. To ensure that the cell activation 
assay completely lacked endogenous sources of either LBP or CD14, the HEK 293F cells 
were grown in serum-free media and maintained in this media throughout the assay. In 
the absence of LBP or sCD14, 1ng/ml of either Pam3CSK4 or OspA elicited a 20-fold 
induction of NF-κB-driven luciferase activity that was dependent on prior transfection of 
the HEK 293F cells with TLR1 and TLR2 (Fig. 2.7). Nanogram levels of LBP, but not 
sCD14 nor human serum albumin (HSA), enhanced the sensitivity of TLR1- and TLR2-
expressing HEK 293F cells to either Pam3CSK4 or OspA when compared to cells 
stimulated with agonists in the absence of any lipid carrier. We modified the same 
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experiment by pre-incubating either LBP or sCD14 with agonist for one hour at 37
o
C 
prior to addition to the HEK 293F cells. This pre-incubation had little effect on LBP-
mediated cell stimulation, but enabled sCD14 to significantly enhance the stimulation of 
cellular NF-kB to either Pam3CSK4 or OspA (Fig. 2.7). Taken together, these results 
demonstrate that either LBP or sCD14 can enhance cellular responses to lipopeptide or 
lipoprotein. This finding is entirely consistent with our biophysical studies which show 
that TLR1-TLR2-lipopeptide ternary complex formation is enhanced by either protein.  
The fact that sCD14, but not LBP, requires pre-incubation with the agonist to increase 
cellular responses is consistent with our biophysical data suggesting that sCD14 is a poor 
catalyst, compared to LBP, in the delivery of agonist to TLR1 and TLR2 (Fig. 2.6). The 
addition of both LBP and sCD14 further enhanced cellular responses to Pam3CSK4 and 
OspA over that of either sCD14 or LBP alone, suggesting that LBP and sCD14 may act 
in a cooperative manner to efficiently deliver the agonists to the TLRs (Fig. 2.7). 
Discussion 
LBP and CD14 have previously been shown to directly bind diacylated and 
triacylated lipopeptides (Schröder et al., 2004), suggesting a role in delivery of these 
potent agonists to the TLR2 system.  Despite the abundance of evidence demonstrating 
direct binding of lipopeptides to LBP and CD14, only a few studies have carefully 
examined the functional roles of these two proteins in the activation of TLR2. sCD14 has 
been shown to mediate the transfer of lipopeptides to TLR2 on the cell surface of HEK 
293 cells, CHO cells, and primary monocytes in vitro (Manukyan et al., 2005; Nakata et 
al., 2006; Vasselon et al., 2004). Pull-down assays performed with HEK cells 
overexpressing TLR1 and TLR2 have shown that sCD14 does not stably bind to the 
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TLR1-TLR2-Pam3CSK4 complex (Nakata et al., 2006). Additionally, immobilized TLR2 
incubated with preformed lipopeptide-sCD14 complexes has been shown to bind 
lipopeptide but not sCD14 (Vasselon et al., 2004). Our size exclusion chromatography 
experiments using entirely soluble components are consistent with the above findings in 
that LBP and sCD14 drive formation of TLR1-TLR2-Pam3CSK4 ternary complexes but 
are not themselves part of the final complex. Interestingly, in the absence of TLR2 we 
observed that both CD14 and TLR1 elute in earlier fractions (Fig. 2.3A). While not 
proven, this observation supports a model where, upon binding lipopeptide, CD14 stably 
interacts with TLR1 but is then displaced by TLR2 during formation of the final ternary 
complex.   
To date we are unaware of any studies that have formally assessed whether LBP 
and sCD14 function in coordinated or sequential fashion, similar to that established for 
the TLR4 system. Cell-based in vitro studies, suggest that lipopeptides are sequentially 
delivered from LBP to CD14 and then to TLR1-TLR2 (Schröder et al., 2003; Schröder et 
al., 2004). In this paper, we provide physical evidence that either LBP or sCD14 can 
independently catalyze the formation of a TLR1-TLR2-Pam3CSK4 ternary complex. 
Thus, unlike their non-redundant and sequential role in the delivery of LPS to the TLR4 
complex, our data suggests that LBP and sCD14 are functionally redundant in the direct 
presentation of lipopeptides to TLR1 and TLR2. To our knowledge, this is the first report 
demonstrating that LBP can deliver agonists directly to the TLRs in a CD14-independent 
manner. 
In addition to existing as a soluble protein found in body fluids (Krüger et al., 
1991), CD14 also exists as a glycophosphatidylinositol (GPI) anchored membrane 
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receptor (mCD14) predominantly expressed on the surface of myeloid cells (Haziot et al., 
1988). Flow cytometry experiments have demonstrated that LBP transfers lipopeptides to 
mCD14 on peripheral blood monocytes (Schröder et al., 2004). Importantly, in two 
independent studies, anti-CD14 antibodies have been shown to block the responses of 
mCD14-expressing myeloid cells to lipopeptide suggesting that in membrane form, 
CD14 is absolutely required for delivery of lipopeptides to TLR2  (Schröder et al., 2004; 
Sellati et al., 1998). While this may seem to contradict the data presented in this paper 
which shows a redundant function for LBP and sCD14, the mechanism of agonist 
delivery to TLRs may be different for membrane anchored versus soluble forms of CD14. 
Indeed, confocal microscopy and fluorescence resonance energy transfer studies have 
shown that upon lipopeptide binding, mCD14 stably physically associates with TLR1 and 
TLR2 (Manukyan et al., 2005). This situation is quite different from that observed for 
sCD14 which does not form part of the ternary complex. 
Pam3CSK4 is a 1.5kDa amphipathic molecule which forms aggregates or micelles 
in solution and exhibits non-specific hydrophobic interactions. The TLRs, on the other 
hand, recognize monomeric forms of this triacylated lipidated agonist (Jin et al., 2007). 
Thus, the aggregated state of Pam3CSK4 in PBS buffer may explain why the formation of 
ternary complex in solution is inefficient and could be enhanced by the disaggregating 
activities of LBP or sCD14. It is well established that human LBP and CD14 directly 
bind to a variety of TLR2 agonists which largely comprise acylated microbial 
components. The agonists include bacterial lipoproteins (Sellati et al., 1998; Sellati et al., 
1999; Wooten et al., 1998), Gram-positive bacterial lipoteichoic acids (Fan et al., 1999; 
Schröder et al., 2003), mycobacterial lipomannans and lipoarabinomannans (Elass et al., 
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2007), pneumococcal peptidoglycans (Weber et al., 2003), and Treponema-derived 
glycolipids (Opitz et al., 2001). Thus, LBP and CD14 may function to disaggregate and 
deliver a variety of acylated microbial agonists to the TLR2 system. 
LBP-deficient mice are hyporesponsive to LPS as well as to Gram-negative 
bacteria as evidenced by lower levels of serum inflammatory cytokines and lower 
survival rates following infection with Salmonella or E. coli (Jack et al., 1997; Knapp et 
al., 2003; Wurfel et al., 1997). In contrast, the responses of LBP-deficient mice are 
indistinguishable from that of wild-type mice following infection with the Gram-positive 
organisms Staphylococcus aureus (Fierer et al., 2002) and Streptococcus pneumoniae 
(Branger et al., 2004). Additionally, LBP deficiency has no effect on murine responses to 
intranasal infection with mycobacterial pathogens (Branger et al., 2005). Similar to LBP 
knockouts, CD14 deficient mice are resistant to septicemic shock mediated by either LPS 
injection or by Gram-negative bacterial infection (Haziot et al., 1996). However, 
following exposure to either live or killed Staphylococcus aureus, CD14-deficient and 
control wild-type mice exhibit similar symptoms of shock and proinflammatory cytokine 
production (Haziot et al., 1999). Additionally, following intravenous infection with 
Mycobacterium avium, CD14-deficient mice and wild-type control mice have 
indistinguishable levels of serum TNF-α production, macrophage inducible nitric oxide 
synthase expression and bacterial loads (Ehlers et al., 2001). The phenotypes of both LBP 
and CD14 knock-out mice support the idea that LBP and CD14 have a non-redundant 
function in the delivery of Gram-negative bacterial LPS to the TLR4 complex but a 
redundant function in the delivery of Gram-positive bacterial or mycobacterial 
components to the TLR1-TLR2 system. 
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Taken altogether, we have demonstrated that recognition of lipoproteins by TLR1 
and TLR2 involves multiple players that assist in the delivery of agonists to the final 
receptor complex. Understanding this fluid and dynamic process of TLR sensing of 
agonists mediated by LBP and CD14 has a profound impact on therapeutic strategies 
designed to treat chronic inflammatory conditions, sepsis, and infection. The use of 
neutralizing antibodies or inhibitory molecules against human CD14 has been suggested 
as a possible therapeutic approach against sepsis (Piazza et al., 2010; Schimke et al., 
1998). While this approach may be effective for treating Gram-negative bacterial sepsis, 
it may not be as effective in the treatment of sepsis caused by other bacteria due to the 
redundancy of function between LBP and CD14 for the direct delivery of lipoproteins, or 
other bacterial agonists, to the TLR1-TLR2 system. 
LBP is an acute phase protein and clinical studies have shown that serum 
concentrations increase about 10- to 50-fold in human patients with either Gram-negative 
or Gram-positive bacteremia (Froon et al., 1995). While it has been shown that high 
concentrations of LBP in acute phase serum may confer protection to the host by 
inhibiting LPS response in human monocytes (Zweigner et al., 2001), the opposite has 
been observed for lipoproteins. Human monocytes stimulated with either triacylated or 
diacylated lipopeptides exhibit an increase in tumor necrosis factor (TNF) expression that 
is proportional to the amount of added LBP (Schröder et al., 2004). This may lead to an 
overwhelming systemic inflammatory response and consequently a profound deleterious 
effect on the host. Thus, understanding the role of LBP in the TLR2 system may be 
essential for treating bacterial-induced septicemia. 
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Figures 
 
Figure 2.1. Recombinant soluble TLR (sTLR) proteins are monomeric, properly folded 
and biologically functional. (A) 100ug of each purified sTLR protein, as indicated, was 
loaded on a 7.5% SDS-PAGE gel and stained with Coomassie blue dye. (B) Each 
purified sTLR protein, as indicated, was analyzed by size exclusion chromatography 
using a Superdex 200 column. (C) Soluble TLRs were incubated in microtiter plate wells 
coated with either the anti-TLR1 mAb (clone GD2F4) or the anti-TLR2 mAb (T2.5), as 
indicated. Binding of soluble TLR1, TLR1315L, or TLR2 was detected using either HRP-
conjugated anti-HA and anti-FLAG mAbs. (D) SW620 cells were co-transfected with full 
length TLR1, TLR2, an IL-8 promoter-driven luciferase reporter gene and a Renilla 
luciferase transfection control. 48 hours post-transfection the cells were stimulated with 
10ng/ml Pam3CSK4, with or without 1ug/ml of soluble TLR1 or TLR2, as indicated. 
Firefly luciferase activities were normalized to that of the Renilla luciferase control.  
These values were normalized to that of empty CMV vector whose value was taken as 1. 
Error bars represent the standard deviation of three independent events. 
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Figure 2.2. LBP and soluble CD14 enhance soluble TLR1-TLR2-Pam3CSK4 ternary 
complex formation but are not part of the final ternary complex. Various combinations of 
0.25uM TLR1, 0.05uM TLR2, 2.5uM Pam3CSK4, 0.05uM LBP and/or 0.25uM sCD14 
were incubated for two hours at 37
o
C in a 500ul volume of PBS buffer pH 7.4, as 
indicated. Protein complexes were separated by size exclusion chromatography. The 
expected molecular weight of the TLR monomers and dimers was estimated by column 
calibration using known molecular weight standards. Proteins in eluted fractions were 
separated on a 7.5% SDS-PAGE gel, transferred by Western blotting and TLR1, TLR2, 
LBP or sCD14 were detected using suitable antibodies and HRP conjugates (see 
Materials and Methods). The results shown are representative of at least three 
independent experiments. 
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Figure 2.3. Soluble TLRs do not form homodimers when incubated with Pam3CSK4. 
0.5uM TLR1 (A), or 0.5uM TLR2 (B), 0.25uM each of TLR1 and TLR2 (C), or 0.25uM 
each of TLR1315L and TLR2 (D) were pre-incubated with a 5 fold molar excess of 
Pam3CSK4 (2.5uM) together with 0.05uM LBP and 0.25uM sCD14 in PBS pH 7.4 buffer 
for two hours at 37
o
C in a 500ul reaction volume. Proteins and protein complexes were 
separated and analyzed as described in the legend of Fig. 2.2. The results shown are 
representative of at least three independent experiments. 
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Figure 2.4. LBP and soluble CD14 enhance complex formation between TLR1, TLR2 and 
the OspA lipoprotein of B. burgdorferi. Various combinations of 0.25uM TLR1, 0.25uM 
TLR2, 1.25uM OspA, 0.05uM LBP and/or 0.25uM sCD14 were incubated for two hours 
at 37
o
C in a 500ul volume of PBS buffer pH 7.4, as indicated. Proteins and protein 
complexes were separated and analyzed as described in the legend of Fig. 2.2. The results 
shown are representative of at least three independent experiments. 
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Figure 2.5. Either LBP or soluble CD14 can independently enhance TLR1-TLR2-
Pam3CSK4 ternary complex formation. 0.25uM TLR1, 0.25uM TLR2 and 2.5uM 
Pam3CSK4 were incubated with (A) 0.25uM BSA, (B) 0.05uM LBP, and (C) 0.25uM 
sCD14 for two hours at 37
o
C in a 500ul volume of PBS pH 7.4 buffer. Proteins and 
protein complexes were separated and analyzed as described in the legend of Fig. 2.2. 
The results shown are representative of at least three independent experiments. 
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Figure 2.6. Sub-stoichiometric concentrations of either LBP or soluble CD14 are 
sufficient to enhance TLR1-TLR2-Pam3CSK4 ternary complex formation. 0.25uM TLR1, 
0.25uM TLR2, and 2.5uM Pam3CSK4 were incubated with various concentrations 
(250nM, 50nM, 10nM, 5nM, and 0nM) of either LBP (left panel) or sCD14 (right     
panel) for two hours in a 500ul volume at 37
o
C in PBS buffer pH 7.4.  Proteins and 
protein complexes were separated and analyzed as described in the legend of Fig. 2.2. 
The results shown are representative of at least three independent experiments. 
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Figure 2.7. Either LBP or soluble CD14 enhance cellular responses to Pam3CSK4 and 
OspA. HEK 293F cells were co-transfected with vectors expressing full length TLR1 and 
TLR2, or empty CMV control vector as indicated, together with an NF-kB-promoter 
driven luciferase reporter gene and a Renilla luciferase reporter gene. About 48-hours 
post transfection cells were stimulated with 1ng/ml  Pam3CSK4, OspA, or the non-
acylated Ac2CSK4 control in the presence of 0.1ug/ml LBP, sCD14 or human serum 
albumin (HSA), as indicated (left side). In one set of experiments agonists were pre-
incubated with proteins for one hour at 37
o
C prior to addition to transfected cells (right 
side). Cell Values on the Y-axis represent the level of constitutive reporter activation 
normalized to the empty CMV vector control (value of 1). Error bars represent the 
standard deviation of three independent values. 
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CHAPTER THREE 
MEASUREMENT OF TLR-LIPOPEPTIDE INTERACTION TO ASSESS 
COMPETITION BETWEEN TLR1 AND TLR10 FOR MICROBIAL AGONISTS 
AND THE CO-RECEPTOR TLR2 
Introduction 
Human TLRs play an important role in the recognition of microbe-associated 
molecular patterns. The TLR2 subfamily, comprised of TLRs 2, 1, and 6 are 
differentially expressed on the surface of myeloid as well as some non-myeloid cells 
(Kawai & Akira, 2010). TLR2 mediates cellular responses to a wide variety of microbial 
cell wall components, most of which are acylated molecules. The most potent, and well 
characterized agonists recognized by TLR2 are lipopeptides and lipoproteins. It has been 
demonstrated that TLR2 requires either TLR1 or TLR6 in order to mediate cellular 
responses to triacylated or diacylated lipopeptides, respectively (Massari et al., 2006; 
Ozinsky et al., 2000; Sandor et al., 2003; Takeuchi et al., 2001; Takeuchi et al., 2002; 
Vasselon et al., 2004; Wyllie et al., 2000). Upon TLR2 engagement with its co-receptor 
and ligand, a core signaling pathway is initiated leading to the activation of NF-kB, AP-1, 
CREB, and other transcription factors that drive the expression of proinflammatory 
mediators such as cytokines, chemokines, and co-stimulatory molecules (O'Neill et al., 
2013). 
TLR10 is an orphan receptor that belongs to the TLR2 subfamily and is most 
closely related to TLR1 and TLR6. The genes encoding TLRs 1, 6 and 10 are tandemly 
arranged on chromosome 4 and phylogenetic analysis suggests that they arose from 
successive gene duplication of an ancestral gene (Roach et al., 2005). Notably, the gene 
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for TLR10 arose before TLR1 and TLR6, suggesting that it is independently maintained 
and may have a distinct function (Roach et al., 2005). This functional divergence is 
manifested in the unique expression profile of TLR10. Unlike the wide expression pattern 
of TLR1 and TLR6, TLR10 expression, as measured by mRNA levels, appears to be 
more tissue-specific. TLR10 mRNA is detected in lymphoid tissues such as the spleen, 
lymph nodes, thymus, tonsils, and lung (Chuang & Ulevitch, 2001). TLR10 is also highly 
expressed in B cells following stimulation with microbial agonists (Bourke et al., 2003). 
Despite extensive studies on TLRs, the ligand and function of TLR10 remain unknown. 
Recently, it has been demonstrated that TLR2 directly interacts with TLR10 
(Guan et al., 2010). Curiously, TLR2 and TLR10 recognize the same set of agonists 
recognized by the TLR1 and TLR2 pair (Guan et al., 2010). However, TLR2 and TLR10 
fail to activate cells in response to cognate microbial agonists, suggesting that its 
signaling mechanism is different from its related family members (Guan et al., 2010). 
Whether there is a competition between TLR1 and TLR10 for its co-receptor TLR2 
and/or agonist Pam3CSK4 is not known, but there are several cell populations that express 
TLR1, TLR2, and TLR10 on the surface. It is possible that TLR10 competes with TLR1 
in recognition of TLR1/TLR2 agonists, and because it does not signal via the canonical 
TLR2-mediated signaling pathway, it may be acting as a negative regulator to dampen 
the immune response upon bacterial infection. 
The mechanisms of ligand recognition by TLRs have not been completely 
investigated. The extracellular TLR2 domain directly binds to agonists that have vastly 
different chemical structures, e.g. lipopeptides (Vasselon et al., 2004), peptidoglycan 
derived from Staphylococcus aureus (Iwaki et al., 2002) and zymosan (Sato et al., 2003) 
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to name a few. The elucidation of the crystal structure of human TLR2 bound to either 
TLR1 or TLR6 and their respective synthetic lipopeptide agonists provided detailed 
insights into TLR heterodimerization and lipopeptide binding (Jin et al., 2007; Kang et 
al., 2009). The triacylated lipopeptide  bridges the two receptors together to form an m-
shaped ternary complex with two acyl chains of Pam3CSK4 bound by the TLR2 
hydrophobic pocket found at the central LRR domain and the amide-linked lipid chain 
accommodated by a narrow hydrophobic channel in the convex side of TLR1 (Jin et al., 
2007). Despite knowledge of the final TLR1/TLR2/Pam3CSK4 crystal structure, no 
information is available with regard to the order of assembly, binding affinity, and 
kinetics of TLR1/TLR2/Pam3CSK4 ternary complex formation. There are also conflicting 
reports on the existence of pre-formed TLR2 homodimers or heterodimers (Triantafilou 
et al., 2006) in contrast to ligand-induced ternary complex formation.  
In this study, we aimed to examine the mechanism of TLR2 complex formation 
following recognition of microbial agonists by performing biochemical and biophysical 
experiments on functional soluble forms of TLR1, TLR2, and TLR10 extracellular 
domains (ECDs). Specifically, we defined the ligand recognition and physical 
interactions leading to the formation of cell-activating complexes by measuring receptor-
receptor interactions in the presence or absence of the synthetic lipopeptides. Since TLR1 
and TLR10 share interactions with TLR2 and common microbial agonists, we also 
assessed competition between these two receptors for those common components. 
  
60 
 
Materials and Methods 
Reagents  
The synthetic bacterial lipopeptides N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R)-
propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine x 3 CF3COOH (R-
Pam3CSK4) and the non-acylated synthetic peptide S-[2,3-bis(acetyloxy)-(2RS)-propyl]-
[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine x 3 CF3COOH (Ac2CSK4) 
were purchased from EMC Microcollections (Tuebingen, Germany). The Macrophage-
activating lipopeptide-2, S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-
GNNDESNISFKEK] (MALP-2) was purchased from Enzo Life Sciences (formerly 
Alexis Biochemicals; Plymouth Meeting, PA).  
HRP-conjugated anti-FLAG (clone M2) monoclonal Ab was purchased from Sigma 
Aldrich (St. Louis, MO), while the HRP-conjugated anti-hemagglutinin (HA) monoclonal 
antibody was purchased from Miltenyi Biotec Inc. (Auburn, CA). The unconjugated anti-
human TLR1 mAb (clone GD2.F4, CD281) and anti-human TLR2 mAb (clone T2.5, 
CD282) were obtained from eBioscience (San Diego, CA). 
Cloning  
Soluble extracellular domains of FLAG-tagged TLR2, HA-tagged TLR1, HA-
tagged TLR1P315L , and HA-tagged TLR10 were produced using the hybrid LRR 
technique described by Jin, MS et al.(Jin et al., 2007). The soluble TLR-Fc fusion 
expression vectors were constructed by overlap extension PCR using primers and 
methods described previously (Guan et al., 2010). Briefly, coding regions for the 
extracellular domains of TLR1 (both wild-type and a P315L mutant), TLR2, TLR6, or 
TLR10 (aa 22-476, 17-508, 25-481, and 20-474 respectively) were fused to the highly 
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conserved LRR C-terminal capping module of a hagﬁsh variable lymphocyte receptor 
(VLRB.61) by overlap extension PCR and subsequently cloned as BglII/NheI fragments 
into a modified pDisplay vector (kindly provided by Dr. David M. Kranz, Department of 
Biochemistry, University of Illinois at Urbana Champaign). This vector contains the Fc 
domain of human IgG1 downstream of the NheI site, and the sequence for either the 
FLAG or HA tag upstream of the BglII site. A thrombin cleavage site (LVPRGS) was 
added at the 3’-end of the TLRvlr hybrid to allow cleavage of the soluble TLR from the 
Fc fusion protein. Recombinant DNA plasmids were verified by DNA sequencing (UIUC 
Core Sequencing Facility). 
Cell Culture 
Freestyle HEK 293F cells (Invitrogen Life Technologies) adapted to grow in 
Freestyle serum-free expression medium (Invitrogen Life Technologies) were cultured at 
37˚C in a humidiﬁed environment containing 8% CO2. Stable HEK 293F cell lines 
expressing soluble TLR1, TLR1P315L, TLR2, TLR6, and TLR10 were generated by 
transfection followed by G418 selection and limiting dilution as previously described 
(Guan et al., 2010). Stable cell lines were grown in Freestyle serum-free expression 
medium containing 0.25 mg/ml G418 and cultured in suspension at 37
o
C with continuous 
shaking at 125 rpm in a humidified environment containing 8% CO2. 
Protein Purification 
Soluble TLR-Fc fusion proteins were purified from stable HEK 293F cell 
supernatant by affinity chromatography using Protein G sepharose for fast flow (GE 
Healthcare; Piscataway, NJ) on an AKTA prime purification system (GE Healthcare), as 
previously described (Guan et al., 2010). The Fc tag was removed after the first round of 
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purification by adding restriction grade thrombin protease (Novagen; Madison, WI) at a 
concentration of 1U thrombin per 0.25mg TLR-ECD-Fc protein. After 18 hours 
incubation at room temperature, the TLR extracellular domain was separated from the Fc 
fragments by another round of affinity chromatography in the AKTA prime system using 
a 1ml pre-packed protein A column (Pierce, Rockford, IL) and PBS pH 7.4 running 
buffer. The TLRs were concentrated from the flow-through using an Amicon Ultra-4 
centrifugal device (Millipore) and centrifuged at 2500xg for 15-25 minutes at 4
o
C, to a 
volume of 0.5ml. The concentrated protein was then loaded on a Superdex 200 10/300GL 
gel filtration column (GE Healthcare) in PBS pH 7.4 running buffer at a flow rate of 0.5 
ml/min. The eluted fractions containing monomeric TLR extracellular domains were 
pooled and concentrated using size exclusion centrifugation (Amicon). Final protein 
concentration after three rounds of purification was measured using the Pierce BCA 
protein assay kit (Rockford, IL). Protein purity was determined by mass spectrometry 
(Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois at 
Urbana-Champaign) using MALDI as the ionization technique and sinapinic acid as a 
calibration matrix. 
Receptor binding assays using microtiter plates  
HA-tagged TLR1 and TLR10 purified proteins (10 μg/ml in PBS pH 7.4) were 
coated onto 96-well microtiter plates at 4
o
C overnight. For all ELISAs, binding steps 
were performed at room temperature in 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer pH 7.5, and wells were washed with PBS containing 0.05% Tween-20. Non-
specific binding was blocked with a commercially available blocking buffer (Pierce, 
Rockford, IL) for 2 hours. The wells were then washed and incubated for 2 hours with an 
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equimolar amount of FLAG-tagged TLR2 that had been pre-incubated for 2 h at 25°C 
with various concentrations of the synthetic ligands Pam3CSK4, MALP-2, and 
Ac2CSK4 in MES buffer pH 7.5. One set of pre-incubation reactions contained 20 μg/ml 
blocking anti-TLR2 mAb (T2.5). Binding of soluble TLR2 to either TLR1 or TLR10 
immobilized on the wells was detected using HRP conjugated anti-FLAG antibody, 
followed by the addition of o-phenylenediamine (OPD) substrate dissolved in 0.05 M 
phosphate-citrate buffer pH 5.0 containing 0.05% H2O2. The colorimetric detection was 
quantified by measuring absorbance at 490 nm using an ELISA plate reader. 
Surface plasmon resonance using BIAcore 
Interactions between the triacylated synthetic lipopeptide Pam3CSK and each of 
the TLR receptors 1, 2, and 10 were measured by surface plasmon resonance using the 
BIAcore X system (GE Healthcare). All experiments were conducted at 25
o
C. Pam3CSK4 
were immobilized on a carboxymethyldextran (CM5) biosensor chip using standard 
amine-coupling procedure through EDC [1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride] and NHS (N-hydroxysuccinimide). Briefly, a continuous 
flow of 5 μl/min was maintained over the sensor in HBS-EP buffer (10 mM HEPES, 150 
mM NaCl, 3 mM EDTA, and 0.005% Tween-20). The matrix of the chip was activated 
by a 10 min injection of 50uL of 1:1 mixture of EDC and NHS, followed by a 6 min 
injection of 20ug/ml Pam3CSK4 in 10 mM sodium acetate pH 5.5 in one flow cell, and 
20ug/ml Ac2CSK4 in 10mM sodium acetate pH 5.5 in another flow cell. The procedure 
was completed by a 7-min exposure to 50ul of 1.0 M ethanolamine hydrochloride pH 8.5 
to inactivate residual esters. Using MES pH 7.5 as the binding buffer, monomeric TLRs 
1, 2, and 10 were injected at a flow rate of 10 μl/min over the immobilized Pam3CSK4 
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and Ac2CSK4 in Flow Cells 2 and 1, respectively. Varying concentration of TLRs (at 
0.2uM, 0.4uM, 0.6uM, 0.8uM, 1.0uM, 2.0uM, and 4.0uM) was injected to the flow cells 
in each cycle for 2 minutes, followed by a dissociation time of 5 minutes. Sensors were 
regenerated after each cycle by sequential injection of 40ul of 1M NaCl (5 pulses) and 
0.1% SDS (2 pulses) at a flow rate of 100ul/min to dissociate the analyte from the ligand 
and regenerate the surface back to the original baseline. The final sensograms were 
calculated by subtracting the signal of the control (Flow Cell 1) from that of the test 
(Flow Cell 2), and the results expressed in response units. The BIAcore 3.0 evaluation 
software was used to analyze data and generate dissociation constants for the analyte-
ligand interaction. 
Purification of Lipoprotein (Lip12) from E. coli 
An E. coli Lip 12 gene cloned into pET28b vector and expressed in E. coli BL21 
(DE3) strain were kindly provided by Dr. Peter Tobias and Dr. Hyun-Ku Lee (The 
Scripps Research Institute, La Jolla, CA). A 1 liter culture of Lip12-expressing E. coli 
BL21 cells (OD600 = 0.6) grown in LB broth supplemented with 30mM Kanamycin were 
induced for 3 hours with 1mM IPTG.  The cell pellet obtained after centrifugation at 
10,000xg for 10mins were lysed using the BugBuster Master Mix (Novagen) following 
the manufacturer’s protocol. The expressed proteins with a COOH-terminal 6× histidine 
tag were batch-purified from the cell lysate by cobalt affinity chromatography using 
Pierce His-Pur Cobalt resin (Fisher Scientific) on a gravity column. After letting the cell 
lysate flow through the column, the resin was washed with a high-salt wash buffer 
(300mM NaCl + 50mM Na2HPO4 + 20mM imidazole, pH 8.0). His-tagged Lip12 
proteins were eluted using a gradient elution buffer (300mM NaCl + 50mM Na2HPO4 + 
65 
 
50mM-500mM imidazole, pH 7.4). The eluted fractions containing the purified Lip 12 
proteins were pooled and concentrated using a size exclusion centrifugation (Amicon), 
and the buffer was dialyzed to PBS pH 7.4. The final protein concentration was measured 
using the Pierce BCA protein assay kit (Rockford, IL).   
Kinetic analysis using ForteBio Octet 
The Octet analysis was performed at 37°C in PBS pH 7.4 running buffer. The 
buffer and samples to be analyzed were placed on a 96-well black, flat-bottom, 
polypropylene microplate (Greiner Bio-One) and agitated at 1000 rpm. Protein A sensor 
tips were equilibrated in the running buffer for 120 sec, followed by saturation with 30 
μg/mL Fc-tagged TLRs for 900 sec. Unbound Fc-tagged TLRs were washed in the 
running buffer for another 900 sec. The sensors containing the immobilized Fc-tagged 
TLRs were then dipped onto wells containing Lip12 purified from E. coli and prepared in 
varying concentrations (0.0uM, 2.0uM, 5.0uM, 10.0uM, and 20.0uM). Association 
between the Fc-tagged TLRs and the Lip12 ligand was monitored for 900 sec and 
dissociation into the buffer was followed for another 900 sec. Data analysis was 
performed using the Octet software. 
Cell stimulation assays 
SW620 cells were co-transfected with various combinations of TLRs (or the 
empty vector pFLAG-CMV) together with a firefly luciferase gene driven by the IL-8 
promoter and a Renilla luciferase gene driven by a basal promoter (pRL-null) as a 
transfection control (Promega; Madison, WI). Transfections were performed using a 
cationic lipid agent, Fugene-6 (Roche), at a 4:1 lipid:DNA ratio. Forty-eight hours post-
transfection, the cells were stimulated for 6 hours with the indicated synthetic or purified 
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agonists. Following the manufacturer’s protocol for the dual luciferase assay (Promega), 
cell lysates were collected 6 hours post-stimulation and analyzed for firefly and Renilla 
luciferase activity using a BioTek Synergy HT plate reader (BioTek; Winooski, VT). The 
transfection efficiency across different wells was normalized by dividing the firefly 
luciferase activity by the Renilla luciferase control. After correcting for transfection 
efficiency, all values were normalized to those of unstimulated cells transfected with the 
empty pFLAG-CMV vector. 
Results 
In order to measure protein-protein interactions in solution using biochemical and 
biophysical assays, we purified the extracellular domain of TLRs. As described in detail 
in Chapter 2, we engineered the ECD of TLRs 1, 2, 6, and 10 fused to an Fc fragment and 
expressed the recombinant proteins in human embryonic kidney (HEK) 293F cells. 
Proteins were purified from the culture supernatant of cells stably expressing the fusion 
proteins by affinity chromatography on a protein G column. Monomeric HA-tagged 
TLRs 1 (both wild-type and a P315L mutant), 2, 6, and 10, together with a FLAG-tagged 
TLR2, were generated after cleavage of the Fc tag and were verified to be properly folded 
using monoclonal antibodies that only recognize the native form of TLRs. The purified 
proteins were loaded on a Coomassie-stained gel to determine relative molecular weight 
(Figure 3.1A), and were also submitted for mass spectrometry analysis to determine their 
purity and molecular mass (Figure 3.1B). The protein yield from 1L of culture 
supernatant of TLR1, TLR2, and TLR10 is typically ~630ug, ~215ug, and ~319ug, 
respectively. Due to the low protein yield for TLR6, we decided not to include this TLR 
in this study (Figure 3.1A). 
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Binding of TLR2 to either TLR1 or TLR10 is induced by Pam3CSK4 and is specific 
We performed preliminary binding studies using microtiter plate assays to 
optimize buffer conditions and qualitatively examine ligand-induced TLR 
heterodimerization. By comparing different buffers and pH of solution, we observed that 
TLR complex formation in the presence of Pam3CSK4 was optimal under MES buffer pH 
7.5. Having optimized the conditions for microtiter plate assays, we proceeded to vary the 
order in which we form the ternary complex. We performed sequential addition of 
proteins by immobilizing one receptor on the plate, followed by addition of the 
lipopeptide or the co-receptor (in succession or together), and assayed for the formation 
of the ternary complex by measuring the binding of the receptor that was in solution. We 
observed formation of a stable complex when the co-receptor and lipopeptide agonist 
were added together, but not when they were sequentially added to the plate, suggesting 
that all three components of the ternary complex have to be present in close proximity in 
order to assemble a stable complex.  
Addition of increasing concentrations of triacylated agonist Pam3CSK4 but not a 
diacylated or non-acylated synthetic lipopeptides increased TLR2 binding to either TLR1 
or TLR10 coated on microtiter plates (Figure 3.2 A and B). To further show specificity, 
TLR2 binding was reduced in the presence of a neutralizing monoclonal antibody to 
TLR2 (T2.5). Binding was also found to be saturable upon addition of increasing 
concentrations of TLR2 to a TLR1-coated plate in the presence of Pam3CSK4 at a 
constant molar ratio of TLR2:Pam3CSK4 = 1:5 (Figure 3.3A). We also observed that 
TLR1 formed a ternary complex with Pam3CSK4 at lower TLR2 concentrations 
compared to TLR10 (Figure 3.3 A and B). In contrast, TLR2 pre-incubated with MALP-
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2, the diacylated lipopeptide agonist for TLR2/TLR6, did not form complexes with either 
TLR1 or TLR10 on the plate. Similarly, the non-stimulatory compound Ac2CSK4, which 
lacks the acyl-  and amide-bound fatty acid chain of Pam3CSK4, did not enhance the 
binding of TLR2 to either TLR1 or TLR10, showing that the lipid chains are required for 
the formation of a stable heterodimer (Figure 3.2 and 3.3).  
We also performed complex formation in the reverse order, where we added 
TLR1 pre-incubated with different agonists to TLR2 immobilized on the plate. In this 
order of addition, we observed that binding is more efficient (i.e. higher absorbance 
values) if TLR1 pre-incubated with Pam3CSK4 is added to TLR2 on the plate (Figure 
3.4). Time course experiments suggest that a stable TLR1/TLR2/Pam3CSK4 complex 
forms in 30 minutes on microtiter plates but can form at a faster rate (about 5 minutes) if 
TLR1 is in solution (i.e., TLR2 is coated onto microtiter plates, while TLR1 and 
Pam3CSK4 are added in solution), suggesting that TLR1 may undergo conformational 
changes upon binding to the agonist and/or the co-receptor. In contrast, a stable TLR2/ 
TLR10/Pam3CSK4 complex formed in 30 minutes irrespective of order of addition to the 
plate (data not shown).  
Quantitative measurement of protein-ligand interaction using BIAcore and Octet 
Based on the crystal structure (Jin et al., 2007), both TLR1 and TLR2 directly 
interact with Pam3CSK4. To quantitatively measure the kinetics of ternary complex 
formation in real time, surface plasmon resonance studies using BIAcore were 
performed. We started by measuring the interaction of a two-component system, i.e. the 
interaction between two TLRs in the absence of any agonists or the interaction between a 
TLR and Pam3CSK4. Using a carboxymethylated sensor (CM5 chip), we immobilized 
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TLR1 on the chip surface via amine coupling. We then added the co-receptor TLR2 in 
solution at varying concentrations. We observed that even at high concentrations of 
TLR2, there was no detectable interaction between two TLRs in the absence of any 
agonist (Table 3.1). When we measured the interaction between TLR1 on the sensor and 
Pam3CSK4 in solution, we encountered two problems: (1) the lipopeptide is a relatively 
small molecule (1.5kDa), and its binding could not be detected by the machine very well; 
and (2) Pam3CSK4 has a tendency to form aggregates or micelles in solution and exhibit 
non-specific hydrophobic interactions with the carboxymethylated matrix of the sensor 
chip. However, since Pam3CSK4 has a series of lysine residues in its peptide component, 
we were able to immobilize Pam3CSK4 on the CM5 sensor chip via amine coupling. In 
theory, this may have allowed the acyl chains of the lipopeptide to be freely exposed to 
the aqueous environment. Using this approach, we added varying concentration of TLRs 
1, 2, and 10. All three TLRs were observed to directly bind to Pam3CSK4 immobilized on 
a sensor chip. TLR1 exhibited a fast on-rate as well as a fast off-rate, suggesting that 
TLR1-Pam3CSK4 interaction is weak. Both TLR2 and TLR10, on the other hand, 
exhibited relatively slower on- and off-rates, suggesting that they bind more tightly to 
Pam3CSK4 compared to TLR1. The dissociation constants, KD, were measured between 
TLR1-Pam3CSK4, TLR2-Pam3CSK4, and TLR10-Pam3CSK4, and were found to be 1x10
-
6
M, 7.57x10
-9
M, and 1.68x10
-8
M, respectively (Table 3.1).  
Measuring the KD in a three-component system to quantitatively measure ternary 
complex formation remains a big challenge in this study, mostly due to the difficulties in 
handling Pam3CSK4 in solution, regenerating sensor chips, and TLR protein aggregation 
as the cycle number increases. As mentioned above, upon dilution in polar solvents, 
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Pam3CSK4 has a greater tendency to form aggregates and exhibit non-specific binding 
with the carboxymethylated matrix of the sensor chip due to hydrophobic interactions. 
The surface regeneration steps (using 0.1% SDS buffer) after each binding cycle affected 
the population of active ligand (Pam3CSK4) reacting with the analyte (TLRs). Even in a 
2-component system, we have encountered difficulties replicating the binding data for 
TLR binding to Pam3CSK4 immobilized on the sensor chip. The non-uniformity of the 
ligand population at each binding event or cycle leads to an inconsistent binding curve 
and a high chi
2
 value for the computed KD after curve fitting. We also observed non-
specific binding of either TLR1 or TLR2 to an “empty” or reference CM5 sensor, which 
masks actual binding to the co-receptor that is immobilized on another sensor, thus giving 
a negative binding curve upon subtraction of the data from the reference cell. 
Furthermore, we noticed that the TLRs immobilized on the sensor chip are only active for 
the first few rounds of injection cycle, and are easily denatured by the regeneration buffer 
used (1M NaCl + 0.1% SDS). Collectively, our data suggest that the use of Pam3CSK4 as 
agonist in a simplified 3-component system (i.e. in the absence of either LBP or CD14), 
as well as the non-uniformity of successive binding events brought about by the 
regeneration steps in the protocol, are the two major hurdles that need to be overcome in 
order to achieve the objectives of this study.  
 To address the sensor chip regeneration problem, we decided to switch from 
Biacore to the ForteBio Octet QK System. Although both systems rely on biolayer 
interferometry, the ForteBio Octet sensors are designed for single use and can be loaded 
on a multichannel holder that can simultaneously run eight biosensors, thus eliminating 
the need for regeneration steps as well as achieving uniformity of binding conditions. 
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Proteins are immobilized on the biosensors, which are dipped in the wells of a microtiter 
plate containing the analyte(s) of interest. The Octet instrument passes a white light 
through the biosensor and measures the interference patterns of the light that is reflected 
back. The binding event is recorded as a plot of wavelength change versus time.  We 
initially started our experiments using amine reactive sensors to covalently link one TLR 
to the sensor. Although we were able to immobilize all TLRs on the sensor, when we 
checked for proper protein folding using anti-TLR mAbs, only TLR1 was recognized by 
the anti-TLR1 monoclonal antibody (GD2.F4). TLR2, TLR10, and TLR4 (as a control) 
were weakly recognized by corresponding monoclonal antibodies, suggesting that either 
the immobilization steps may have rendered the mAb binding site inaccessible or the 
immobilization steps may have denatured the proteins.  
To overcome the above sensor coupling problem, we decided to switch to a 
protein A sensor to immobilize our Fc-tagged TLR (TLR-Fc) proteins directly on the 
surface, taking advantage of the tight interaction (~10
-10 
- 10
-11
 M KD) between protein A 
and the human IgG1 Fc fragment. In this way, we were able to orient the TLRs 
uniformly, making the active sites available for binding. The caveat to this approach is 
that the Fc tag in the TLR-Fc proteins causes the proteins to dimerize in an unknown 
conformation, and only the removal of the Fc tag after thrombin cleavage yields 
monomeric TLRs. Using the monoclonal antibodies anti-TLR1 (GD2F4) and anti-TLR2 
(T2.5), the epitopes of which are known to be at or close to the active site of TLR1 and 
TLR2, respectively), we verified that the proteins are folded properly and that the active 
site of the dimeric proteins remains accessible for ligand recognition (Figure 3.5). To 
establish the reliability of the Octet system, we measured the interaction between the 
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TLRs and their respective mAbs (Table 3.2) and calculated dissociation constants in the 
sub-nanomolar range for TLR1, TLR2, and TLR10 binding to anti-TLR1 mAb (GD2.F4), 
anti-TLR2 mAb (T2.5), and anti-TLR10 mAb (3C10C5), respectively. All the chi
2
 values 
for the association and dissociation curves were low and statistically significant (Table 
3.2). As expected, the anti-TLR1 mAb (GD2.F4) did not bind stably with the TLR1P315L 
mutant and exhibited a thirty-fold lower dissociation constant compared to the wild-type 
TLR1. 
To address the aggregation of Pam3CSK4, we decided to use a larger and more 
soluble agonist for TLR1/TLR2. We performed the microtiter plate assay to screen for 
naturally-occurring agonists that were reported to induce TLR1/TLR2 activation, such as 
LTIIbB5 from E. coli (Liang et al., 2009), Neisserial PorB (Massari et al., 2006), 
Treponema denticola periplasmic flagella (Ruby et al., 2007), and mannosylated 
lipoarabinomannan (Elass et al., 2007; Tapping & Tobias, 2003). None of these agonists 
induced the formation of a stable TLR1/TLR2 heterodimer in plate assays (data not 
shown). This observation, coupled with the fact that these agonists are less potent cell 
activators than lipoproteins, suggests that the binding affinity of TLR1 and TLR2 towards 
these agonists is lower compared to that of lipopeptides and lipoproteins. Alternatively, it 
is also possible that the agonists used in original reports were contaminated with minute 
amounts of lipoproteins. Another possibility is that these agonists may require an 
accessory molecule in order for them to be recognized by TLR1 and TLR2.  
In efforts to examine a larger more soluble lipoprotein agonist, we acquired a 12 
kDa lipoprotein (Lip12) from E. coli, expressed as a recombinant protein in E. coli BL21 
cells with a histidine tag at the C-terminus of the protein (a gift from Dr. Peter Tobias and 
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Dr. Hyun-Ku Lee), which has been shown to play a role in TLR2-mediated cell activation 
(Lee et al., 2002). This 12kDa triacylated lipoprotein was isolated from commercial 
preparations of LPS that were found to activate cells through TLR2 as well as TLR4 (Lee 
et al., 2002). We purified his-tagged Lip12 using a cobalt column, and dialyzed the 
proteins in PBS buffer (Figure 3.6A). We tested the activity of this lipoprotein by 
stimulating SW620 epithelial cells transfected with various TLRs and an IL-8/luciferase 
reported gene. Lip12 was shown to stimulate SW620 cells transfected with TLR1/TLR2 
but not TLR2/TLR6 (Figure 3.6B). 
To assess Lip12 binding, we added varying concentrations of Lip12 (2 uM, 5 uM, 
10 uM, and 20 uM) to TLR1, TLR2, TLR10, and TLR4 immobilized on different protein 
A sensors. As shown in Figure 3.7, Fc-tagged TLRs immobilized on a protein A sensor 
interacted with Lip 12 and produced a binding curve with a fast on-rate (kon) and a slow 
off-rate (koff). Using the Octet software to compute for the KD of the interaction between 
TLRs and Lip 12 based on a 1:1 Langmuir binding model, the dissociation constants of 
wild-type TLR1, TLR1P315L, TLR2, and TLR10 to Lip12 was measured to be 7.45x10
-7
 
M (chi
2
: 0.0193), 1.13x10
-6
 M (chi
2
: 0.01747), 1.58x10
-6
 M (chi
2
: 0.02892), and 3.34x10
-
7
 M (chi
2
: 0.07317), respectively (Table 3.3). As a negative control, we measured the 
binding of TLR4 to Lip12, and we were not able to measure any interaction. 
Furthermore, pre-incubation of either TLR1 or TLR2 with a known blocking antibody 
prevented interaction with Lip12 on the sensor, suggesting that the binding events were 
real and specific (data not shown). 
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Discussion 
In Chapter 2, we established that LBP and CD14 are two accessory proteins that 
independently and transiently deliver a triacylated lipoprotein to TLRs 1 and 2 to enhance 
ternary complex formation. In this chapter, we aimed to define the order of events that 
lead to the formation of the final TLR1/TLR2/Pam3CSK4 complex and to gain further 
insights into the competition between TLR1 and TLR10 both for their agonist and co-
receptor TLR2. Our qualitative measurements of protein-protein interactions using 
microtiter plate assays demonstrated that the triacylated lipopeptide Pam3CSK4 induces 
the formation of the TLR1/TLR2 and TLR2/TLR10 heterodimeric complexes. We have 
further shown that ternary complex formation is ligand-specific and can be blocked by 
monoclonal antibodies against TLR2. In this system, where one of the TLR receptors is 
immobilized on the plate, we have observed formation of a stable complex only when the 
co-receptor and lipopeptide agonist are present at the same time, but not when they are 
sequentially added and washed off, suggesting that all three components of the ternary 
complex need to be present in order to assemble a stable complex.  
This study defines, for the first time, the binding kinetics of TLRs 1, 2, and 10 to 
immobilized lipopeptides or lipoproteins using both surface plasmon resonance (SPR, 
BIAcore) and biolayer interferometry (Octet). We found that the Octet system proved to 
be a more reliable and repeatable method compared to SPR. Prior to this study, there was 
limited information on TLR2-related binding kinetics. One of these studies examined the 
interaction between TLR2 and an early secreted antigenic target protein 6 (ESAT-6) from 
Mycobacterium tuberculosis (Pathak et al., 2007). ESAT-6 has a six-residue polypeptide 
found at the C-terminal domain that is sufficient for interaction with TLR2. Using SPR, 
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this same group later demonstrated that this short ESAT-6 polypeptide binds to TLR2, 
but not TLR4 immobilized on a sensor chip (Chambers et al., 2010). In addition, this 
group also reported that an acylated glycoprotein (MPB83) from Mycobacterium bovis is 
able to activate TLR2. However, a recombinant non-acylated form of the M. bovis 
glycoprotein (RecMPB83), which activates TLR2 more weakly compared to the acylated 
form, was used to demonstrate TLR2 binding in their SPR experiments (Chambers et al., 
2010). In 2009, a different group looking at TLR2-peptidoglycan interaction reported 
binding kinetics between TLR2 immobilized on sensors and different forms of highly-
purified synthetic peptidoglycan derived from both Gram-positive and Gram-negative 
bacteria (Asong et al., 2009). In all studies mentioned, it is noteworthy that the agonists 
chosen in their SPR studies are soluble in nature and lack the typical acyl chains observed 
in most TLR2 agonists including the more potent lipopeptides. Our study is the first to 
address the kinetics of interaction between TLRs and triacylated lipoproteins, which are 
amphipathic in nature.  
Other notable SPR studies did not directly involve TLR2, and instead looked at 
the direct interaction between the accessory protein CD14 and microbial agonists. CD14 
was among the first recognized so-called pattern recognition receptors, and plays an 
important role in the recognition of cell wall structures of Gram-positive as well as Gram-
negative microbes (Pugin et al., 1993). CD14 is an accessory protein known to enhance 
the sensitivity of TLR4-expressing cells to LPS and TLR1/TLR2-expressing cells to a 
variety of lipidated agonists. Among these agonists, mycobacterial lipomannans (LM) 
and lipoarabinomannans (LAMs) isolated from M. kansaii were shown to interact with 
CD14 immobilized on a sensor (Elass et al., 2007). In chapter 2, we described in detail 
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the direct role of CD14 in the delivery of Pam3CSK4 to TLR1/TLR2. Using SPR, Nakata 
et al. (Nakata et al., 2006) reported a KD of 5.7x10
-6
 M for the interaction between 
Pam3CSK4 and CD14 immobilized on the sensor. One of the limitations of this study is 
the lack of appropriate controls for their SPR experiment. They showed Pam3CSK4 
binding to CD14 immobilized on the sensor, but they did not have any positive control 
such as LPS binding to CD14 for comparison. Another limitation in this experiment is 
that they used the 1.5 kDa Pam3CSK4 as the analyte in solution. The binding of a small 
molecule such as Pam3CSK4 is too small to be detected in BIAcore, and most likely, what 
the group was able to measure was the binding of Pam3CSK4 aggregates to CD14 on the 
sensor. Nevertheless, if the measured CD14-Pam3CSK4 dissociation constant is real, then 
a low KD is consistent with the delivery function of CD14. CD14 is most likely going to 
transfer Pam3CSK4 to a receptor with a higher affinity for the lipopeptide.        
Based on the crystal structure, two acyl chains of the triacylated lipopeptide 
Pam3CSK4 are bound by TLR2 in its hydrophobic pocket, while the remaining acyl chain 
interacts with TLR1. Since a TLR2-Pam3CSK4 complex has one less exposed acyl chain 
in solution compared to a TLR1-Pam3CSK4 complex, we hypothesized that TLR2 
initially binds to the triacylated lipopeptide, and subsequently delivers the agonist to its 
partner receptor (either TLR1 or TLR10) to confer specificity and initiate appropriate 
cellular responses. In our BIAcore experiments, all three TLRs exhibited direct binding to 
Pam3CSK4 immobilized on an amine-reactive sensor chip (CM5). The KD values were 
measured based on a 1:1 Langmuir Model for TLR1-Pam3CSK4, TLR2-Pam3CSK4, and 
TLR10-Pam3CSK4  interaction, and were found to be 1.0x10
-7
 M, 7.57x10
-9
 M, and 
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1.68x10
-8 
M, respectively. However, we have very low confidence with these calculated 
KD values since the chi
2
 values for the global curve fitting were in the range of 35.5-600. 
In the Octet system, we used a purified 12kDa triacylated lipoprotein (Lip12) that 
is bigger compared to Pam3CKS4 (1.5kDa). The KD values that we were able to calculate 
for TLR1-Lip12, TLR2-Lip12, and TLR10-Lip12  interaction were 7.45x10
-7
 M, 1.58x10
-
6
 M, and 3.34x10
-7 
M, respectively. The KD values that were obtained from Octet are 
notably different from those measured using SPR, but the low chi
2
 values suggest that the 
Octet was a more reliable measure compared to SPR. Surprisingly, the affinity of TLR2 
to Lip12 was lower compared to that of TLR1-lipoprotein, as well as that reported for 
CD14-Pam3CSK4 (Nakata et al., 2006). Taken together, our data suggests that CD14 
delivers a lipopeptide/lipoprotein to TLR1 and that the resulting TLR1-lipopeptide 
complex then binds to TLR2 to form the final ternary complex. It should be noted though 
that the N-terminal region of CD14 has been reported to directly bind to TLR2, and this 
interaction can be prevented using a monoclonal antibody against CD14 that also blocks 
CD14-mediated LPS/endotoxin binding (Iwaki et al., 2005). Further studies are required 
to fully elucidate the sequence of events leading to the formation of the final ternary 
complex. 
Several attempts and approaches were made to measure the affinity constants of a 
3-component system using both SPR and the Octet system. Our SPR data suggest that the 
aggregation state of the Pam3CSK4 agonist as well as the regeneration steps in the 
protocol are major concerns. Using the Octet system, our attempts to measure the kinetics 
of ternary complex formation involved immobilizing an Fc-tagged TLR, and exposing 
this sensor to Lip12 followed by (or together with) the monomeric TLR co-receptor. 
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However, aggregation of both lipoproteins and the monomeric TLRs was encountered 
and a significant binding curve was not observed. It is possible that the dimeric nature of 
the Fc-tagged TLRs on the sensors causes steric hindrance that prevents formation of a 
stable ternary complex with a soluble monomeric TLR and Lip12. We showed in Chapter 
2 that either LBP or CD14 can independently deliver Pam3CSK4 to TLR1 and TLR2. 
Addition of LBP and/or CD14 to this system did not improve the binding curve; rather, 
these accessory proteins further complicated the results due to non-specific aggregation 
to the sensors. 
TLR1 P315L is a naturally-occurring but rare TLR1 single nucleotide 
polymorphism that exhibits attenuated responses towards the synthetic lipopeptide 
Pam3CSK4 as well as a variety of other microbial cell wall components known to 
stimulate TLR1/TLR2 (Omueti et al. , 2007). Additionally, a purified TLR1 ECD with a 
mutation at this amino acid position failed to form a ternary complex with TLR2 upon 
addition of Pam3CSK4 in solution (Chapter 2) This point mutation in TLR1 is located in 
the outer loop of leucine-rich repeat motif 11, which is close to the entrance of the 
hydrophobic lipid-binding pocket of TLR1 and at the interface that interacts with TLR2. 
Interestingly, the TLR1P315L mutant, exhibited only a 1.5-fold lower binding affinity 
towards Lip12 compared to the wild-type TLR1 (Table 3.3), suggesting that the mutation 
at this position weakens but does not significantly alter the ability of TLR1 to bind to a 
lipoprotein. More importantly, this data suggests that proline at position 315 may be 
important for the formation of a dimer interface with TLR2, and a L315 mutation may 
have affected ternary complex formation, thus leading to an attenuated response in cells 
stimulated with Pam3CSK4. The next chapter of this dissertation takes a closer look at the 
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important regions of the TLR1 extracellular domain that are required for interaction with 
TLR2 upon formation of a ternary complex with an agonist. 
TLRs are differentially expressed in myeloid and non-myeloid cells (Kawai & 
Akira, 2010). In some cell populations such as B cells, high levels of TLR1, TLR2, and 
TLR10 mRNA have been detected (Bourke et al., 2003) and it is highly likely that they 
are expressed together on the cell surface. The functional role of TLR10 is still largely 
unknown mainly because it does not signal via the known TLR-mediated signaling 
pathways. Additional data from other colleagues in our lab who are looking at TLR10 
suggest that this receptor may be independently acting as a global suppressor to dampen 
the cell’s immune response (Jiang, Li, Hess, and Tapping, unpublished results). However, 
TLR10 shares agonists with TLR1 and like TLR1, uses TLR2 as a co-receptor (Guan et 
al., 2010). Our SPR and Octet systems reveal that both TLR1 and TLR10 can bind to 
triacylated lipopeptides/lipoproteins. Thus, TLR10 may be acting as a negative regulator 
to dampen the immune response by competing with TLR1. Our microtiter plate assays 
show that TLR1 requires less TLR2 to form a ternary complex with Pam3CSK4 compared 
to TLR10. Moreover, when we formed the complexes in solution, we were able to 
observe a TLR1/TLR2/Pam3CSK4 ternary complex as measured by size exclusion 
chromatography (see Chapter 2) but not a TLR2/TLR10/Pam3CSK4 complex, even with 
the addition of LBP and CD14 (data not shown). This suggests that the affinity of TLR2 
for TLR10 is weaker compared to that of TLR1. Our preliminary competition 
experiments on microtiter plates show that TLR2/Pam3CSK4 binding to TLR1 coated on 
microtiter plates gradually decreased when TLR2/Pam3CSK4 is pre-incubated with an 
increasing concentration of TLR10 prior to addition to the TLR1-coated plates (data not 
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shown). Further investigation is needed to determine whether there is a competition 
between TLR1 and TLR10. Given their different expression pattern and dissimilarity in 
signaling output (Guan et al., 2010), the ability of TLR1 and TLR10 to compete for 
TLR2 and/or the agonist is likely to have significant functional consequences. 
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Figures 
 
Figure 3.1. Purified TLR ECDs are monomeric. (A) Purified TLR ECD proteins loaded 
onto 7.5% acrylamide gel and stained with Coomassie blue dye. (B) The purity and actual 
molecular mass of the purified proteins were determined by mass spectrometry using 
MALDI as the ionization technique and sinapinic acid as the calibration matrix. 
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Figure 3.2. Binding of TLR2 to either TLR1 or TLR10 is ligand-induced and specific. (A) 
HA-tagged TLR1 ECD or (B) HA-tagged TLR10 ECD immobilized on microtiter plates 
were incubated with FLAG-tagged TLR2 pre-incubated with increasing concentrations of 
Pam3CSK4 (with or without T2.5 mAb), MALP-2, or Ac2CSK4 as indicated. Protein 
binding was detected through an HRP-conjugated anti-Flag antibody. Data are 
representative of a least three independent replicates. 
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Figure 3.3. Binding of TLR2 to TLR1 is saturable and more efficient compared to TLR10. 
(A) HA-tagged TLR1 ECD or (B) HA-tagged TLR10 ECD immobilized on microtiter 
plates were incubated with increasing concentrations of FLAG-tagged TLR2 together 
with a 5-fold molar excess of Pam3CSK4, MALP-2, and Ac2CSK4. Protein binding was 
detected through an HRP-conjugated anti-Flag antibody. Data are representative of a least 
three independent replicates. 
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Figure 3.4. Order-of-addition experiment show that binding is more efficient if TLR1-
Pam3CSK4 is added to TLR2 immobilized on a plate. HA-tagged TLR1 ECD pre-
incubated with Pam3CSK4, MALP-2, or Ac2CSK4 were added to Flag-tagged TLR2 
immobilized on a microtiter plate (blue bars), and compared to the addition of TLR2 pre-
incubated with the same set of agonists to TLR1 immobilized on a plate (orange bars). 
Protein binding was detected through an HRP-conjugated anti-Flag antibody. Data are 
representative of a least three independent replicates.  
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Figure 3.5. Fc-tagged TLR ECD proteins are recognized by their respective mAbs. Fc-
tagged TLRs immobilized on protein A sensor tips and allowed to react with their 
respective mAbs in PBS pH 7.4 binding buffer as indicated. The incubation period of the 
TLRs with the antibodies (association phase) was set for 900 seconds (15 minutes). The 
sensors were then dipped on a different well containing PBS buffer to wash the unbound 
antibodies. This dissociation phase was also set for another 900 sec (15 min). 
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Figure 3.6. A 12kDa triacylated lipoprotein from E.coli stimulates TLR1/TLR2-
transfected human epithelial cells. (A) His-tagged Lip12 protein from E. coli cell lysate 
was purified on a cobalt resin by affinity chromatography. Following a stringent wash 
step, the protein was eluted using a gradient elution buffer (containing 50-500mM 
imidazole). Legends: CL – cell lysate, FT – flow through, W – wash step, E1-E6 – 
elution with 50, 100, 200, 300, 400, and 500mM imidazole, B – beads. (B) SW620 cells 
were co-transfected with vectors expressing full length TLR1/TLR2, TLR2/TLR6, or 
empty CMV control vector as indicated, together with an IL-8-promoter driven luciferase 
reporter gene and a Renilla luciferase reporter gene. About 48-hours post transfection 
cells were stimulated with Lip12 or the controls Pam3CSK4, and MALP-2. Firefly 
luciferase activities were normalized to that of the Renilla luciferase control.  These 
values were normalized to that of empty CMV vector whose value was taken as 1. Error 
bars represent the standard deviation of three independent events.  
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Figure 3.7. Fc-tagged TLR ECDs bind to triacylated Lip12 lipoprotein. Fc-tagged TLR1 
(A), TLR1P315L (B), TLR2 (C), and TLR10 (D) immobilized on protein A sensor tips 
were incubated with increasing concentrations of purified Lip12 in PBS pH 7.4 binding 
buffer as indicated. The association phase was set for 900 sec. During the dissociation 
phase, the sensors were then dipped for another 900 sec on a different well containing 
PBS buffer to wash the unbound Lip12 proteins. The solid black curves represent the 
calculated Global Fit following a 1:1 Langmuir binding model. 
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Tables 
Table 3.1. TLR1, TLR2, and TLR10 have different affinities for Pam3CSK4 based on 
surface plasmon resonance (BIAcore instrument). 
 
 
Table 3.2. The binding affinities of TLR1, TLR2, and TLR10 to their respective 
monoclonal antibodies based on biolayer interferometry (Octet instrument). 
 
 
 
 
 
89 
 
Table 3.3. TLR1, TLR2, and TLR10 have different affinities for Lip12WT based on 
biolayer interferometry (Octet instrument). 
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CHAPTER FOUR 
A COMMON EXTRACELLULAR REGION OF HUMAN TOLL-LIKE 
RECEPTOR 1 (TLR1) IS REQUIRED FOR CELLULAR RESPONSES TO A 
VARIETY OF MICROBIAL CELL WALL COMPONENTS
5
 
Introduction 
Toll-like receptors are central to the initiation of the innate immune responses in 
animal cells upon recognition of distinct bacterial, viral, and fungal components. 
Currently, there are ten known Toll-like receptors in humans, designated as TLR1 to 
TLR10, expressed either on the cell surface or in endosomal compartments (Takeda & 
Akira, 2005). These TLRs are able to sense the presence of microbe-associated molecular 
structures such as lipopolysaccharide (TLR4), flagellin (TLR5), double-stranded RNA 
(TLR3), single-stranded RNA (TLR7 or TLR8), or unmethylated double-stranded DNA 
(TLR9) [Reviewed in (Akira & Hemmi, 2003)]. 
Studies on knock-out mice have shown that TLR2 recognizes triacylated and 
diacylated lipopeptides/lipoproteins by pairing with TLR1 or TLR6, respectively 
(Takeuchi et al., 2001; Takeuchi et al., 2002). The unique ability of TLR2 to 
heterodimerize with either TLR1 or TLR6 contributes to expanding the diversity of 
molecules that they can recognize. In addition to triacylated lipoproteins, the TLR1/TLR2 
pair is able to recognize other microbial cell wall components that differ in molecular 
structure such as atypical lipopolysaccharide (LPS) from non-enteric bacteria, 
peptidoglycan and lipoteichoic acid (LTA) from Gram-positive bacteria, lipomannans 
and lipoarabinomannans from mycobacteria, and zymosan from yeast  to name a few 
                                                          
5
 Ranoa, DRE, Omueti KO, Mazur DJ, Weber BR, and Tapping RI. Manuscript in Progress. 
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(Darveau et al., 2004; Iwaki et al., 2002; Liang et al., 2009; Massari et al., 2006; 
Quesniaux et al., 2004a; Sato et al., 2003; Tapping & Tobias, 2003). 
TLR2, together with TLR1 and TLR6, are predominantly expressed on the 
surface of myeloid-derived cells including monocytes, macrophages and dendritic cells, 
as well as on non-myeloid cells (Muzio et al., 2000; Zarember & Godowski, 2002). The 
genes for all three are located in human chromosome 4 (Roach et al., 2005). Evolutionary 
studies have shown that TLR1 and TLR6 are highly related and may have arisen as a 
product of gene duplication events (Roach et al., 2005). The greatest amount of 
variability between TLR1 and TLR6 occurs in the ECD, which is the region responsible 
for ligand recognition. The TLR ECD forms an evolutionarily conserved structure called 
the leucine rich repeat (LRR) motif, each made up of 22-29 amino acid residues with a 
consensus sequence of LxxLxLxxN (Bell et al., 2003; Botos et al., 2011; Kang & Lee, 
2011). The TLR1, TLR2, and TLR6 ECD each have 20 LRRs stacked in a bent solenoid-
shaped structure, and capped at both ends with an LRR-NT and LRR-CT capping 
modules (Jin et al., 2007; Kang et al., 2009). Crystal structure analyses revealed that the 
ectodomain of TLRs 1, 2, and 6 can be divided into three sub-domains: the N-terminal, 
central, and C-terminal domain. The N-terminal sub-domain, made up of the LRR-NT 
capping module and LRRs 1-4, have the asparagine ladder and the phenylalanine spine 
observed in typical LRR consensus motifs (Jin et al., 2007; Kang et al., 2009). In 
contrast, the LRR motifs seen in the central and C-terminal sub-domain contain atypical 
sequences and have no asparagine and phenylalanine spine, resulting in a conformation 
that deviates from the standard LRRs (Jin et al., 2007; Kang et al., 2009). More 
importantly, the boundary between the central and the C-terminal sub-domain of the 
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TLR1 and TLR2 ectodomain (LRRs 9-12) opens into a hydrophobic binding pocket 
where the prototypical triacylated lipopeptide ligand can be accommodated (Jin et al., 
2007). The crystal structure of human TLR1 and TLR2 bound to Pam3CSK4 reveals that 
the lipopeptide coordinately binds to both receptors at this central region to form a stable 
TLR1/TLR2/Pam3CSK4 ternary signaling complex, with the N-terminal ends facing away 
from each other and the C-terminal ends brought together in closer proximity (Jin et al., 
2007). Once this “m-shaped” conformation is assembled, the TLRs initiate a series of 
intracellular signaling cascades through their intracellular Toll-Interleukin Receptor 
(TIR) signaling domain that leads to the activation and expression of proinflammatory 
cytokines, chemokines and co-stimulatory molecules (Jin et al., 2007). 
The objective of this study is to identify the molecular basis of interaction 
between non-lipoprotein microbial cell wall components and the TLR1/TLR2 
heterodimer through mutational studies on TLR1. We have previously demonstrated that 
LRRs 9 through 12 in both TLR1 and TLR6 are essential for enabling TLR2 to recognize 
and discriminate between synthetic triacylated and diacylated lipopeptides (Omueti et al., 
2005). We found that the same region in TLR1 is required for recognition of various 
microbial components. Through random mutagenesis, we generated a library of clones 
with single amino acid substitutions within the LRRs 9-12 region of TLR1. We identified 
the same set of key residues in the TLR1 LRRs 11 and 12 that are responsible for 
recognizing different microbial components regardless of their molecular structures, 
suggesting that these amino acids in the TLR1 ECD are important for the formation of a 
dimer interface with the co-receptor TLR2 in order to achieve the final m-shaped ternary 
complex. In addition, we have also identified the putative conformational epitope of an 
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anti-TLR1 blocking mAb, GD2.F4 to specific residues found in LRRs 10-12 of TLR1. 
These studies contribute to the knowledge needed for accurately designing small 
inhibitory molecules or developing therapeutic strategies to dampen the immune response 
via TLR1/TLR2 activation upon microbial infection. 
Materials and Methods 
Reagents 
The synthetic bacterial lipopeptides N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R)-
propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine x 3 CF3COOH (R-
Pam3CSK4) and N-Acetyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-
seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine x 3 CF3COOH (Pam2AcCSK4) were 
purchased from EMC Microcollections (Tuebingen, Germany). The Macrophage-
activating lipopeptide-2, S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-
GNNDESNISFKEK] (MALP-2) was purchased from Enzo Life Sciences (formerly 
Alexis Biochemicals; Plymouth Meeting, PA). The natural TLR2 agonists used in these 
experiments are whole or particulate components of pathogens.  They include: heat killed 
Listeria monocytogenes (HKLM) from InvivoGen (San Diego, CA), LPS from 
Porphyromonas gingivalis (P. gingivalis LPS) from InvivoGen (San Diego, CA), 
Mycobacterial Membrane Fractions (NIAID contract N01 AI-75320 entitled Tuberculosis 
Research Materials and Vaccine Testing), heat killed Staphylocccus aureus (HKSA) 
from Invitrogen (Carlsbad, CA), non-mannose-capped lipoarabinomannan (ARALAM) 
from the cell wall of M. smegmatis obtained from Dr. J.T. Belisle (Department of 
Microbiology, Colorado State University), and Zymosan-A yeast particles from 
Invitrogen (Carlsbad, CA). 
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The unconjugated mouse anti-human TLR1 mAb (clone GD2.F4, CD281) and the 
isotype control, a mouse IgG1 mAb, were obtained from eBioscience (San Diego, CA). A 
mouse anti-FLAG mAB was purchased from Sigma (St. Louis, MO). A biotin-conjugated 
donkey anti-mouse secondary Ab and a streptavidin-phycoerythin (PE)-conjugated 
tertiary antibody were acquired from Jackson ImmunoResearch Laboratories, Inc. (West 
Grove, PA).   HRP-conjugated anti-FLAG (clone M2) monoclonal Ab was purchased 
from Sigma Aldrich (St. Louis, MO), while the HRP-conjugated anti-hemagglutinin 
(HA) monoclonal antibody was purchased from Miltenyi Biotec Inc. (Auburn, CA). 
Unconjugated polyclonal anti-human LBP and anti-human CD14 goat IgG antibodies 
were kind gifts from Dr. Peter Tobias (The Scripps Research Institute, La Jolla, CA). The 
secondary antibodies, HRP-conjugated rabbit anti-goat IgG and HRP-conjugated goat 
anti-rabbit IgG were purchased from Jackson ImmunoResearch Laboratories (West 
Grove, PA). 
Cell Culture 
SW620 cells, a human colonic epithelial cell line (American Type Culture Collection 
no. CCL-227), were cultured in RPMI 1640 media containing 10% heat-inactivated FBS 
(Hyclone, Logan, UT), 2mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin (Invitrogen). Human embryonic kidney 293T cells were cultured in DMEM 
containing 10% heat-inactivated FBS, and 2mM L-glutamine. Cells were maintained in a 
37˚C in a humidiﬁed environment containing 5% CO2. 
Construction of the TLR1 and TLR6 chimeras  
The TLR1 and TLR6 ECD chimeras used in this study were generated as N-
terminal FLAG-tagged constructs within a pFLAG-CMV vector using the techniques 
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described in (Omueti et al., 2005). Briefly, we engineered different restriction sites at the 
end of LRRs 5, 8, and 12 of both TLR1 and TLR6. The T6(1-5)/T1, T6(1-8)/T1, T6(1-
12)/T1, T1(1-5)/T6, T1(1-8)/T6, and T1(1-12)/T6 chimeric receptors were constructed by 
digesting the modified TLR1 and TLR6 with the appropriate restriction enzymes 
followed by re-ligation reactions. On the other hand, the T6(1-17)/T1 and T1(1-17)/T6 
chimeric receptors were generated from wild-type TLR1 and TLR6 using a natural 
HindIII site present at the end of the LRR 17 of both receptors. Recombinant DNA 
plasmids were verified by DNA sequencing (UIUC Core Sequencing Facility). All clones 
were tested and found to be expressed on the surface of transfected HEK 293T cells 
(Omueti et al., 2005).  
Random mutagenesis of the TLR1 ECD LRRs 9-12  
A library of TLR1 clones was generated by random mutagenesis by PCR. To this 
end, we engineered XbaI restriction sites flanking the LRRs 9-12 region of TLR1 cloned 
on a pFLAG-CMV vector, and subsequently excised this 300bp region by XbaI digestion 
for one hour at 37
o
C. Excision was confirmed by running the digest on a 1% agarose gel, 
and this region was purified using Qiagen gel extraction kit.  Error prone PCR as 
described in (Wilson & Keefe, 2001) was conducted on this fragment using the following 
primers: Forward [CCAATCTAGAAACAACTTGGAATTCTTTCATTAGGATCC] and 
Reverse [CCAATCTAGATTGTTTAAGGTAAGACTTGATAAGTTTGG] (The Xba I 
sites have been underlined).  PCR products were ligated into the modified TLR1 pFLAG-
CMV vector which had been previously digested with Xba I to remove the original LRRs 
9-12.  Clone Checker (Invitrogen, Carlsbad, CA) was used in accordance with the 
manufacturer’s instructions to screen the library generated for clones which contained the 
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insert in the correct orientation.  Unique clones were identified by DNA sequencing 
(UIUC Core Sequencing Facility). 
Cell Activation Assays  
SW620 cells were co-transfected with various combinations of TLRs together 
with a firefly luciferase gene driven by the IL-8 promoter and a Renilla luciferase gene 
driven by a basal promoter (pRL-null) as a transfection control (Promega; Madison, WI). 
Transfections were performed using a cationic lipid agent, Fugene-6 (Roche), at a 4:1 
lipid:DNA ratio. The total amount of transfected plasmid DNA was equalized by 
supplementing with empty vector, pFLAG-CMV. Forty-eight hours post-transfection, the 
cells were stimulated for 6 hours with the indicated agonists. Following the 
manufacturer’s protocol for the dual luciferase assay (Promega), cell lysates were 
collected 6 hours post-stimulation and analyzed for firefly and Renilla luciferase activity 
using a BioTek Synergy HT plate reader (BioTek; Winooski, VT). The transfection 
efficiency across different wells was normalized by dividing the firefly luciferase activity 
by the Renilla luciferase control. After correcting for transfection efficiency, all values 
were normalized to those of unstimulated cells transfected with reporters and empty 
pFLAG-CMV vector. 
Flow cytometry 
 Human embryonic kidney (HEK) 293T cells were transfected with 3.0 µg of 
FLAG-tagged TLR constructs or empty vector.  Fugene-6 (Roche Inc., Indianapolis, IN) 
was used as the transfection reagent to introduce the DNA vectors into the cells.  Cell 
media was changed 6 hours post-transfection.  48 hours post-transfection, cells were 
removed from the plate with chilled PBS (pH 7.4) and these cell suspensions were 
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transferred to 1.5ml microcentrifuge tubes.  These cells were incubated with either a 
mouse anti-FLAG M2 antibody or anti-TLR1 (GD2.F4) mAb, followed by a biotinylated 
donkey anti-mouse secondary antibody, and finally a streptavidin PE-conjugated tertiary 
antibody.  The cells were then washed, fixed, and then quantified for surface fluorescence 
using a Coulter Epics XL instrument.  Overlays were created using the Summit software 
program. 
Size exclusion chromatography assays 
The TLR1-TLR2-lipopeptide ternary complex was formed by pre-incubating 
0.25uM TLR2, 0.25uM TLR1, and 2.5uM Pam3CSK4 (with or without 0.05uM LBP 
and/or 0.25uM sCD14) in PBS pH 7.4 buffer to a final volume of 0.5ml. The mixture was 
incubated in a 37
o
C water-bath for 2 hours and injected into a Superdex 200 10/300GL 
gel filtration column (GE Healthcare) at a flow rate of 0.5 ml/min in PBS pH 7.4 running 
buffer. Twenty minutes after injection of the sample, 0.5ml fractions were collected 
covering one column bed volume (about 24ml, 48 min). The chromatogram was recorded 
using a manual UV recorder. The data was then re-plotted using the xyExtract v5.1 graph 
digitizer software (Wilton and Cleide Pereira da Silva; Campina Grande, Paraíba, Brazil). 
Eluted fractions were separated on a 7.5% SDS-PAGE gel and transferred to an 
Immobilon-P PVDF membrane (Millipore). The membranes were blocked with 5% non-
fat dry milk (NFDM) in TBS buffer containing 0.05% Tween-20. Western blotting was 
performed to detect TLR1 and TLR2 using HRP-conjugated anti-HA and anti-FLAG 
antibodies (both diluted at 1:1000 in 5% NFDM), respectively. LBP and/or CD14 was 
detected using either a polyclonal goat anti-LBP or goat anti-CD14 (diluted 1:500 in 5% 
NFDM), followed by a HRP-conjugated rabbit anti-goat IgG polyclonal antibody (diluted 
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1:5000 in 5% NFDM). Chemiluminescence was detected using the Pierce ECL Western 
blotting substrate (Rockford, IL). Membranes were then exposed to a HyBlot CL 
autoradiograpy film (Denville Scientific Inc.; Metuchen, NJ) and developed. 
Visualization and structural analysis of the TLR1 ECD 
The TLR1 structure visualization was carried out using the information from the 
solved crystal structure of TLR1/TLR2/Pam3CSK4 (Jin et al., 2007) uploaded at the 
RCSB Protein Data Bank (template PDB 2Z7X ), and were analyzed using the Visual 
Molecular Dynamics (VMD) software developed at the University of Illinois at Urbana-
Champaign (Humphrey et al., 1996). 
Results 
LRRs 9-12 of TLR1 are essential to cellular responses to synthetic and naturally-
occurring TLR1-TLR2 agonists 
Previous studies in our lab have shown that the LRRs 9-12 of TLR1 and TLR6 
ECD are important for distinguishing a triacylated from a diacylated lipopeptide (Omueti 
et al., 2005). To determine if the same region of TLR1 is required for recognition of other 
TLR1/TLR2 natural microbial agonists, we used the same reconstitution experiments to 
test different TLR1 and TLR6 chimeric receptors for their ability to recognize a variety of 
microbial products. SW620 cell lines, a human epithelial carcinoma line, were transfected 
with TLR2 together with different TLR1 and TLR6 chimeras as previously described 
(Omueti et al., 2005). SW620 cells are deficient in TLR1 and TLR2, and express very 
little TLR6. Consistent with our previous studies, TLR1 in partnership with TLR2, 
recognized the triacylated synthetic agonist Pam3CSK4, while the TLR6/TLR2 pair 
responded to the diacylated MALP-2, as measured by the relative IL-8-luciferase reporter 
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activity (Figure 4.1, top panel). There are eight different N-terminal chimeras with 
domain exchanges between TLR1 and TLR6 at LRRs 1-5, 1-8, 1-12, and 1-17.  All of 
these FLAG-tagged chimeric receptors were shown to be expressed on the surface of 
transfected SW620 cells by flow cytometry using an anti-FLAG mAb. With the 
exception of T1(1-8)/T6, all other N-terminal chimeras appear to be properly folded and 
biologically active. As TLR1 was gradually replaced with TLR6 ECDs at the N-terminal 
domain, the response to Pam3CSK4 diminished. Relative to wild-type TLR1, a TLR1 
chimera whose LRRs 1-5 were replaced with that of TLR6 [T6(1-5)/T1] only exhibited 
about 50% IL-8 luciferase activity towards Pam3CSK4, while a TLR1 chimera that has 
TLR6 LRRs 1-8 at the N-terminal region [T6(1-8)/T1] have shown only 20% activity 
upon Pam3CSK4 stimulation. When this N-terminal replacement was extended to LRR 12 
[T6(1-12)/T1], the IL-8-luciferase activity in response to Pam3CSK4 was almost 
completely lost, but was able to exhibit MALP-2 activity at about 44% relative to wild-
type TLR6. The TLR1 chimera whose LRRs 1-17 have been replaced with TLR6 [T6(1-
17)/T1] also exhibited diminished activity towards Pam3CSK4, but was able to recognize 
MALP-2 at similar levels compared to wild-type TLR6. On the other hand, the reverse 
chimeras demonstrated that when the LRRs 1-12 or 1-17 of TLR6 were replaced with 
that of TLR1 [T1(1-12)/T6 and T1(1-17)/T6, respectively], the ability to recognize 
Pam3CSK4 was restored. Consistent with our previous resport (Omueti et al., 2005), the 
LRRs 9-12 of TLR1 and TLR6 were shown to be important for recognition of their 
respective synthetic agonists.  
Using the same chimeric receptors, we tested various known naturally-occurring 
TLR1/TLR2 agonists (Figure 4.1, middle and bottom panels). We observed that P. 
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gingivalis LPS activated cells transfected with TLR1/TLR2, but not TLR2/TLR6. The 
data also demonstrated that when the wild-type TLR1 was replaced with increasing 
amounts TLR6 at the N-terminal domain, the IL-8-luciferase activity of cells in response 
to P. gingivalis LPS decreased. The T6(1-5)/T1 and T6(1-8)/T1 chimeric receptors 
exhibited 60% and 55% luciferase activity, respectively, compared to wild-type TLR1. 
More importantly, when the domain exchange was extended to LRRs 1-12 and 1-17 
[constructs T6(1-12)/T1 and T6(1-17)/T1], the transfected cells were no longer able to 
respond to P. gingivalis LPS. This suggests that the residues in LRRs 9-12 of TLR1 play 
a role in mediating recognition of P. gingivalis LPS. In support of this, the TLR6 chimera 
whose N-terminal domain was replaced with LRRs 1-12 and LRRs 1-17 of TLR1 
[constructs T1(1-12)/T6 and T1(1-17)/T6] exhibited greater than 60% IL-8-luciferase 
activity upon stimulation with P. gingivalis LPS, comparable to that of wild-type TLR1. 
Both the non-mannose capped lipoarabinomannan (AraLAM) from mycobacterial 
cell walls as well as a preparation of mycobacterial membrane fractions (Mtb mem) 
activate cells transfected with TLR2 and wild-type TLR1. Not surprisingly, we did 
observe TLR2/TLR6-mediated activity (about 45% relative to TLR1/TLR2 activity) in 
cells stimulated with mycobacterial membrane fractions, since the preparation of this 
agonist may contain some TLR2/6 agonists such as diacylated lipoproteins.  Similar to 
what has been observed with P. gingivalis LPS, cells that were transfected with a 
chimeric TLR1 whose LRRs 1-12 and 1-17 have been replaced with the that of TLR6 
[constructs T6(1-12)/T1 and T6(1-17)/T1, respectively] and stimulated with either 
AraLAM or mycobacterial membrane fractions exhibited an IL-8 luciferase activity was 
less than 20% relative to wild-type TLR1. This suggests that LRRs 9-12 of TLR1 are also 
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required for their recognition. However, in the reverse construct where TLR1 LRRs 1-12 
were placed in TLR6 [construct T1(1-12)/T6], the cell response towards the two agonists 
was not rescued. Only when the substitution was extended to TLR1 LRRs 1-17 [construct 
T1(1-17)/T6] did we observe a greater than 65% IL-8-luciferase activity in stimulated 
cells, suggesting that a larger region of the TLR1 region may be necessary for full 
recognition of AraLAM and mycobacterial membrane fractions. 
The next agonists that we tested were a derivative of yeast cell wall (Zymosan-A 
particles) and preparations of heat-killed Staphylococcus aureus (HKSA), both of which 
preferentially activate TLR1/TLR2 (Figure 4.1, bottom panel). Like all TLR1/2 microbial 
agonists tested thus far, TLR2 co-transfected with either T6(1-12)/T1 or T6(1-17)/T1 
have very low IL-8-luciferase activity upon stimulation with Zymosan-A and HKSA. 
This activity was rescued in cells co-transfected with TLR2 and T1(1-17)/T6. These 
results are consistent with our previous data from other TLR1/TLR2 agonists, suggesting 
that the same critical regions which include LRRs 9-12 of TLR1 are required for cellular 
sensing of these different types of agonists. 
Finally we tested heat-killed Listeria monocytogenes (HKLM) in our system 
(Figure 4.1, bottom panel). This agonist preferentially activates cells transfected with 
TLR2 and TLR6. TLR6-mediated activity was still observed after replacement of the first 
five LRRs with that of TLR1 [T1(1-5)/T6]. However, this activity was lost when the 
domain replacement from TLR6 to TLR1 was extended to LRR 8 [T1(1-8)/T6], LRR 12 
[T1(1-12)/T6], and LRR 17 [T1(1-17)/T6]. Furthermore, in the reciprocal experiment, the 
response to HKLM was only restored when LRRs 1-17 of TLR6 are substituted in the 
TLR1 chimera [T6(1-17)/T1], suggesting that a large region of TLR6 is necessary, an 
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area that covers LRRs 6-17 of TLR6, for mediating TLR6 response to this microbial 
agonist. However, it is important to note that LRRs 9 through 12 still falls within the 
region needed to stimulate activity to HKLM. 
The epitope of anti-TLR1 blocking mAb, clone GD2.F4, maps to the central region 
(LRR 11) of TLR1 
When we generated our FLAG-tagged TLR1 chimeric constructs and the TLR1 
single point mutants, we tested for their expression on the surface of HEK 293T cells 
using an anti-FLAG antibody as evidenced by the data we previously reported in 2005 
(Omueti et al., 2005). To test for proper protein folding, we used an anti-TLR1 mAb 
(clone GD2.F4), which is known to bind endogenous TLR1 expressed on the surface of 
human monocytes (Wyllie et al., 2000). To this end, we show that GD2.F4 binds to wild-
type TLR1 but not TLR6, and as we gradually replaced the N-terminal region of TLR1 
with that of TLR6, we observed that the GD2.F4 mAb was not able to recognize the 
chimeric TLR1 whose N-terminal LRRs 1-12 and 1-17 have been replaced with that of 
TLR6 [constructs T6(1-12)/T1 and T6(1-17)/T1, respectively] (Figure 4.2). Moreover, 
when we tested the TLR6 chimeric constructs, the antibody bound to the constructs T1(1-
12)/T6 and T1(1-17)/T6 but not to T1(1-5)/T6 and T1(1-8)/T6. Taken altogether, the data 
revealed that only the chimeras that contain LRRs 9-12 of TLR1 are recognized by the 
GD2.F4 mAb, suggesting that the epitope of the anti-TLR1 monoclonal antibody lies 
within this region of TLR1.  
To map the epitope of the anti-TLR1 mAb, we performed random mutagenesis on 
the LRRs 9-12 of TLR1. We generated fifty-nine single point mutants, expressed them on 
HEK 293T cells, and analyzed for their binding to the anti-FLAG and the anti-TLR1 
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(clone GD2.F4) mAbs (Figure 4.3 and Table 4.1 columns 2 and 3). Any TLR1 mutants 
that fall below 50% mean fluorescence intensity (MFI) relative to the wild-type TLR1 
upon anti-Flag mAb staining were deemed poorly expressed on the surface and were 
removed from the data set. Using this set criteria, we found a total of 41 point mutants 
(11 of which are located in LRR 10, 23 are in LRR 11, and 7 are in LRR 12) that 
exhibited good surface expression (Figure 4.3). When we stained the cells with GD2.F4, 
fourteen single point mutants had an MFI that is less than 50%  relative to that of the 
wild-type TLR1, suggesting that these mutants were poorly recognized by the anti-TLR1 
mAb (Figure 4.3). Those that have <5% MFI relative to wild-type fluorescence were the 
point mutants S309N, D310V, F312S, F314L, P315L, and Q316K. We mapped these 
residues on the variable loop of LRR 11 of the TLR1 ECD using the PDB structure 
reported by Jin et al. in 2007 (Jin et al., 2007) and the VMD software to illustrate the 
possible binding site of the GD2.F4 mAb. Interestingly, GD2.F4 inhibits agonist-induced 
activation of TLR1 (Omueti et al., 2007), suggesting a crucial role for LRR 11 in receptor 
function. 
Figure 4.4A shows the ribbon diagram of TLR1 ECD (in blue) highlighting its 
LRRs 9-12, while Figure 4.4B shows the space-filling model of TLR1 with the LRRs 9-
12 in an alternating color scheme (blue and light gray). Pam3CSK4 is also included in 
both figures 4.4A and 4.4B to demonstrate that one of its acyl chains inserts into the 
hydrophobic channel located between LRRs 11 and 12 of TLR1. Figures 4.4C and 4.4D 
show the location of the 41 critical residues in the TLR1 ECD in the ribbon and space-
filling model, respectively. The amino acid residues S309, D310, F312, F314, P315, 
Q316, S317, and Y320 are all found in the variable loop of LRR 11, which line the 
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entrance of the hydrophobic channel of TLR1. L287 and R290 are mapped at the 
periphery of the convex surface, flanking F314 and P315. On the other hand, S279 and 
V307 are found on concave side, lining part of the β-sheet structures. Finally, F331 is 
buried inside the hydrophobic pocket. Taken together, data suggests that the putative 
conformational epitope of the GD2.F4 mAb encompasses the region where amino acid 
residues S309, D310, F312, F314, P315, Q316, S317, and Y320 from the variable loop of 
LRR 11 are located, and that mutations in S279, V307, and F331 may have changed the 
over-all folding of the LRRs 10-12, thus indirectly affecting binding of the GD2.F4 
antibody (Figure 4.4D). 
Amino acid residues located at LRRs 11 and 12 of the TLR1 ECD contribute to cellular 
responses to triacylated lipopeptide (Pam3CSK4) 
The data presented thus far have highlighted the importance of LRRs 9-12 of 
TLR1 in sensing various TLR1/TLR2 agonists. To identify the important residues in this 
region, we generated a mutant library by random mutagenesis. As previously mentioned, 
we screened our FLAG-tagged single-point mutants for surface expression and their 
ability to bind to the anti-TLR1 mAb GD2.F4 (see Table 4.1). Based on our surface 
expression data, point mutants that were poorly expressed on the cell surface were 
excluded from our data analysis (see Table 4.1). Using our cell-based reconstitution 
assay, we further screened our mutant library for function by transfecting SW620 cells 
with the different TLR1 point mutants together with TLR2, a luciferase reporter gene 
under the control of an IL-8 promoter, and a Renilla transfection control. This was 
followed by stimulation with the potent synthetic triacylated lipopeptide agonist 
Pam3CSK4. To analyze the functional data, mutants displaying ≤ 20% of wild-type TLR1 
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activity are considered poorly responsive to Pam3CSK4. This cut-off was based on the 
relative IL-8-luciferase activity of SW620 cells transfected with TLR2 alone and 
stimulated with Pam3CSK4.  
For most of the clones we isolated, the single amino acid change did not affect 
their expression on the cell surface or their ability to recognize the triacylated agonist 
Pam3CSK4. Figure 4.5 summarizes selected TLR1 single point mutants that are found in 
LRRs 11 and 12 and their response to Pam3CSK4 as measured by the relative IL-8 – 
luciferase activity in our cell-based reconstitution assay. Comparing this data with the 
results from the GD2.F4 mAb binding experiment, most of the single point mutants that 
failed to bind to the GD2.F4 mAb (S309N, D310V, F312S, F312Y, S317G, and Y320N) 
exhibited normal response to the agonist Pam3CSK4. In contrast, we identified three 
clones in the variable loop of LRR11 (F314L, P315L, and Q316K) and one in LRR12 
(V339D) that strikingly did not respond to Pam3CSK4 even though they were all 
expressed on the cell surface as measured by the anti-FLAG mAb  (Table 4.1). This data 
suggests that the four amino acids at positions 314, 315, 316, and 339 are important for 
TLR1 recognition of Pam3CSK4 and the formation of a dimer interface with the co-
receptor TLR2. This region was also identified to be important for binding the amide-
linked acyl chain of Pam3CSK4 as revealed by the crystal structure (Jin et al., 2007).  The 
TLR1/TLR2/Pam3CSK4 crystal structure also shows that the oxygen in the amide group 
of the Cysteine residue in Pam3CSK4 forms H-bonds with the side chain of Q316 in 
TLR1 (Jin et al., 2007). Thus a mutation from glutamine to lysine at position 316 may 
have altered this interaction between TLR1 and Pam3CSK4. 
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We have previously demonstrated that TLR1P315L, which is a rare but naturally-
occurring single nucleotide polymorphism observed in individuals of African descent, 
confers a greatly attenuated response to lipopeptide agonists (Omueti et al., 2007).  We 
have also previously shown by gel filtration chromatography that the formation of the 
final TLR1/TLR2/Pam3CSK4 ternary complex is ligand-induced and requires the 
assistance of either LBP or soluble CD14 for the efficient delivery of the monomeric 
agonist to the TLRs (Ranoa et al., 2013; Chapter 2). Using purified, monomeric, and 
functional TLR1 and TLR2 extracellular domains, we compared the ability of wild-type 
TLR1 and TLR1P315L to form the ternary complex with TLR2 and the triacylated agonist 
Pam3CSK4 in solution. In contrast to wild type TLR1, TLR1P315L did not form a stable 
ternary complex with TLR2 and Pam3CSK4, as indicated by the presence of a smaller 
peak with a calculated relative molecular weight of 183kDa (Figures 4.6A and 4.6B, left 
panel). The bigger peak that came out at a later time represents the protein monomers, 
which have a calculated relative molecular weight of 70kDa and 80kDa for TLR1 and 
TLR2, respectively. When we analyzed the eluted fractions by Western blot, both wild-
type TLR1 and TLR2 were detected in earlier eluted fractions containing the ternary 
complex (Figure 4.6A, right panel), whereas TLR1P315L incubated with TLR2 both came 
out in the later fractions containing the monomeric proteins (Figure 4.6B, right panel). 
The fact that TLR1 proline at amino acid position 315 is critical for ternary complex 
formation explains the highly attenuated responses of this naturally occurring TLR1 
variant to triacylated lipopeptides. As an additional control, we show in Figure 4.3C that 
a diacylated synthetic agonist Pam2AcCSK4 does not induce complex formation between 
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wild-type TLR1 and TLR2 suggesting that the third acyl chain of the lipopeptide is 
necessary for conferring specificity to TLR1/TLR2-mediated responses. 
The critical amino acids of TLR1 at LRRs 11-12 required for receptor function are 
strikingly similar across all naturally occurring TLR1/TLR2 agonists, irrespective of 
their chemical nature 
Similar to what we did with the TLR1 chimeric receptors, we also tested our 
single point mutants in their ability to sense naturally-occurring agonists such as P. 
gingivalis LPS, mycobacterial membrane fractions, and Zymosan particles from yeast 
cells (Figure 4.7). We transfected SW620 cells with TLR2 together with the different 
TLR1 point mutants, and measured the relative IL-8 – luciferase activity after stimulation 
with the aforementioned agonists. The summarized data from single point mutants shown 
in Figure 4.7 are mapped in LRRs 11 and 12 of the TLR1 ECD. When transfected cells 
were stimulated with P. gingivalis LPS, the F314D, P315L, Q316K, and V339D mutants 
were highly attenuated, showing less than 20% IL-8 – luciferase activity. The V311E and 
E321V mutants were weakly attenuated in sensing P. gingivalis LPS, with about 40-60% 
IL-8 – luciferase activity. The mutated residues that conferred a highly attenuated 
response to P. gingivalis LPS are strikingly similar to what was observed with Pam3CSK4 
(Figure 4.5), suggesting that the same region in TLR1 may be required for binding to or 
recognizing one of the acyl chains of P. gingivalis LPS.   
Similarly, we also observed that the response of SW620 cells expressing the 
TLR1 mutants F314D, P315L, Q316K, and V339D mutants were also highly attenuated 
when stimulated with mycobacterial membrane fraction and Zymosan particles, while the 
mutants V311E, Y320N, and E321V exhibited a weakly attenuated response. These 
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suggest that even with a heterogeneous mixture of agonist whose structures may differ 
from the typical lipidated TLR1/TLR2 agonists, the region required for TLR1 recognition 
remains the same.  
Using the information from the TLR1/TLR2/Pam3CSK4 crystal structure 
uploaded at the Protein Data Bank (PDB 2Z7x) and the VMD software, we mapped these 
important residues on the TLR1 ECD. Figure 4.8A shows the ribbon diagram of the 
TLR1 LRRs 10-12 and the relative position of the residues V311, F314, P315, Q316, 
Y320, E321, and V339 on the flexible loops on the convex surface of LRRs 11 and 12. 
Figure 4.8B shows the same information, with the critical residues illustrated in space-
filling model to demonstrate that the residues V311, F314, P315, Q316, Y320, and V339 
all line the entrance of the hydrophobic pocket of TLR1 formed between LRRs 11 and 
12, and where the third acyl chain of Pam3CSK4 binds in the crystal structure. This 
explains why the mutants F314D, P315L, Q316K, and V339D were unresponsive to 
Pam3CSK4, P.gingivalis LPS, mycobacterial membrane fraction, and Zymosan particles 
(Figures 4.5 and 4.7). More importantly, these residues may be critical for the formation 
of a dimer interface with the co-receptor TLR2.  
Figure 4.8C reveals the dimer interface between LRRs 10*-13* of TLR2 (left 
side, shaded in gray) and LRRs 10-12 of TLR1 (right side, shaded in blue), as viewed 
from the top of the ternary TLR1/TLR2/Pam3CSK4 ternary complex structure. For 
orientation, two of the acyl chains of Pam3CSK4 are inserted inside the hydrophobic 
pocket of TLR2 formed between LRRs 12* and 13*, while the third acyl chain of 
Pam3CSK4 is inserted inside the hydropobic channel formed by LRRs 11 and 12 of 
TLR1. The hydrophobic/non-polar, polar, acidic, and basic residues are shaded in yellow, 
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green, red, and blue, respectively.  The side chains of the TLR1 amino acid residues 
V311, P315, Y320, and V339 are all predicted to have hydrophobic interactions with 
some residues in TLR2 (Jin et al., 2007). For example, the hydrophobic V311 residue of 
TLR1 is predicted to interact with the residues L350*, P352*, and Y376* of TLR2. The 
P315 residue of TLR1 is predicted to interact with the TLR2 Y323*.  The polar Y320 of 
TLR1 is predicted to interact with TLR2’s F322*, Y323*, and L324*.  Finally, V339 of 
TLR1 is predicted to interact with F322*, F349*, and L371* of TLR2. On the other hand, 
the acidic amino acid residue E321 found at the periphery of the convex surface of TLR1 
is predicted to form ionic bonds with the basic residues H318* and R321* found in the 
flexible loop of LRR11* of TLR2.   
Taken altogether, the critical residues important for recognition of a variety of 
TLR1/TLR2 agonists that we have identified in our random mutagenesis studies are 
located in regions of the TLR1 ECD that are important for formation of dimer interface 
with TLR2. Our data were found to be consistent with the published 
TLR1/TLR2/Pam3CSK4 crystal structure and provides strong support to most of the 
predicted important interacting residues in TLR1 (Jin et al., 2007). 
Discussion 
Lipoproteins or lipopeptides are potent agonists of TLR2 and its co-receptors 
(Aliprantis et al., 1999; Brightbill et al., 1999; Takeuchi et al., 2000). Through the 
reciprocal domain exchange of two homologous TLRs, TLR1 and TLR6, our previous 
studies have shown that the residues of LRRs 9-12 of TLR1 and TLR6, though not 
sufficient, are required for discriminating between triacylated and diacylated lipopeptides 
(Omueti et al., 2005). Other researchers such as (Grabiec et al., 2004) and (Andersen-
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Nissen et al., 2007)  have demonstrated the role of central LRRs of TLR2 and TLR5 in 
mediating species-specific agonist specificity to different lipopeptides and flagellin, 
respectively.  
This study aims to further define the specific region(s) in the TLR1 ECD that is 
required for recognition of various microbial cell wall components that are known to 
activate the TLR1/TLR2 receptor pair. The first purified microbial component that we 
tested on SW620 epithelial cells were purified atypical LPS from Porphyromonas 
gingivalis (P. gingivalis). This Gram-negative bacterium is the causative agent of chronic 
oral inflammation that leads to periodontal disease (Holt et al., 1999). It has been 
demonstrated that a preparation of P.gingivalis LPS may contain various Lipid A species, 
some of which are recognized by TLR4, while others are sensed by TLR1/TLR2; but 
stringent purification procedures can separate the different Lipid A species (Darveau et 
al., 2004; Hirschfeld et al., 2001).   
In addition to P. gingivalis LPS, we also used other heat-killed microbial 
preparations or microbial products previously demonstrated to be TLR2 dependent 
agonists, which include arabinose lipoarabinomannan (ARALAM) from mycobacterial 
sp. (Means et al., 1999); zymosan yeast particles (Sato et al., 2003; Underhill et al., 
1999); mycobacteria membrane fractions; heat killed Staphylococcus aureus (HKSA); 
and heat-killed Listeria monocytogenes (HKLM). Mycobacterial membrane fractions are 
rich in TLR2 agonists such as lipomannans, lipoarabinomannans, glycolipids, and various 
species of lipoproteins (Gehring et al., 2004; Gilleron et al., 2003; Means et al., 1999; 
Noss et al., 2001; Pecora et al., 2006; Quesniaux et al., 2004). S. aureus and L. 
monocytogenes are both Gram-positive organisms. The cell wall of gram positive 
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organisms is known to be rich in peptidoglycan and lipoteichoic acids (Dziarski & Gupta, 
2005; Schwandner et al., 1999). It has been shown that heat-killed whole cell preparation 
of S. aureus induced NF-kB activation in TLR2-transfected CHO cells (Yoshimura et al., 
1999). It has also been observed that TLR2-deficient mice are highly susceptible to S. 
aureus, whereas TLR4-deficient mice are not (Takeuchi et al., 2000). 
All the microbial agonists that we tested in this study require LRRs 9-12 of TLR1 
to be involved in their recognition. Interestingly, the heat-killed microbial agonists and 
particulates, showed a requirement for not only LRRs 9 through 12 but for a larger region 
extending before or after this LRR region. The reason for this observation is currently not 
known. A possibility is that these particulate agonists do need a larger contact surface 
area of TLR1 in order to be recognized by the receptor. Regardless of the surface area 
required, a theme that emerges from the N-terminal and internal chimera results is that 
when the TLR1 LRRs 9-12  are missing, or not part of the chimeric receptor, the cell 
activation observed upon stimulation is very minimal.  
Since LRRs 9-12 of TLR1 were repeatedly shown to be the smallest region of 
importance in the recognition of various microbial agonists, a library of clones with 
single amino acid substitutions within this region of TLR1 was created.  We tested for 
cell surface expression and the ability of the single point mutants to bind to an anti-TLR1 
mAb GD2.F4.We have previously shown that GD2.F4 is a neutralizing anti-TLR1 mAb 
that failed to bind to the TLR1P315L mutant (Omueti et al., 2007). In this study, we have 
demonstrated that the putative epitope of the anti-TLR1 blocking mAb, GD2.F4, maps to 
the flexible loop of LRR 11of TLR1 and includes the amino acid positions S309, D310, 
F312, F314, P315, Q316, S317, and Y320. The knowledge of the antibody epitope could 
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potentially lead to the design of therapeutic inhibitory compounds that could either serve 
as an antagonist to TLR1/TLR2 or as a competitive inhibitor to the natural microbial 
agonists. 
More importantly, by combining our results from the GD2.F4 binding 
experiments and the screening of TLR1 single point TLR1 mutants for their response to 
various agonists such as Pam3CSK4, P. gingivalis LPS, mycobacterial membrane 
fraction, and yeast Zymosan, our data demonstrate that the amino acid residues F314, 
P315, Q316, and V339 of TLR1 are required for sensing various microbial components 
known to activate TLR1/TLR2 regardless of the microbial component’s chemical 
structure. Interestingly, three of the amino acids (F314, P315, and Q316) that lay side-by-
side in the outer loop of LRR11 lining the entrance of the TLR1 hydrophobic pocket, was 
also identified to be a part of the putative epitope of the GD2.F4 mAb. The mutants 
F314L, P315L, Q316K failed to bind to GD2.F4 and also failed to respond to the 
microbial agonists used in this study. The V339D mutant, on the other hand, was 
unresponsive to the microbial agonists tested but was able to bind to the GD2.F4 mAb. 
While it is possible that the mutations at F314L, P315L, and Q316K simply destroyed or 
altered the structure of the TLR1 extracellular domain, the V339D mutant demonstrate 
that our results are real and add to the argument that collectively, these regions are 
important specifically for the formation of a dimer interface with TLR2. V339 lies within 
the outer loop of LRR12 just below the three residues in LRR11, also part of the 
hydrophobic residues lining the entrance of the TLR1 binding pocket (Figure 4.5).  The 
physical proximity of F314, P315, Q316 and V339 to the hydrophobic binding pocket of 
TLR1 combined with the loss-of-function data resulting from mutations of these residues 
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suggests a functional patch that may affect the interaction of TLR1 with both the agonist 
and the co-receptor TLR2. Based on the TLR1/TLR2/Pam3CSK4 crystal structure (Jin et 
al., 2007), the amino acid residues P315 and V339 of TLR1 are predicted to form 
hydrophobic interactions with several amino acid residues from TLR2 (Figure 4.8.C).  
Kinetic measurements performed on soluble wild-type TLR1 and the TLR1P315L 
extracellular domain binding to lipoproteins reveal that there is only a 1.5-fold difference 
in their affinity for the agonist, where TLR1-lipoprotein KD = 7.45x10
-7
 while TLR1P315L 
KD = 1.13x10
-6
 (see Chapter 3 Table 3.3). However, cells that were stimulated with 
TLR1P315L failed to respond to Pam3CSK4 (Omueti et al., 2007). Furthermore, purified 
TLR1P315L ECD failed to form a ternary complex with TLR2 in the presence of excess 
amounts of Pam3CSK4 (Figure 4.6). All these data suggest that proline at position 315 is 
more important for the formation of a dimer interface with TLR2.  
It is noteworthy to mention that the amino acid residues V311, P315, Y320, R337, 
and V339 of TLR1 were found to be necessary for the recognition of a non-lipidated 
protein ligand, the pentameric ganglioside-binding (B5) sub-unit of the type IIb 
enterotoxin from E. coli (LT-IIb-B5) (Liang et al., 2009). The molecular docking studies 
performed by this group suggest that the relatively huge LT-IIb-B5 protein binds to 
hydrophobic residues found at the convex surface of both TLR1 and TLR2 LRRs 9-12 
domain (Liang et al., 2009). This interaction leads to the formation of a similar “m-
shaped” TLR1/TLR2 heterodimer, suggesting that the critical TLR1 residues identified in 
their mutational studies are located on the TLR1/TLR2 dimer interface region (Liang et 
al., 2009). 
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Phylogenetic studies on TLR1 reveal that the TLR1 gene has undergone positive 
selection over the course of evolution (Wlasiuk & Nachman, 2010). Numerous amino 
acid sites were predicted to be important either for ligand binding or formation of dimer 
interface with TLR2. Comparing our TLR1 mutational studies with their computational 
data, we found that only a few amino acid sites are in common, namely, amino acids at 
position 289, 293, 303, 313, 321, and 337 (Wlasiuk & Nachman, 2010). Computational 
data also suggest that amino acid position 303 and 313 are important for ligand binding, 
while 321 and 337 are necessary for the formation of a dimer interface with TLR2. We 
generated mutants F289I, D293Y, S303Y, E321V, E321K, E321D, and R337H. With the 
exception of R337H, all mutants were expressed well on the cell surface, however, their 
response to Pam3CSK4 as measured by the IL-8-luciferase activity is similar to wild-type 
TLR1 (Table 4.1), suggesting that these mutations did not affect function of TLR1 in 
terms of recognizing Pam3CSK4 nor binding with TLR2. A few evolutionary and 
polymorphic studies have also suggested amino acid positions located in other LRRs of 
TLR1 that may be important for the formation of dimer interface. This includes the SNPs 
L443I, V542A, and T565S that are found in LRR17 and the C-terminal capping region of 
the TLR1 ECD (Georgel et al., 2009; Jin et al., 2007). However, these regions are outside 
the scope of our random mutagenesis study.  
Taken altogether, our data suggest that irrespective of their assumed chemical 
nature, the microbial agonist induces the formation of an “m-shaped” 
TLR1/TLR2/agonist ternary complex. To date, the crystal structures of seven TLRs in 
complex with their respective ligands have already been solved: TLR1/TLR2/Pam3CSK4 
(Jin et al., 2007), TLR2/TLR6/Pam2CSK4 (Kang et al., 2009), TLR4/MD2/LPS (Park et 
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al., 2009), TLR3/double-stranded RNA (Liu et al., 2008), TLR5/FliC flagellin (Yoon et 
al., 2012), and TLR8/single-stranded RNA (Tanji et al., 2013). The unifying theme taken 
from all these available TLR-ligand crystal structures is the fact that upon ligand binding, 
the TLRs undergo conformational changes to form a stable “m-shaped” complex that 
allows the C-terminal regions, and consequently the TIR cytoplasmic domain of the two 
interacting TLRs, to come into close proximity with one another thus setting up the stage 
that allows a signaling cascade to occur. [Reviewed in (Akira et al., 2006; O'Neill, 
2008)].  
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Figures 
 
Figure 4.1. The LRRs 9-12 of TLR1 are important for recognition of a variety of 
microbial agonists. SW620 epithelial cells were co-transfected with TLR2 and either a 
TLR1 or a TLR6 N-terminal chimera, an IL-8-driven luciferase gene, and a Renilla 
transfection control. Cells were then stimulated with 20ng/ml Pam3CSK4, 20ng/ml 
MALP-2, 100ng/ml P. gingivalis LPS (Pg LPS), 10μg/ml of non-mannose-capped 
lipoarabinomannan (AraLAM) from Mycobacterial cell walls, 6μg/ml of Mycobacterial 
membrane fraction (Mtb mem), 1x10
7
 particles/ml of Zymosan particles, 200μg/ml of 
heat-killed Staphylococcus aureus (HKSA), and  1x10
8
 cells/ml of heat-killed Listeria 
monocytogenes (HKLM). Six hours post-stimulation, the luciferase activity was 
measured following manufacturer’s protocol. Firefly luciferase activities were 
normalized to that of the Renilla luciferase control.  These values were normalized to that 
of empty CMV vector whose value was taken as 1. Error bars represent the standard 
deviation of three independent events. Chimeric constructs are indicated at the bottom, 
with black areas indicating regions of TLR1 and gray areas indicating regions of TLR6. 
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Figure 4.2. N-terminal TLR1 and TLR6 chimeras demonstrate that the epitope of anti-
TLR1 mAb, GD2.F4, maps to the central LRRs 9-12 of TLR1. HEK 293T cells were 
transfected with either FLAG-tagged empty CMV vector (red-dotted line), FLAG-tagged 
TLR1 (green), FLAG-tagged TLR1 chimera (yellow) labeled specifically in each box, or 
FLAG-tagged TLR6 (blue). After 48 hours, cells were removed from the plate and 
incubated sequentially with anti-TLR1 mAb, GD2.F4, followed by biotinylated donkey 
anti-mouse secondary Ab, and a streptavidin-PE-conjugated tertiary antibody. After 
labeling, the cells were washed, fixed, and analyzed by flow cytometry for surface 
expression of TLRs. 
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Figure 4.3. The putative epitope of anti-TLR1 mAb (GD2.F4), a blocking antibody 
against TLR1, extends from S279P to F331S. HEK 293T cells were transfected with 
either FLAG-tagged wild-type TLR1 or any of the fifty-nine single-point TLR1 mutants. 
After 48 hours, cells were removed from the plate and incubated sequentially with either 
an anti-FLAG (A) or an anti-TLR1 mAb, GD2.F4 (B) as the primary antibody, followed 
by biotinylated donkey anti-mouse secondary Ab, and a streptavidin-PE-conjugated 
tertiary antibody. After labeling, the cells were washed, fixed, and analyzed by flow 
cytometry for surface expression of TLRs. The data were normalized to that of the wild-
type TLR1 whose value was set at 100% mean fluorescence intensity (MFI). Single point 
mutants that had less than 50% MFI relative to wild-type TLR1 upon staining with the 
anti-TLR1 monoclonal antibody (GD2.F4) were marked with *.  
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Figure 4.4. Structural model for the conformational epitope of the anti-TLR1 mAb 
(GD2.F4) using the PDB file 2Z7X and the VMD software. (A) Ribbon diagram of TLR1 
LRRs 9-12 (in dark blue), together with Pam3CSK4 (in orange). One of the acyl chains of 
Pam3CSK4 in inserted between LRRs 11 and 12 of TLR1. (B) Space-filling model of the 
same region shown in (A), with the LRRs in alternating color. LRRs 9 and 11 are in blue, 
while LRRs 10 and 12 are in light gray. The hydrophobic pocket of TLR1 formed 
between LRRs 11 and 12 is the area where one of the acyl chains in Pam3CSK4 (orange) 
is inserted. (C) Ribbon diagram of TLR1 together with the different amino acid residues 
that were found to be critical for binding the anti-TLR1 mAb: S279, L287, R290, V307, 
S309, D310, F312, F314, P315, Q316, S317, Y320, and F331. The amino acids are 
colored according to their name (ser: yellow, leu: pink, arg: grayish-white, val: tan, asp: 
red, phe: purple, pro: ochre, gln: orange, and tyr: green). (D) Space-filling model of the 
same region shown in (C). 
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Figure 4.5. The TLR1 single-point mutants F314L, P315L, Q316K, and V339D exhibit 
highly-attenuated responses to the triacylated lipopeptide Pam3CSK4. SW620 epithelial 
cells were co-transfected with TLR2 and different TLR1 single-point mutants, an IL-8-
driven luciferase gene, and a Renilla transfection control. Cells were then stimulated with 
20ng/ml Pam3CSK4. Six hours post-stimulation, the luciferase activity was measured 
following manufacturer’s protocol. Firefly luciferase activities were normalized to that of 
the Renilla luciferase control.  These values were normalized to that of empty CMV 
vector whose value was taken as 1. Error bars represent the standard deviation of three 
independent events. 
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Figure 4.6. TLR1P315L does not form a ternary complex with TLR2 and Pam3CSK4 in 
solution. 0.5uM wild-type TLR1 (A) or 0.5uM TLR1P315L (B) were pre-incubated with 
0.5uM TLR2, a 5 fold molar excess of Pam3CSK4 (2.5uM), 0.05uM LBP, and 0.25uM 
sCD14 in PBS pH 7.4 buffer for two hours at 37
o
C in a 500ul reaction volume. In (C), 
2.5uM Pam2AcCSK4 was added to wild-type TLR1, TLR2, LBP and CD14 instead of 
Pam3CSK4. Protein complexes were separated by size exclusion chromatography. The 
expected molecular weight of the TLR monomers and dimers was estimated by column 
calibration using known molecular weight standards including bovine thyrogloblulin (670 
kDa), bovine γ-globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and 
vitamin B-12 (1.35 kDa). Proteins in eluted fractions were separated on a 7.5% SDS-
PAGE gel, transferred by Western blotting, and TLR1, TLR2, LBP or sCD14 were 
detected using suitable antibodies and HRP conjugates (see Materials and Methods). The 
results shown are representative of at least three independent experiments. 
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Figure 4.7. The same single-point TLR1 mutants F314L, P315L, Q316K, and V339D 
exhibited highly attenuated responses to a variety of microbial agonists. SW620 
epithelial cells were co-transfected with TLR2 and different TLR1 single-point mutants, 
an IL-8-driven luciferase gene, and a Renilla transfection control. Cells were then 
stimulated with 100ng/ml P. gingivalis LPS (Pg LPS), 6μg/ml of Mycobacterial 
membrane fraction (Mtb mem), and 1x10
7
 particles/ml of Zymosan particles. Six hours 
post-stimulation, the luciferase activity was measured following manufacturer’s protocol. 
Firefly luciferase activities were normalized to that of the Renilla luciferase control.  
These values were normalized to that of empty CMV vector whose value was taken as 1. 
Error bars represent the standard deviation of three independent events. 
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Figure 4.8. Structural model of the critical residues found in LRRs 11 and 12 of TLR1 
required for recognition of different microbial agonists using the PDB file 2Z7X and the 
VMD software. (A) Ribbon diagram of TLR1 LRRs 10-12 (in dark blue), together with 
the amino acid residues V311, F314, P315, Q316, Y320, E321, and V339 colored 
according to amino acid name (val: tan, phe: purple, pro: ochre, gln: orange, and tyr: 
green). A gray sketch of Pam3CSK4 was included for orientation purposes. (B) Space-
filling model of the same region shown in (A). (C) Ribbon diagram of the top view of the 
TLR1/TLR2/Pam3CSK4 ternary complex (PDB 2Z7X) highlighting the critical 
interacting amino residues between TLR1 and TLR2. TLR1 LRRs 10-12 are shown in 
blue on the right, while TLR2 LRRs 10*-13* are shown in gray on the left. The critical 
amino acid residues in TLR1 are shown in blue font, while those of TLR2 are shown in 
black font marked with a *. The residues were color-coded according to amino acid 
properties: non-polar is yellow, polar is green, acidic is red, and basic is blue. The 
predicted hydrophobic and ionic interactions between specific TLR1 and TLR2 residues 
are summarized at the bottom of the figure. Pam3CSK4 is partly shown in light gray 
sketch with two of its acyl chain inserted between LRRs 12* and 13* of TLR2, and the 
third acyl chain inserted between LRR 11 and 12 of TLR1. 
124 
 
Table 
Table 4.1. TLR1 clones with single amino acid substitution within LRRs 9-12. The first 
column indicates the amino acid change of the clone. Columns two and three summarize 
the data obtained from HEK 293T cells transfected with the clones and their relative 
mean fluorescence intensity with respect to wild-type TLR1 upon staining with anti-
FLAG and anti-TLR1 mAb, respectively. The fourth column shows the IL-8-luciferase 
data from SW620 cells transfected with the clone and TLR2 and stimulated with 20ng/ml 
Pam3CSK4 (as described in Materials and Methods section), while the fifth column 
reflects the standard deviation calculated from three independent trials. 
AMINO ACID 
CHANGE 
%WT 
Fluorescence 
(anti-FLAG) 
%WT 
Fluorescence 
(anti-TLR1) 
Pam3CSK4 (+/-) Error 
TLR2 ALONE - - 10.53 (7.09) 
TLR1 100.00 100.00 100.00 (10.23) 
LRR 9 
V268G 8.9 2.69 10.44 (4.97) 
V268I 84.85 84.46 131.73 (31.70) 
LRR 10  
H270Y 109.00 103.23 92.55 (12.40) 
H270R 60.94 55.41 74.37 (73.65) 
T271I 50.62 56.73 205.64 (6.60) 
T272S 114.38 102.58 102.98 (18.07) 
V273E 28.50 10.90 33.79 (5.77) 
W274R 24.79 5.37 98.53 (33.20) 
W274C 80.10 99.98 78.14 (68.20) 
Y275F 92.74 102.22 199.84 (47.14) 
F276S 73.13 74.23 93.72 (35.27) 
I278T 79.03 70.46 213.36 (29.08) 
S279P 65.57 12.87 59.82 (28.37) 
S279T 77.54 89.96 103.19 (35.30) 
V281M 75.29 86.87 73.74 (52.20) 
V281A 84.56 75.48 136.67 (12.77) 
G285K 35.29 26.99 120.22 (8.52) 
Q286P 112.50 120.17 94.38 (55.84) 
Q286K 67.16 62.75 116.29 (16.40) 
L287Q 86.61 46.66 167.66 (56.60) 
F289I 92.17 81.44 107.15 (2.56) 
R290S 92.26 47.96 152.64 (9.02) 
D293Y 61.66 65.64 117.33 (2.43) 
LRR 11 
T297S 116.98 113.32 133.83 (3.83) 
K300M 91.73 88.56 84.95 (48.90) 
A301V 110.10 92.86 158.29 (27.81) 
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Table 4.1. (continued) 
S303Y 104.80 96.90 110.57 (39.30) 
I304M 109.88 60.33 94.77 (27.50) 
I304K 4.90 3.69 36.34 (9.90) 
Q306H 120.21 106.10 84.60 (30.50) 
V307A 107.39 37.59 139.48 (19.68) 
S309N 132.25 3.61 97.35 (5.83) 
D310V 75.95 2.44 87.39 (22.10) 
V311E 181.96 113.17 95.55 (8.25) 
F312S 145.74 3.76 75.42 (14.40) 
F312Y 127.57 47.36 125.39 (48.40) 
F312I 155.34 101.56 155.83 (57.90) 
F312L 142.05 127.02 150.68 (45.10) 
F314L 103.93 1.56 23.08 (7.45) 
P315L
6
 60.03 0.65 21.85 (8.04) 
Q316K 75.03 1.03 12.74 (2.81) 
S317G 123.44 39.35 145.97 (1.29) 
Y320N 119.48 25.32 68.58 (8.74) 
E321V 70.63 77.83 120.89 (20.41) 
E321K 96.86 89.85 132.99 (11.76) 
E321D 102.24 87.62 105.32 (17.35) 
F323L 66.66 72.27 117.32 (9.96) 
LRR 12 
N327Y 58.28 61.57 95.45 (27.14) 
N327I 91.56 94.61 121.89 (5.02) 
I328N 49.68 46.55 29.07 (4.56) 
F331S 64.20 18.55 78.01 (16.92) 
S334Y 64.19 80.02 111.58 (7.88) 
G335D 96.79 109.12 125.88 (9.38) 
G335S 93.06 128.43 93.60 (53.50) 
R337H 27.76 5.80 131.71 (30.64) 
V339D 104.02 132.59 14.99 (6.05) 
V339L 109.92 134.35 100.46 (7.70) 
V339I 89.40 104.73 195.01 (11.36) 
L342H 106.83 119.98 80.32 (48.95) 
 
 
 
  
                                                          
6
 From Omueti KO, Mazur DJ, Thompson KS, Lyle EA, Tapping RI. J Immunol. 2007 May 15; 
178 (10): 6387-6394. 
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CHAPTER FIVE 
CONCLUSION 
Summary 
Through recognition of specific microbe-associated molecular patterns (MAMPs), 
including bacterial lipoproteins, the TLR1 and TLR2 receptor pair plays a pivotal role in 
the induction of host inflammatory responses following infection. TLR2 is an extensively 
studied receptor in innate immunity. Its importance in host inflammatory responses to 
infection has been demonstrated in studies using knockout mice. However, these types of 
studies do not provide insights into the structure/function relationship or in the 
interactions with actual ligands and/or co-receptors. The availability of the crystal 
structure of TLR1/TLR2/Pam3CSK4 has been a tremendous contribution to the 
knowledge on structure/function relation, and provided validation to numerous 
mutational and overexpression studies performed to understand TLR2 interaction with 
TLR1. This dissertation sought to gain further insights on the order of events that lead to 
TLR1/TLR2/Pam3CSK4 ternary complex formation as well as to identify critical regions 
in the TLR1 ECD that are required for ligand recognition and/or interaction with TLR2.  
The most commonly studied TLR2 ligands are the synthetic tri- and diacylated 
lipopeptides Pam3CSK4 and Pam2CSK4, as well as the Mycoplasma-derived lipoproteins 
macrophage-activating lipopeptide-2 (MALP2) and FSL-1. Bacterial lipoproteins are 
characterized by a diacyl-glycerol that is connected to the sulfur atom of the N-terminal 
cysteine. Depending on the microbe and whether or not it is producing a certain type of 
enzyme, an additional lipid chain is added to the cysteine amino terminus via an amide 
bond (Nakayama et al., 2012). Stimulation of cells by soluble bacterial triacylated 
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lipoproteins involves formation of a ternary TLR1/TLR2/lipoprotein complex. However, 
even though the TLR1/TLR2 pair is able to recognize soluble lipoproteins, in the intact 
cell wall of microbes, the lipoproteins are anchored in the microbial membrane and 
therefore inaccessible to the receptors (Underhill & Gantner, 2004). Chapter 2 described 
how cell stimulation is enhanced by either serum LBP or sCD14, two pattern recognition 
receptors which were demonstrated to act by catalytically delivering lipopeptides directly 
to TLR1/TLR2. Using purified proteins that are monomeric, properly folded, and 
biologically functional, we were able to demonstrate by size exclusion chromatography 
that LBP and sCD14 enhance TLR1/TLR2/Pam3CSK4 formation but are not part of the 
stable ternary complex. Either LBP or sCD14 were shown to independently deliver 
Pam3CSK4 to TLR1 and TLR2. This is the first report demonstrating that LBP can 
deliver agonists directly to TLR1/TLR2 independent of CD14. Unlike the TLR4 system, 
our data suggests that there is a redundancy of function between LBP and CD14 in terms 
of presenting lipopeptides directly to TLR1 and TLR2. Likewise, we were also able to 
show that cellular responses of epithelial cells to microbial lipoproteins are enhanced by 
either LBP or sCD14, but sCD14 requires a longer time to bind to triacylated lipopeptides 
compared to LBP.  
The question of whether or not TLRs form pre-formed homodimers or 
heterodimers were also addressed in Chapter 2. In the absence of any agonists, pre-
incubation of TLR1 either with itself or with TLR2 did not lead to the formation of stable 
homodimers and/or heterodimers. We also have physical evidence showing that the 
triacylated lipopeptide Pam3CSK4 induces the formation of TLR1/TLR2 heterodimers but 
not homodimers. Our data supports the numerous findings demonstrating that TLR2 must 
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heterodimerize with its co-receptors upon ligand recognition to initiate the appropriate 
signaling response (Ozinsky et al., 2000; Takeuchi et al., 2001; Wyllie et al., 2000). We 
acknowledge that our studies mainly involved the use of soluble TLR ECDs, and that the 
TLR transmembrane and/or the TIR domains may contribute to the homodimerization or 
heterodimerization observed by other groups (Triantafilou et al., 2006).  
Chapter three described the biophysical measurements we performed to address a 
possible competition between TLR1 and TLR10 for microbial agonists and the co-
receptor TLR2. It is noteworthy to take a closer look at the TLR2/10 interaction and 
compare that with the TLR1/2 pair, given that we have previously reported that TLR10 is 
able to interact with TLR2 in response to agonists that are shared with TLR1 (Guan et al., 
2010). It is also interesting to note that TLR10 expression is high in B cells, but very low 
in macrophages and plasmacytoid dendritic cells [Reviewed in (Janssens & Beyaert, 
2003]. Knowing that TLR10 does not signal via the known TLR2-mediated signaling 
pathway leading to the expression of pro-inflammatory cytokines and chemokines, we 
believe that TLR10 competes with TLR1 in recognizing TLR1/TLR2 agonists leading to 
a different, yet unknown,  cellular response. Additional data from other colleagues in our 
lab who are looking at TLR10 suggest that this receptor may be independently acting as a 
global suppressor to dampen the cell’s immune response (Jiang, Li, Hess, and Tapping, 
unpublished results).  
 Our qualitative experiments using microtiter plate assays demonstrated that 
TLR2 binding to either TLR1 or TLR10 is ligand-induced, saturable and agonist-specific. 
Compared to TLR1, TLR10 required more TLR2 to form a complex with Pam3CSK4 in 
microtiter plates. We were able to demonstrate in Chapter 2 that we could form the 
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TLR1/TLR2/Pam3CSK4 ternary complex in solution. However, using the same size 
exclusion chromatography assay, we were not able to observe a stable 
TLR2/TLR10/Pam3CSK4 complex formation in solution. The results of our microtiter 
plate assays and the size exclusion chromatography column suggest that the affinity of 
TLR2 to TLR10 is weaker compared to that of TLR1. 
To measure kinetics of interaction between the receptors and the agonist, we 
performed biolayer interferometry on an Octet instrument, which was shown to be a more 
reliable method for measuring protein interactions in a two-component system compared 
to surface plasmon resonance on a BIAcore machine. We have evidence showing that Fc-
tagged TLRs 1, 2, and 10 all directly bind to a 12kDa lipoprotein (Lip12) purified from 
E. coli that has been previously verified to stimulate TLR1/TLR2- but not TLR2/TLR6-
transfected cells. Amongst the three TLRs tested, TLR1 showed the highest affinity or 
lowest dissociation constant for the lipoprotein (KD = 7.45x10
-7
 M), followed by the 
TLR10-Lip12 (KD = 3.34x10
-7
M), and finally by TLR2-Lip12 (KD = 1.58x10
-6
M). To our 
knowledge, this is the first time that the interactions between TLRs and lipoprotein have 
been quantitatively measured. All previous available data showed the interaction of TLR2 
towards soluble agonists such as peptidoglycan (Asong et al., 2009).  However, the 
limitation of this experiment is the use of Fc-tagged TLRs immobilized on protein A 
sensors. We found that Fc-tagged TLRs are forming non-specific dimers due to the Fc 
protein domain. We think that this dimerization of TLRs provides a conformational steric 
hindrance that interferes with the formation of a ternary complex upon addition of the 
monomeric co-receptors. Our attempts to measure the ternary complex formation by 
addition of the co-receptor to these pre-formed TLR-Lip12 complexes using either the 
130 
 
Octet system or BIAcore failed to give consistent, quantifiable, and reliable results due to 
technical difficulties encountered with the dimeric nature of the Fc-tagged TLRs 
immobilized on the sensor as well as the aggregation of the lipoproteins in solution. We 
also found that the TLRs could not be immobilized on amine-reactive sensors via 
chemical coupling due to the sensitive nature of the purified TLR ECDs.  
Even though we were not able to measure the kinetics of ternary complex 
formation in solution, one important finding that emerged from our TLR-lipoprotein 
measurements was additional insight into the order of events that lead to complex 
formation. Since TLR1 exhibited the highest affinity towards Lip12 compared to TLR2 
and TLR10, our data suggest that lipoproteins will be delivered to TLR1 first, followed 
by a TLR1-lipoprotein binding to the co-receptor TLR2. If the reported dissociation 
constant for a CD14-Pam3CSK4 interaction (KD = 5.7x10
-6
M) is correct (Nakata et al., 
2006), one could deduce based on the KD values that CD14 will preferably deliver 
Pam3CSK4 to TLR1 over TLR2. 
Interestingly, in the absence of TLR2 we observed that both CD14 and TLR1 
eluted in earlier fractions in our size exclusion chromatography column (see Chapter 2, 
figure 2.3A), while in the presence of TLR2, sCD14 eluted in later fractions as a 
monomeric protein (figure 2.3B right panel). This suggests that sCD14 and TLR1 interact 
in a Pam3CSK4-dependent fashion. Since sCD14 was shown to not be a part of the final 
ternary complex, Figure 2.3C suggests that the binding of TLR2 to the sCD14-TLR1-
Pam3CSK4 complex displaces sCD14 leading to formation of the final ternary TLR1-
TLR2-Pam3CSK4 ternary complex.  This observation supports a model where, upon 
binding lipopeptide, sCD14 stably interacts with TLR1 but is then displaced by TLR2 
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during formation of the final ternary complex.  This is in contrast to what has been 
previously suggested by other groups that CD14 might be interacting with soluble TLR2, 
which as a decoy receptor, would prevent CD14 from delivering lipopeptides to 
membrane-bound TLR2 (LeBouder et al., 2003). CD14 has previously been 
demonstrated to interact directly with TLR2 using immunoblot assays (Iwaki et al., 2002; 
Iwaki et al., 2005) and this interaction was blocked by a monoclonal antibody against 
CD14 that is known to block CD14-mediated LPS loading (Iwaki et al., 2005). However, 
the group did not look at any interaction between CD14 and TLR1.  
Chapter 4 provided an in-depth analysis of the important regions in the TLR1 
ECD that is required for ligand binding and formation of a dimer with the co-receptor 
TLR2. We also gained insights as to how the TLR1/TLR2 pair recognizes various 
microbial components other than lipoproteins. We have shown that LRRs 9-12 of TLR1 
are required for discrimination of all TLR1/TLR2 microbial agonists that we tested in this 
study. Random mutagenesis of TLR1 LRRs 9-12 residues resulted in single point mutants 
that are not recognized by anti-TLR1 antibody clone GD2.F4, thus revealing the putative 
epitope of this neutralizing antibody, which maps close to the entrance of the 
hydrophobic binding pocket of TLR1. Amino acid residues found at the entrance of the 
hydrophobic binding pocket of TLR1 at LRRs 11 and 12 are important for recognition of 
the triacylated lipoptide Pam3CSK4. The same TLR1 point mutants fail to respond to 
Pam3CSK4 and other TLR1/TLR2 microbial agonists. Taken together, the critical amino 
acids of TLR1 required for receptor function are strikingly similar across all naturally 
occurring TLR1/2 agonists, irrespective of their assumed chemical nature, suggesting that 
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TLR1 uses the same contact points to form a dimer interface with TLR2 regardless of the 
agonist type.  
We have also demonstrated in Chapter 4 that a naturally occurring polymorphic 
variant of TLR1, with proline at position 315 mutated to leucine (P315L), exhibited 
impaired responses to a variety of TLR1/2 agonists including lipoproteins. Additionally, 
a purified TLR1 ECD with a mutation at this amino acid position failed to form a ternary 
complex with TLR2 upon addition of Pam3CSK4 in solution (Chapter 2 and 4). 
Interestingly, this SNP is relatively rare in human populations. Although no individuals 
homozygous for the L315 allele have been found to date, a small percentage (3.4% allele 
frequency) of heterozygous individuals of African-American descent, and a much smaller 
population (0.8% allele frequency) of individuals with European ancestry, has been 
observed (www.ncbi.nlm.nih.gov/SNP). It is not known whether the impaired response of 
heterozygotes to TLR1/2 agonist is due to a dominant negative effect or a gene dosage 
effect. Our results in Chapter 4, together with the crystal structure of 
TLR1/TLR2/Pam3CSK4, suggest that the proline at amino acid position 315 in TLR1 
contributes to hydrophobic interactions that line the TLR1/2 dimer interface, and a 
mutation to leucine at this region disrupts TLR1 and TLR2 dimerization, thus preventing 
the formation of the ternary complex. Using the Octet system, we were able to 
demonstrate in Chapter 3 that TLR1P315L is still able to bind the lipoprotein immobilized 
on a sensor, with measured dissociation constant (KD = 1.13x10
-6
M) that is only 1.5-fold 
larger than that of the wild-type TLR1 (KD = 7.45x10
-7
M). This provides additional proof 
that proline at position 315 is important for the formation of a dimer interface with TLR2. 
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Using size exclusion chromatography, we failed to form a ternary complex of 
TLR1/TLR2 together with the natural microbial agonists in solution, even in the presence 
of LBP and CD14. It is possible that the affinity of the TLRs to these microbial agonists 
is much lower compared to their affinity towards lipoproteins, thus requiring a higher 
concentration of agonists to form a complex or to stimulate cells. It is also possible that 
they may require some other accessory molecules for delivery to the TLRs. There are 
some scavenger receptors that act like pattern recognition receptors, and although not yet 
well-studied, they may also assist in the delivery of some microbial ligands and/or intact 
microbes to the TLRs [reviewed in (van Bergenhenegouwen et al., 2013)]. 
 
Significance and Future Work 
Assessing the order of events in TLR1/TLR2/Pam3CSK4 ternary complex formation  
Due to the technical difficulties we encountered using our purified TLRs and 
lipoproteins, we were not able to measure the kinetics of a ternary complex formation 
using the Octet system in this study. What we learned from our experiments is that we 
could not use Fc-tagged TLRs on the sensor, and we also could not covalently 
immobilize TLRs on the sensor via standard amine coupling procedure. We have 
attempted to immobilize the TLRs indirectly on the sensor via their FLAG- or the HA-
tags, however, the interaction between the FLAG(HA)-tag and the anti-FLAG(HA) mAb 
was not strong enough to stably hold the TLRs on the sensors. One possibility that we did 
not explore in this study is to generate biotinylated TLR constructs, and take advantage of 
the strong interaction between streptavidin and biotin.  
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Alternatively, we could also perform a different assay to measure kinetics of 
interaction. We have attempted to use a microcalorimeter to examine ternary complex 
formation. However, this technique requires a large amount of purified proteins, and our 
HEK 293F stable cell lines do not express soluble TLRs at a high enough concentration, 
thus limiting our protein yield. A nanocalorimeter that requires less amount of starting 
material would be a good alternative to try to measure complex formation.     
Gaining more insights on the competition between TLRs 1 and 10 for TLR2 and/or 
their agonists 
 Based on our microtiter plate assays and the Octet kinetic measurements, we were 
able to show that similar to TLR1, TLR10 could also bind to lipoproteins and form a 
complex with TLR2, suggesting that there is a possible competition between TLR1 and 
TLR10. Our preliminary data show that TLR2 prefers TLR1 over TLR10 as a co-
receptor. However, additional kinetic measurements are needed to be able to understand 
the nature of this competition. This is an important question to answer, since we know 
that TLR10 does not signal via the known TLR2 signaling pathway. If one of the roles of 
TLR10 is to act as a negative regulator to dampen immune responses towards 
lipoproteins, then the kinetics data that we generate for TLR10 interaction with TLR2 in 
comparison with TLR1 would help increase our understanding of the difference in 
signaling output between the two competing TLRs.  
Distinguishing critical regions in the TLR1 ECD that are important for ligand 
recognition and formation of dimer interface with TLR2 
To further study the critical regions of the TLR1 ECD, experiments that could 
differentiate regions that are important for ligand binding and/or formation of dimer 
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interface should be designed and performed. One could start by comparing our TLR1 
mutational analysis with other groups’ computational as well as evolutionary studies on 
the critical sites on TLR1 and/or TLR2. For example, a study conducted by Georgel et al. 
in 2009 revealed that 1% of the Caucasian genomic DNA that they analyzed have the 
L443I, V545A, and T565S SNPs in their TLR1 gene, and mutations at any of these sites 
may potentially impair TLR1/TLR2 heterodimer formation (Georgel et al., 2009). In 
addition, the group that solved the TLR1/TLR2/Pam3CSK4 crystal structure have 
predicted several important residues in TLR1 ECD that are important for interaction with 
the TLR2 ECD via formation of hydrogen bonds, ionic bonds, and hydrophobic 
interactions (Jin et al., 2007). Another group has performed computational studies to 
identify critical regions in TLR1 and have identified that amino acid positions 284, 303, 
308, and 313 of the TLR1 ECD are important for ligand binding, while residues 321 and 
337 are important for dimerization interface (Wlasiuk & Nachman, 2010). However, 
there has been very little experimental data available which demonstrates that these 
predicted amino acid sites are critical for TLR1 function. This is where the TLR1 single 
point mutants become valuable tools to validate the existing data generated via 
computational studies. We acknowledge that our random mutagenesis approach of the 
TLR1 ECD was not able to control the specific amino acid sites mutated or the nature of 
the mutation itself. For example, we may have generated single point mutants that did not 
affect overall function of the protein due to similarity in amino acid properties. 
Additional insights may be generated by performing site-directed mutagenesis of the 
TLR1 ECD at the predicted sites.  
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Investigating the biological role of the naturally-occurring soluble TLR2 
In humans, there are naturally occurring soluble forms of TLR2 (sTLR2), which 
consist of the TLR2 extracellular domain. sTLR2 is released by monocytes and is present 
in plasma, breast milk (LeBouder et al., 2003), saliva (Kuroishi et al., 2007), and 
amniotic fluid (Dulay et al., 2009) as a product of post-translational modifications (the 
protein fragments vary in size). The amount of sTLR2 and the expression pattern of the 
different forms of sTLR2 detected in the serum vary from individual to individual and 
may be affected by race, ethnicity, or genetic variability, although nobody has shown this 
correlation yet. The full extent of sTLR2’s negative regulatory capacity, the mechanism 
underlying it, and its biological significance in vivo has not yet been determined. One 
group reported that sTLR2 binds to CD14 as a decoy receptor, thus preventing the latter 
from binding to membrane-bound TLR2 (LeBouder et al., 2003; Raby et al., 2009). 
sTLR2 in human breast milk has been found to be protective against HIV-1 infection 
(Henrick et al., 2012), while depletion of sTLR2 from serum renders monocytes and 
leukocytes sensitive to lipopeptides and other known TLR2 microbial agonists (LeBouder 
et al., 2003; Raby et al., 2009). Interestingly, these studies did not examine how TLR1 or 
TLR6 might come into play in this system. A previous graduate student in the lab 
(Johnson and Tapping, unpublished results) have shown that upon stimulation of 
monocytes with synthetic ligands for TLR2, there is an upregulation of TLR2 
transcription and a down-regulation of both TLR1 and TLR6. How this correlates with 
the production of soluble TLR2 and the latter’s role in ligand selectivity and functional 
specificity remains to be elucidated. Other than sTLR2, no naturally occurring soluble 
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form of a mammalian TLR has been identified to date, although a soluble TLR4 has been 
reported in mice as a splicing variant (Iwami et al., 2000). 
Assessing the existence of TLR2 homodimers and other co-receptors of TLR2 
Another important question that needs to be addressed involves the possibility of 
TLR2 homodimer formation. A corollary question to this would be “Do TLR2 bind with 
other PRRs, without the need for either TLR1 or TLR6?” For example, CD36 is a 
scavenger receptor that was shown to deliver LTA and MALP2 from Gram-positive 
bacteria to TLR2 and TLR6 (Hoebe et al., 2005). This PRR is a glycoprotein with several 
functions such as lipid transport, hemostasis, and angiogenesis (Greenwalt et al., 1992). 
There have been reports of TLR2/TLR6 requiring additional help from CD36 for initial 
ligation of specific lipopeptides prior to CD14 loading (Triantafilou et al., 2006). There 
are also a number of other ligands that have been reported to stimulate TLR2-expressing 
cells, but do not appear to require the presence of TLR1 or TLR6. These include 
microbial components such as lipoteichoic acids (Schwandner et al., 1999) and also 
endogenous components or damage-associated molecular patterns (DAMPs) such as 
heat-shock protein 60 (Vabulas et al., 2001). However, most of these reported studies 
were performed on cell lines that may have endogenous expression of TLR2 co-receptors 
TLR1, 6, and 10, and therefore were not carefully taken into consideration. While it is 
possible that TLR2 may be interacting with an as yet unidentified co-receptor(s), if not 
forming homodimers with itself, it is imperative that careful experiments be performed to 
address this issue.  
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Testing for bonafide naturally occurring TLR2 agonists 
Over the years, several agonists for TLR2, both microbial and endogenous 
compounds, have been identified. To our knowledge, there are very few physical data 
showing direct interactions between the receptors and the more recently reported 
agonists, especially the endogenous ones. By performing physical studies with the 
soluble TLRs and a wide variety of purified compounds, we should be able to address 
which components are bonafide TLR2 agonists, and be able to quantitatively measure 
their kinetics of interaction with the TLRs using the Octet system that we have optimized 
for lipoproteins. Some of the naturally-occurring microbial ligands that are commercially 
available in purified form are atypical LPS from P. gingivalis, lipoteichoic acid, and 
lipomannans or lipoaribomannans from mycobacterial species. Other purified microbial 
components that are known to stimulate TLR2 may also be obtained from other research 
groups through collaboration, examples of which include B subunit of type II Heat-Labile 
enterotoxins (LT-IIb) from E. coli, Neisseria porB from meningococcal species, and 
Treponema denticola flagella. A more interesting set of TLR2 ligands to examine are the 
endogenous ligands that are implicated in sterile chronic inflammation (i.e. amyloid β, 
serum amyloid A, β-defensins, α-synuclein, and eosinophil-derived neurotoxins) (Cheng 
et al., 2007; Gariboldi et al., 2008; Kim et al., 2013; Liu et al., 2012; Yang et al., 2008). 
To our knowledge, there is very little information available that shows direct interaction 
between these ligands and the TLRs. Alternatively, it is also possible that these reported 
agonists of TLR2 are contaminated with minute amounts of lipoproteins. To determine 
whether or not a given microbial component is a genuine TLR2 agonist, it is important to 
consider that preparation and purification of recombinant microbial components from 
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typical bacterial expression systems inherently produce lipoprotein contaminants. A 
stringent purification method or synthetic preparation of agonists would be a preferred 
option when designing experiments aimed to identify genuine agonists or antagonists of 
the TLR2 family of receptors. 
Therapeutic targeting of TLR1 and TLR2 
Activation of TLRs in response to microbial infection leads to the production of a 
variety of proinflammatory cytokines, chemokines, and costimulatory molecules, an 
excess of which could lead to profound deleterious effects, including septic shock and 
death. A number of reports have implicated TLR2 in the pathogenesis of chronic 
inflammatory, autoimmune, and infectious diseases [Reviewed in (van 
Bergenhenegouwen et al., 2013)]. A better understanding of host-microbe interaction 
may lead to new and improved therapeutic strategies targeting TLR2 function in health 
and disease. Several therapeutic approaches could be designed using humanized 
inhibitory TLR monoclonal antibodies (Arslan et al., 2012), antagonistic oligonucleotides 
(Chang et al., 2009), and recombinant soluble TLRs, all of which are capable of 
minimizing the activation of the TLR1/TLR2 pathway. A series of novel synthetic 
phospholipids and high affinity aptamers have been recently designed and were shown to 
be antagonists of TLR2 (Arslan et al., 2012; Spyvee et al. 2005), however, functional 
data are still lacking. Using our TLR1 single point mutants, we could screen these 
synthetic antagonists and compare the critical regions in TLR1 that differentiate a 
receptor’s response towards an antagonistic versus an agonistic ligand. Alternatively, 
there have been reports on the use of synthetic agonists such as lipopeptides as adjuvants 
because of their ability to activate antigen-presenting cells like macrophages and 
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dendritic cells, thus improving the immunogenicity of an otherwise weak vaccine (Kaisho 
& Akira, 2002). This is consistent with Janeway’s original observation that several 
microbial products are potent vaccine adjuvants and likely work through TLRs 
(Medzhitov & Janeway Jr, 1996). 
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